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1. De kans op het vinden van een mutatie in het LlCAM gen hangt af van het aantal 
klinische kenmerken bij de patient en het aantal aangedane familieleden van 
deze patient (dit proefschrift). 
2. Mutaties in het L1CAM gen leiden vaker dan gedacht tot een ernstig ziektebeeld 
bij meisjes (dit proefschrift). 
3. lnformatie over de betrokkenheid van genomische variaties bij een aandoening 
kan het best worden verkregen door vergelijking met de genomische sequenties 
van de meest aan de mens verwante dieren. 
4. In het licht van stelling 3 zou het 1000 Genomes Project niet a Ileen het humane 
genoom van een groot aantal mensen moeten onderzoeken, maar juist ook het 
genoom van nauw aan de mens verwante dieren. 
5. Ten onrechte wordt de invloed van silent en missense mutaties op de mRNA 
splicing vaak niet onderkend en daarom niet onderzocht (dit proefschrift). 
6. Het vergaren van kennis over het effect van mutaties op de functionaliteit van 
genproducten verdient een even hoge prioriteit als het steeds sneller kunnen 
genereren van veel sequentiedata. 
7. Vaten communiceren vaak beter dan mensen. 
8. Nadenken suggereert ten onrechte dat dit achteraf dient te geschieden. 
9. Voor sommige schaatscoaches is het de verkeerde baan. 
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Ll syndrome is an X-linked recessive disorder caused by mutations in the L1CAM gene[1,21• The 
phenotypic spectrum associated with these mutations includes four different neurological 
syndromes[31• The first one, X-linked hydrocephalus, also referred to as hydrocephalus due to 
�tenosis of the £queduct of Sylvius (HSAS, MIM # 307000), was first described in 1949 by 
Bickers and Adams[41• Seven males in two successive generations were born with hydrocephalus 
and some of them died at birth. At autopsy, structural brain malformations with a narrowing 
of the aqueduct of Sylvius was seen and proposed to be the primary cause of the congenital 
hydrocephalus. 
X-linked hydrocephalus is the most frequent genetic form of congenital hydrocephalus[51, with 
a prevalence of approximately one in 30,000 newborn boys[61• It accounts for approximately 
7-15% of all congenital hydrocephalus cases[61• The diagnosis can be established in males 
with characteristic clinical and neuropathological findings and a family history consistent 
with X-linked inheritance. However, the clinical symptoms are variable. In most families, the 
affected boys die before, during, or soon after birth [71• Post partum, it has been observed that, 
in addition to the characteristics of hydrocephalus (viz. macrocephaly, bulging fontanelle and 
sunset eye phenomenon), adducted thumbs are present in at least 50% of patients (figure 1)[51• 
On an MRI scan of the brain or post mortem, agenesis or dysgenesis of the corpus callosum, and 
a small brainstem can be observed in addition to ventricle dilatation[81• The bilateral absence 
of the pyramids (corticospinal tract) is an important and almost pathognomonic finding [91• An 
aqueduct stenosis is not always found to be associated with this syndrome [101• 
A second, less severe form of the disease was published under the acronym MASA syndrome 
(MIM # 303350) and originally described in 1974(111• This syndrome consists of slight to 
moderate mental retardation, £phasia, �huffling gait and £dducted thumbs. Brain scans of men 
with this syndrome usually show abnormalities such as enlargement of the ventricle system[121• 
Occasionally, phenotypic variation ranging from the severe X-linked hydrocephalus type to the 
less severe MASA syndrome can be found in one and the same family[12,131_ 
The third and fourth syndromes that are part of the Ll syndrome are X-linked complicated 
hereditary spastic paraplegia type 1 (SPGl, MIM # 303350)[141 and X-linked complicated corpus 
callosum agenesis (X-linked ACC, MIM # 304100), although both these are seen much less 
frequently. The two complicated forms may be accompanied by mild to moderate mental 
12 
retardation, and X-linked ACC with variable spastic 
paraplegia[15•161• 
Female carriers of an L1CAM mutation are sometimes 
mildly affected with slightly adducted thumbs and a 
cognitive level significantly lower than their non-carrier 
sister(s). A severe form with hydrocephalus is rarely 
found in girls[111• 
It is the clinical characteristics of each of these four 
syndromes that give rise to a suspicion that a patient 
may have a mutation in the L1CAM gene. The seven 
most important characteristics of Ll syndrome are 
Figure 1. Adducted thumb 
Introduction 
hydrocephalus, aqueduct stenosis, mental retardation, adducted thumbs, agenesis/dysgenesis 
of the corpus callosum, aphasia (delayed speech development) and spastic paraplegia. 
Beside patients with these characteristics, we also describe rare syndromic patients in whom 
the L1 syndrome characteristics are only part of the phenotype. An example of a disease 
frequently found associated with Ll syndrome is Hirschsprung's disease (HSCR); at least 13 
cases have been describedr15,is-251_ This suggests a non-random association, since the frequency 
of Ll syndrome is approximately 1:30,000 newborn boys and that of HSCR is 1:5,000 newborns, 
so by chance this coincidence would only occur in approximately 1:150,000,000 newborns. 
Other examples of syndromic cases with Ll syndrome comprise association with a specific 
form of congenital idiopathic intestinal pseudo-obstruction (CIIP)r261, with bilateral duplex 
kidneys and uretersr211, with Nephrogenic Diabetes lnsipidus (NDl)r241, with pure lq43-qter 
deletion syndromer281 and with Down syndrome (chapter 2: appendix). In most of these patients 
a mutation in the L1CAM gene was found, sometimes in addition to another chromosomal 
aberration, such as the lq43-qter deletion or chromosome 21 trisomy, suggesting involvement 
of L1CAM in the Ll syndrome associated diseases. However, some of the syndromic cases can 
not be explained by L1CAM mutations. 
The gene 
In the 1980s different linkage studies mapped the disease locus on the long arm of the X 
chromosome at Xq28r12•14•29•301• Later, the disease locus was narrowed down to a region of 1.5 
mbr311• The gene encoding the cell adhesion molecule Ll (L1CAM gene), known to be involved in 
brain development r32•331, was the most obvious candidate genel311• Shortly thereafter, mutations 
in the L1CAM gene were shown to be responsible for the disorder r1,34•351_ 
The L1CAM gene is 16 kb in length and consists of 29 exons. The first exon of 125 bp is non­
coding and was discovered later r361, which is why this exon, located 10 kb upstream of the ATG 
containing exon 1, is known as exon A instead of exon 1 as is commonly used. 
The L1CAM gene is primarily expressed both in the central nervous system (CNS) and in the 
peripheral nervous system and encodes a protein of 1,257 amino acids, comprising a signal 
peptide of 19 amino acids and a functional Ll protein of 1,238 amino acids. This expression 
is partially controlled by the neural restrictive silencer element (NRSE) located in the first 
intron of the genel361• Tissue-specific expression is further regulated by homeodomain and Pax 
proteins upon binding at the homeodomain and paired-domain binding (HPD) site upstream 
exon 1. In non-neural tissue, alternative RNA splicing generates mRNA which lacks exons 2 and 
27 of the genel37•381• 
Mutations in the L1CAM gene 
169 different disease-causing mutations have been published: 130 of these were reviewed 
in 2001r39l and an additional 39 have been published more recentlyr21•22•26A0-521 • The most are 
private mutations spread over the entire gene (figure 2), comprising not only nonsense, splice 
site and missense mutations, but also deletions and insertions, usually resulting in a frame 
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Figure 3. Schematic representation of the neural cell adhesion molecule Ll (Ll protein). Cyto, cytoplasmic 
domain; TM, transmembrane domain 
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Ll protein lg-domain 1 
Figure 4. Schematic diagrams of the folding of the telokin domain and the first lg-domain of Ll. The folds 
are formed by two �-sheets, shown as bold black lines. The key site residues in telokin are given with their 
one letter code. Horizontal lines between residues represent the main-chain hydrogen bonds that form the 
�-sheets. (Adapted from Bateman et al.[59)). 
Genotype-phenotype studies revealed truncating mutations in the extracellular part (figure 3) 
of the Ll protein to be more severe than missense mutations in the same part of the protein 
or than mutations (truncating as well as missense) in the cytoplasmic domain154,55l_ Since quite 
severe and less severe phenotypes are found within the same family, the existence of modifiers 
is hypothesized; this is also based on indications reported in the literature1561 • 
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Chapter 1 
Although the disorder can be explained by a mutation in the L1CAM gene for only part of the 
group of patients, suggesting the involvement of more than one gene in this disease, so far 
there is no evidence of genetic heterogeneity. However, based on the mutation frequency 
described for the L1CAM gene outlined in the literature, viz. 30% and 46% 152•571, and in this 
thesis, it can be hypothesized that more genes are involved in Ll syndrome. 
The protein 
The neural cell adhesion molecule Ll (Ll protein) belongs to the immunoglobulin superfamily of 
cell adhesion molecules1581 . It is a transmembrane glycoprotein and consists of an extracellular 
part of six immunoglobulin-like domains (lg-domains) and five fibronectin type Ill domains (Fnlll­
domains), followed by a single-pass transmembrane segment, and a short cytoplasmic region 
(figure 3) 1331 • 
Bateman et a/. 1591 derived the outline structure of the six lg-domains and the five Fnlll-domains 
of the Ll protein from the known telokin structure1601, also a member of the lg superfamily, and 
from the known Fnlll structures of neuroglian1611, respectively. By comparing these structures and 
their key residues (telokin contains 35 key amino acid residues (figure 4) and the first Fnlll domain 
from neuroglian contains 27 key residues) with Ll protein, the possible key residues in Ll protein 
were predicted (figure 4). The key residues mentioned determine the conformation of a protein 
Heterophilic interactions: 
Extracellular matrix components e.g. laminin, 
neurocan, phosphocan, tenascin-R; 
















Signaling '111 cascade 
Neurite outgrowth 
Figure 5. Ll interactions. Ll interacts at the neuronal cell surface with Ll present on another surface (Ll-Ll 
interaction). This interaction initiates neurite outgrowth. Ll protein also interacts with other extracellular and 
intracellular components. Some of these may modulate Ll activity. The cytoplasmic domain interacts with the 
cytoskeleton and is subject to phosphorylation by a variety of kinases. (Adapted from Kenwrick et al.[67]) 
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domain. They are believed to be involved in intermolecular packing and hydrogen bonding, or 
have the ability to take up unusual conformationsl59l _ As the key residues are crucial for the protein 
folding, missense mutations affecting these residues are often considered to be pathogenicl591• 
The function 
Ll protein is primarily expressed throughout the central and peripheral nervous systems on 
subsets of developing and differentiated neurons, as well as on Schwann cells of the peripheral 
nervous system. It is also detected in non-neuronal cells, like melanocytes and lymphocytesl621 , 
intestinal crypt cells, and kidney tubule epithelial63.651• The L1 protein mediates cell-cell adhesion 
on differentiated neurons by Ll-Ll interaction at regions of contact between neighboring axons 
and on the growth cones, the structures at the leading tip of axons that are responsible for 
sensing extracellular growth and guidance cues. Both Ll-Ll interactions and Ll-non Ll protein 
interactions (figure 5) play a key role in the development of the nervous system by regulating 
axon outgrowth, axon fasciculation, myelination and neuronal migration 1661 • These interactions 
trigger the activation of several intracellular signaling pathways1671 (figure 5). For instance Ll­
Ll dimerization stimulates axonal growth by activating the tyrosine kinase domains of the 
fibroblast growth factor receptor 168•691• Ll also interacts with TAG-1, triggering intracellular 
events important for neurite outgrowthl701 • In addition, the highly conserved cytoplasmic 
domain of the Ll protein has been shown to signal through Src and mitogen-activated protein 
kinase (MAPK1/ERK2)l71,72I, which are also important for neurite outgrowth. 
Genetic screening 
To date LlCAM is the only gene associated with Ll syndromel56•731 . Genetic testing may be used 
to confirm a diagnosis of Ll syndrome and if a mutation is found carrier detection in the family is 
possible. This presents mothers who carry a mutation with the option of having prenatal testing or 
preimplantation genetic diagnosis (PGD). Usually the mother is a carrier, but de nova disease-causing 
mutations have also been reported l74,75l _ In those cases the risk for an affected male offspring is low, 
but still greater than in the general population because of the possibility of germline mosaicism. 
Prenatal analysis can also be offered in such cases. 
Only a few studies report L1CAM mutation frequencies; they show quite different results 
depending on the composition of the target groups. In a group of patients, suspected of having Ll 
syndrome a frequency of 30% was reportedl571, which increased up to 74% if only patients with at 
least two additional cases in the family were selected. The detection rate was 16% in cases with a 
negative family historyl57l _ A Japanese study1521 showed a relatively high mutation frequency of 46%: 
this high rate, might be due to the selection criteria used. From a group of 390 documented Ll 
syndrome patients, they selected 96 patients from 57 families for LlCAM mutation analysis based 
on the following criteria: (1) cases of hydrocephalus with X-linked inheritance and (2) sporadic 
cases with clinical and neuroimaging characteristics of X-linked hydrocephalus. A mutation was 
detected in 26/57 families (46%). 
In order to avoid the expense of DNA diagnostics as much as possible, it would be helpful to know 
the conditions that yield a high chance of actually finding a mutation in the LlCAM gene. 
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Chapter 1 
Aims of this study 
Since the discovery o f  the gene involved in  Ll syndrome in  1992, we have learned much about 
the gene, the protein it encodes and the mutations involved. However several questions/ 
issues remain: 
Can we develop a tool to estimate the chance of finding a mutation based on the 
phenotypic characteristics and the family anamnesis? Several studies have only partly 
addressed this question. 
There is no L1CAM mutation database addressing questions on the pathogenicity of the 
mutations identified. The existing database is incomplete and does not contain relevant 
information on the clinical characteristics and family anamnesis of L1 syndrome patients. 
How can we determine the pathogenicity of non-truncating mutations and can we confirm 
or detect more genotype-phenotype correlations? 
Many patients suspected of having Ll syndrome do not have a mutation in the LlCAM 
gene, this raises the question: might other genes be involved in the Ll syndrome? 
Can we explain rare syndromic patients with L1 syndrome characteristics by mutations in 
the LlCAM gene alone? 
In order to solve these questions/issues, we set the following aims: 
• To design an algorithm based on genotypical, phenotypical and family data that can predict 
the chance of detecting an LlCAM mutation in patients suspected of having L1 syndrome. 
• To determine/confirm potential genotype-phenotype correlations in the Ll syndrome. 
• To set up an easily accessible LlCAM mutation database and include all the disease-causing 
and non-disease-causing mutations, all variants for which it is not known whether they are 
disease-causing (unclassified variants (UVs)), and all relevant patient data. 
• To determine the potential pathogenicity of some UVs due to incorrect RNA splicing by 
using an ex vivo RNA splicing assay. 
• To determine whether the clinical picture caused by mutations in the LlCAM gene is 
broader than generally thought by analyzing rare syndromic cases with L1 syndrome 
characteristics. 
• To try and identify new genes potentially involved in Ll syndrome. 
Outline of this thesis 
Part I of the thesis deals with the mutation analysis in a large group of patients suspected 
of having Ll syndrome and with the gathering of the clinical characteristics and the family 
anamnesis of these patients. We also describe the statistical analysis of the acquired data. 
Chapter 2 summarizes the results of the mutation analyses of the coding exons and exon-intron 
boundaries of the LlCAM gene in 367 referred cases. An extended analysis was performed in a 
selected group of patients by analyzing regulatory sequences and by looking for duplications. 
The mutation detection rate in the whole group as well as in a selected group of patients was 
determined. Combining these results with the clinical data of the patients, revealed ways to 
predict the group of patients in which the chance of detecting a mutation is highest . This 
chapter further outlines potential genotype-phenotype correlations. 
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Introduction 
Chapter 3 describes in detail a case report on an l1 syndrome patient harboring a missense 
mutation and arguments are given for why this missense mutation should be considered 
disease causing. 
Chapter 4 reports the construction and use of an updated and upgraded LlCAM mutation 
database describing all the mutations we found and those reported in the literature, so that 
it is now easy to check whether a mutation is considered to be disease-causing, non-disease­
causing, potentially disease-causing, or unknown. 
Chapter 5 covers the use of an ex vivo RNA splicing assay to demonstrate possibly incorrect 
RNA splicing to determine the pathogenicity of a few unclassified variants. 
Part II of the thesis reports on mutation analysis in two patients with multiple congenital 
aberrations, including Ll syndrome. 
Chapter 6 describes the analysis of a patient with Ll syndrome plus Nephrogenic Diabetes 
Insipid us. 
Chapter 7 covers the analysis of a patient with Ll syndrome plus Hirschsprung's disease and 
describes the influence of an LlCAM mutation on HSCR disease. 
Part I l l  of the thesis deals with the hypothesis that there are additional genes involved in Ll 
syndrome. Since only 20% of the patients clinically suspected of having Ll syndrome carry a 
mutation in the LlCAM gene, other genes are likely to be involved. 
In Chapter 8 a high density X-chromosome-specific array CGH analysis was used to investigate 
whether deletions on the X-chromosome can be found in any of 60 patients suspected of 
having Ll syndrome who had no mutation in the LlCAM gene. These deletions might indicate 
the localization of genes involved in Ll syndrome. A few of these candidate genes were 
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To develop a comprehensive mutation analysis system with a high rate of detection, to develop 
a tool to predict the chance of detecting a mutation in the L1CAM gene, and to look for 
genotype-phenotype correlations in the X-linked recessive disorder, Ll syndrome. 
Methods 
DNA from 367 referred subjects was analyzed for mutations in the coding sequences of the 
gene. A subgroup of 100 patients was also investigated for mutations in regulatory sequences 
and for large duplications. Clinical data for 106 patients were collected and used for statistical 
analysis. 
Results 
68 different mutations were detected in 73 patients. In patients with three or more clinical 
characteristics of Ll syndrome, the mutation detection rate was 66% compared with 16% in 
patients with fewer characteristics. The detection rate was 51% in families with more than 
one affected relative, and 18% in families with one affected male. A combination of these two 
factors resulted in an 85% detection rate (OR 10.4, 95% Cl 3.6 to 30.1). 
The type of mutation affects the severity of Ll syndrome. Children with a truncating mutation 
were more likely to die before the age of 3 than those with a missense mutation (52% vs 8%; 
p=0.02). 
Conclusions 
We developed a comprehensive mutation detection system with a detection rate of almost 
20% in unselected patients and up to 85% in a selected group. Using the patients' clinical 
characteristics and family history, clinicians can accurately predict the chance of finding a 
mutation. A genotype-phenotype correlation was confirmed. The occurrence of (maternal) 
germline mosaicism was proven. 
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Introduction 
Ll syndrome is an X-linked recessive disease caused by mutations in the L1CAM gene. The 
phenotypic spectrum includes X-linked hydrocephalus, also referred to as hydrocephalus 
due to stenosis of the aqueduct of Sylvius (HSAS, MIM 307000), MASA syndrome (mental 
retardation, aphasia, shuffling gait and adducted thumbs; MIM 303350), X-linked complicated 
hereditary spastic paraplegia type 1 (SPGl, MIM 303350) and X-linked complicated corpus 
callosum agenesis (X-linked ACC; MIM 304100} 11•21 • The seriousness of the disease may vary 
from severe hydrocephalus and prenatal death (HSAS subtype) to a mild phenotype (MASA 
syndrome subtype). These variations may even occur in the same family l3Al. 
The L1CAM gene, coding for the neural Ll cell adhesion molecule (Ll), is located on the X 
chromosome. The gene consists of 29 exons, the first exon being non-coding. The protein 
of 1257 amino acids is a transmembrane glycoprotein belonging to the immunoglobulin (lg) 
superfamily cell adhesion molecules151 and contains, besides a signal peptide, 13 distinct 
domains - that is, six lg and five fibronectin Ill-like domains at the extracellular surface, one 
single-pass transmembrane domain and one short cytoplasmic domain. 
To our knowledge, 169 different L1CAM mutations have been published; 130 of these were 
catalogued in 2001111 and an additional 39 were published more recently16-221 • Most L1CAM 
mutations are unique to each family - that is, they appear to be private mutations. Only a few 
families harbor the same recurrent mutation. 
L1CAM mutation analysis is offered to all patients suspected of having Ll syndrome. Once a 
mutation has been established, prenatal testing can be performed in subsequent pregnancies 
and carriership testing can be carried out to determine the potential presence of an L1CAM 
mutation in female relatives. Optimization of the previously reported L1CAM mutation detection 
system1231 has allowed us to investigate 367 L1 syndrome referrals. The analysis resulted in a 
mutation frequency of almost 20%. Although this is a good score, the question remains whether 
this relatively low frequency is due to the inclusion of large numbers of patients who do not 
have Ll syndrome or whether we have missed mutations and should extend our mutation 
screening procedure. To investigate this, we screened additional regulatory sequences of 
the L1CAM gene for mutations and looked for duplications and deletions. Furthermore, we 
evaluated the clinical data of a large set of patients to see if this could help in predicting the 
mutation status. Finally, we analyzed genotype-phenotype correlations with the severity of 
the disease. 
Patients, materials and methods 
Patients 
All patients (n=367), from various parts of the world, analyzed in our laboratory for diagnostic 
L1CAM testing, were included. If no DNA from the index patient was available (n=47), the 
DNA of the mother (n=38) was analyzed or that of a close family member, a sister (n=6) or 
aunt (n=3). Of these patients, 78% were referred by clinical geneticists, 12% by (paediatric) 
neurologists and 10% by paediatricians. 
To allow investigation of the mutation detection rate for specific subsets of patients, all referral 
clinicians were requested to complete a questionnaire. 
27 
Chapter 2 
Exon A l ntron A El  1 1  E2 E3  
t t 
800 bp promoter region H PD NRSE 
Figure 1. S'site of  the LlCAM gene with regulatory regions: promoter, homodomain and paired domain 
binding site (HPD) and neural restrictive silencer element (NRSE). 
El, Exon 1; 11, lntron 1. Exon A is 125 bp. 800 bp of the promoter region were analyzed. 
Mutation analysis using Denaturing Gradient Gel Electrophoresis 
Mutation analysis of the LlCAM gene was performed, using Denaturing Gradient Gel 
Electrophoresis (DGGE) analysis followed by direct sequencing of fragments showing an 
aberrant DGGE pattern, essentially as previously described 123l _  The amplicons 1, 7, 15, 16B, 18, 
21 and 25 are routinely analyzed by direct sequencing using the same primers as developed 
for DGGE, but with an M13 tail instead of the GC-clamp. 
Sequence analysis of regulatory regions 
Analysis of LlCAM regulatory regions - that is, about 1000 bp of the promoter region (including 
the non-coding first exon of the genel24l, called exon A), the neural restrictive silencer element 
(NRSE) and the homeodomain and paired domain binding site (HPD) (figure 1) - was performed 
by direct sequencing of these regions. The NRSE, within intron 1 of the gene, restricts expression 
of Ll to the nervous systemf24l _ The HPD is a positive regulatory element, which induces LlCAM 
gene expression125l . Four primers sets were designed for the promoter region (PromA-PromD), 
one for the HPD region and one for the NRSE region (table 1). PCR was performed in a total 
reaction volume of 50 µI containing 5 µI lOxPCR buffer (Amersham Biosciences, Roosendaal, 
the Netherlands), 0.17 µI rTaq polymerase (SO00U/ml, Amersham Biosciences), 20 pmol of 
each primer (Eurogentec, Serian, Belgium), 10 pmol dNTPs (Amersham Pharmacia Biotech, 
Piscataway, New York) and 100 ng DNA. In addition, 5 µI dimethyl sulphoxide was added for 
two PCRs (PromA and PromB) . For fragments PromC and Promo, the PCRx Enhancer System 
(lnvitrogen Life Technologies, Breda, the Netherlands) was used with a final PCRx Enhancer 
Solution Concentration of 3x. A standard cycling protocol of 35 cycles was used with different 
annealing temperatures for each fragment (table 1) . The PCR products were analyzed on a 2% 
agarose gel; the remainder were purified with ExoSAP-IT (Amersham Pharmacia Biotech) and 
subjected to direct sequencing using the M13 primers. 
Multiplex ligation-dependent probe amplification (MLPA} analysis 
MLPA was performed using DNA from 98 individuals (75 males and 23 females randomly chosen 
from the cohort of 295 subjects not harboring a mutation in the LlCAM gene). These were 
randomly chosen because we started this analysis before we had evaluated the clinical data. 
Probes for each exon were designed in our laboratory using the 'Designing synthetic MLPA probes' 
protocol (SOP-CUS-DE0l VS) from MRC-Holland. Twenty-four sets were judged to be suitable for 
use after testing and were divided over five mixes, each mix containing three control probes from 
the X chromosome. MLPA was carried out using the standard protocol from MRC-Holland (MLPA 
DNA Detection/Quantification protocol V27). All probe sequences are available upon request. 
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Table 1. Primer sets regulatory regions 
Primer Sequence (5'>3') 
Length Product size AT 
(bp) (bp) (
°C) 
PromA_F CGCCTGTGAGGTCATGGCClTG 22 357 53 
PromA_R GCCCAGTCAGGGTCCTGTTG 20 53 
PromB_F CCCAACACGCTGAGGACGAA 20 291 61.2 
PromB_R CAAGGGAGCCCGCTGTGAAA 20 61.2 
PromC_F AGGCCGAGGCTAAGGGAGCAT 21 345 49.4 
PromC_R GGAGAGGGAGGGAGGAGTGAGAT 23 49.4 
PromD_F TGGCACCAGGGGCTAGGGT 19 318 57 
PromD_R GGCAGAGCGGTGTGGTGTC 19 57 
HPD_F GGCCCTTTCCCCATTCTTTCTT 22 237 53 
HPD_R CTGTGGGGATGAATCCCTGTAT 22 53 
NRSE_F GCGCCTACClTCGCCGCTAT 20 331 50.9 
NRSE_R GGATGGAAGCGGAGGAGTCG 20 50.9 
All primers are designed with an M13 tail: (f)CGACGTTGTAAAACGACGGCCAGT and (r)CAGGAAACAGCTATGAC. 
AT, annealing temperature; HPD, homeodomain and paired domain binding site; NRSE, neural restrictive silencer 
element; Prom, promoter. 
cDNA analysis of a potential RNA splicing mutation 
Total RNA was extracted from peripheral blood, using the RNABee procedure (Cinna Biotecx, 
Friendswood, Texas, USA) and cDNA was obtained using the Ready-To-Go You-Prime First­
Stand Beads for reverse transcription PCR with random hexamers primers pd(N)6 (Amersham 
Biosciences). Primers amplifying a product from exons 5 to 8 (f)CCAAGTGGCCAAAGGAGACAG 
and (r)ACTGCCCAGTGAGTTCTCG were used to characterize the cDNA sequence around 
the c.645C> T mutation in exon 6. The primers (f)CCAAGTGGCCAAAGGAGACAG and (r) 
TGATGGTGGGCGTGGGAAAG were used to verify the results obtained. The PCR products were 
loaded on to a 2% agarose gel, purified with ExoSAP-IT (Amersham Pharmacia Biotech) and 
subjected to direct sequencing using the primers described to confirm the presence of an 
aberrant transcript. 
Statistical analysis 
A study was carried out to determine whether, and in what way, the mutation detection rate 
was influenced by (a) the number of age-independent clinical characteristics (table 2), (b) the 
number of affected relatives and (c) a combination of these factors. 
An analysis was also performed to detect any possible genotype-phenotype correlation, notably 
between the severity of the disease and truncating or missense mutations. The disease was 
defined as severe if a child died before the age of 3. 
For the statistical analysis, the x2 test was carried out, except in cases of small numbers when 
the Fisher exact test was used. A logistic regression analysis was performed to calculate the 
odds ratio (OR). 
The likely disease-causing mutations in these analyses are considered to be disease-causing. 
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Table 2. Characteristics of patients (n = 338) 
Selected group Remnant group 
(n = 106) (n = 232) 
Characteristics n % n % 
> 1 affected relatives 35 33 60 26 
Died at young age 29 27 63 27 
Age-independent characteristics 
Hydrocephalus 91 86 133 57 
Aqueduct stenosis 46 43 15 6 
Adducted thumbs 46 43 51 22 
ACC/DCC 24 23 27 12 
Age-dependent characteristios 
Mental retardation 56 53 46 20 
Aphasia 37 35 10 4 
Spastic paraplegia 36 34 49 21 
No clinical data available 0 0 53 23 
Characteristics of the total group of 367 patients minus the 29 patients tested for Ll syndrome exclusion. 
ACC/DCC, agenesis/dysgenesis of the corpus callosum. 
Results 
Mutation analysis by DGGE 
In total, 367 subjects - that is, 320 index patients and 47 relatives, in most cases the mother 
- were analyzed for the presence of a mutation in the L1CAM gene. With this technique a 
mutation was detected in 72 of the 367 subjects (tables 3 and 4). Sixty-seven different 
mutations were found: three mutations were detected in two families and one mutation in 
three different families. Fifty-two mutations have not been published before. Five mutations 
have previously been reported in co-operation with us !9,10•18•19•261 and 10 mutations were also 
found by others I2, 27-341 (table 3). The disease-causing relevance of seven of the 67 mutations 
remained unclear (table 4). In addition to the 67 mutations, we also detected six variants that 
were probably not disease-causing (table 5). None of the variants in tables 4 and 5 match 
known singlenucleotide polymorphisms (SNPs). 
Sequence analysis of the regulatory regions and MLPA analysis 
We extended our sequence analysis to the L1CAM promoter and the HPD and NRSE regions 
and performed an MLPA analysis to determine whether additional mutations were present in 
the regulatory sequences of the gene, or whether deletions or insertions could partly explain 
why the remaining 80% of patients did not have a detectable coding sequence mutation. 
No mutation was detected in the promoter region, the non-coding sequence of the first exon, 
the HPD region or the NRSE site in 100 of the 295 subjects (randomly chosen) of our cohort not 
harboring a mutation in the LlCAM gene. The regulatory sequences of the other 195 subjects 
have not been analyzed. 
MLPA analysis identified one subject with a duplication from exons 2-10. So, in total, a mutation 
was detected in 73 of the 367 subjects. 
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M p Contr G Bl 
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Figure 2. (A) cDNA analysis of patient 329. Agarose gel electrophoresis of cDNA exon 6 of the patient (P} and 
a control sample (Contr). Wild-type exon 6 is 418bp long. G, genomic; Bl, blank; M, marker. (B) Sequence 
analysis of cDNA exon 6 of patient 329. WT, wild-type; MT, mutant. 
RNA splicing mutation and germline mosaicism 
Reverse transcription PCR was carried out to determine a possible splice effect of the silent 
mutation c.645C> T. Figure 2 clearly shows that this mutation influences RNA splicing .  Sequence 
data confirm that a new splice donor site is introduced in exon 6, causing a deletion of 51 bp 
at the 3' site of the exon (figure 2) . 
I n  this case, a maternal germline mosaicism was also demonstrated; the mother did not carry 
the mutation, but a second male fetus did . 
Patients 
The questionnaire, covering the family anamnesis and the seven most important clinical 
parameters of Ll syndrome, was filled out for 135 of the 367 patients. Twenty-nine of these 
135 patients were referred in order to exclude the disease . Statistical evaluation was therefore 
carried out on 106 patients, 31 of whom carried a mutation .  The most important clinical data 
have been summarized in table 2. Known data for the remaining 232 patients have also been 
included in this table . It is clear that this group is less well characterized. Table 3 contains 
clinical data for patients harboring an L1CAM mutation .  As many patients die before birth or at 
a very young age, a distinction is made in characteristics that can be observed at birth or post 
mortem and those that can be observed only in later stages of life (table 2) . 
We also looked at the co-occurrence of a hydrocephalus (ventriculomegaly) and a macrocephaly 
(head circumference of > 2SD) . In the selected group, out of 91 patients with hydrocephalus, 
36 also had a macrocephaly, 25 of which needed shunting . 
In the event of a positive family history, there is always compatibility with X-linked recessive 
inheritance. However, in a few families comprising only a limited number of affected family 
members, a utosomal recessive inheritance cannot be excluded. 
Statistical analysis 
The clinical data from 106 patients, obtained via the questionnaire were used for statistical 
analysis as summarized in table 6. It can be seen that patients with three or more age­
independent clinical Ll syndrome characteristics had a significantly higher percentage of 
mutations (66%) than patients with fewer than three characteristics (16%) . This is also true for 
families with more than one affected family member, 51% vs 18% for families with only one 
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Table 3. Disease-causing mutations in the LlCAM gene 
w --
1� Ii 9 N # affected I :I 
a 
Family Exon/ 'I Nucleotide change i Consequence Clinical data family Remarks Ref. ril" ID lntron I! � j_ members I\.J •! _J� __ __J ___ ��- - ---� 
312 c.2T>C exon 1 p.Metl? Unknown 1 
145 c.76+1G>A intron 1 RNA splicing defect HC, AT, HP 2 
152 c.78T>A exon 2 p.Tyr26X HC, AT 1 
248 c.92-2A>G intron 2 RNA splicing defect HC, ? 3 
292 c. 110T>A exon 3 p. l le37Asn HC, ? 4 
106 c.196C>T** exon 3 p.Gln66X HC, AT, MR, ACC, SP, HP 2 10 
14 c.198-2A>T* intron 3 RNA splicing defect HC,? 3 32 
251 c.325C>T exon 4 p.Gln109X HC, AT, MR, ACC 1 
63 c.397G>T exon 4 p.Glu133X HC,? 1 de nova by mother 
294 c.400+5G>C intron 4 RNA splicing defect HC, AT 1 
196 c.414G>A exon 5 p.Trp138X HC, ? 1 
89 c.536T>G* exon 6 .I  p. l le179 Ser HC, SP >1  31 
56 c.550C>G exon 6 p.Arg184Gly HC, AT, MR, Aph, SP, HP 10 
235 c.551G>A* exon 6 I p.Arg184Gln HC? 1 30 
52 c.559_594del36 exon 6 p.Met187 _ Val198del unknown 1 
169 c.588_595del8 exon 6 p.Asn197SerfsX37 HC, AT, MR, Aph 5 de nova by mother 
27 c.604G>T** exon 6 p.Asp202Tyr HC, AT, MR, ACC, Aph, SP 1 26 
329 c.645C>T exon 6 p.= Splice defect: 51 bp deleted HC, AT 2 mosaicism by mother 
164 c.761C>A exon 7 p.Ala254Asp HC, ? 4 
3 C. 778 _ 785del8 exon7 p.Leu260GlyfsX45 HC, AT, MR, Aph, SP 2 
348 c.826T>C exon 8 p.Trp276Arg HC, AT 1 de nova by mother 
35 c.938T>C exon 8 p.Leu313Pro HC, AT, ACC 1 de nova 
66 c.991+1G>A intron 8 RNA splicing defect HC, AT, ? 2 
163 c.991+2T>C* intron 8 RNA splicing defect HC, ? 2 de nova by mother 32 
187 c. 1003T>C* exon 9 p.Trp335Arg unknown 1 34 
182 c.1097G>A exon 9 p.Trp366X HC, DCC 2 de nova by mother 
184 c.1107C>A exon 9 p.Asn369Lys HC, MR, Aph, DCC, SP, HP 3 
91 c .1243G>C** exon 10 p.Ala415Pro HC, AT, MR, Aph, ACC, SP 4 9 
29 c.1267C>T* exon 10 p.Gln423X HC 3 32 
305 c.1267+1G>A* intron 10 RNA splicing defect HC, AT, MR, Aph, ACC, SP 1 27 
342 c .1268-lG>A intron 10 RNA splicing defect HC, AT, ? 1 
36 c.1438G>A exon 12 p.Gly480Arg HC, ? 2 
108 c.1546+2T>A intron 12 RNA splicing defect HC, AT, MR, SP 3 
w 
w 
Family I Nucleotide I! Exon/ 1 ; I ID I change lntron 11 Consequence - ·- - --- -
222 c.1547-2A>T intron 12 RNA spl icing defect 
208 c.1933A>T exon 15 p.lle645Phe 
12 c.1939+1G>A intron 15 RNA splicing defect 
149 c.1940-lG>A intron 15 RNA splicing defect 
92 c.1986G>A exon 16 p.Trp662X 
23 c.2140C>T exon 17 p.Pro714Ser 
254 c.2215delC exon 18 p.Arg739GlyfsX112 
80, 
156, c.2254G>A* exon 18 p.Val752Met 
336 
275 c.2260T>A exon 18 p.Trp754Arg 
368 c.2267de1C** exon18 p.Pro7561eufs95X 
227 c.2278C>T exon 18 p.Arg760X 
181 c.2344_2364dup exon 18 p.Val782_ Val788dup 
252 c.2365C>T exon 18 p.Gln789X 
116 c.2433C>G exon 19 p.Tyr811X 
360 c.2673C>A exon 20 p.Tyr891X 
134 c.2701C>T* exon 20 p.Arg901X 
24, 
c.2885dupG exon 22 p.Lys963GlnfsX41 
60 
295 c.2919delC exon 22 p.Glu974AsnfsX7 
74 c.2934_2935delCA exon 22 p.His978GlnfsX25 
325 c.3166+2T>A intron 23 RNA splicing defect 
266 c.3191C>A exon 24 p.Ser1064X 
119 c.3211_3213delAAC exon 24 " p .Asn 1071del 
162 c.3239T>A exon 24 p.Leu1080Gln 
331 c.3531-lG>A intron 26 RNA splicing defect 
62, c.3531-12G>A* 
intron 26 RNA splicing defect 
126 
229 c.3772dupT exon 28 p.Xl257LeufsX96 
178 c.(?_77)_(1267+ _?)dup exons 2-10 duplication 
146 c.(7 _-145)_(*731_ ?}del** deletion entire gene 
* Previously found by other groups. 
** Previously published with our co-operation. 
# affectea 
I• Clinical data family 
�J.._ ��- members 
HC, AT, ? 3 
unknown 1 
HC, ? 1 
HC 3 
HC, ? 2 
HC, MR, Aph, ACC, SP 1 
HC, AT, HP 1 
1. HC,AT,MR,Aph,ACC,SP,HP 7 
--- --
2. HC,? 
3. HC, ? 
HC, ? 
HC, AT, MR, SP, HSCR 
HC, AT, MR, Aph, SP 
AT, MR, SP 
HC, AT, ? 
HC, 7 
HC, AT, MR, Aph, ACC, SP 
HC, AT 
1. HC, AT, DCC 
2 .  HC, ? 
unknown 
HC, AT, ? 
HC 
HC, AT, MR, SP, HP 
HC, ? 
HC, AT, MR, SP 
HC, ? 
1.HC, AT, ? 
2 . AT, M R  
MR, ACC, SP 
HC, AT, MR 



























de novo by mother 
de novo 
de novo by mother 







HC, hydrocephalus; AT, adducted thumbs; MR, mental retardation; SP, spastic paraplegia; Aph, aphasia; ACC/DCC, agenesis/dysgeneis of the corpus callosum; HP, hypotonia; 





























Consequence lr Clinical data 
61, 
c.76+5G>A intron 1 ? 
1.HC, ? 
148 2.HC, ? 
366 c.516G>A exon 5 p.Met172lle H C, M R, SP  
245 
[c.523+9_523+10CG>GA; 
intron 5 ? HC, AT, MR, SP 
c.523+ 12delC] 
HC, AT, M R, Aph, 
200 c.1546G>A exon 12 p.Asp516Asn 
SP, H P  
302 c.1546G>T exon 12 p.Asp516Tyr unknown 
95 c.1574G>A exon 13 p.Arg525H is SP  
320 c.1880C>T exon 15 p.Thr627Met HC, ? 





Consequence Clinical data 
ID intron 
54 c.39C>A Exon 1 p.= HC 
34 c.113C>T Exon 3 p.Thr38Met 
HC, AT, M R, 
Aph, SP 
30 c.523+6T>G lntron 5 None HC, AT, M R  
153 c.992-32C> T intron 8 ? unknown 
174 c.1977T>C Exon 16 p.= AT, MR, Aph, SP 
136, l.AT, M R, SP 
137, c.3458-34C> T lntron 25 None 2 .HC 
144 3. HC, AT, M R  
Remarks; 
1. Also found in an other patient with a nonsense mutation 
2. No influence on RNA splicing 






























affected family member. A combination of these two characteristics - that is, patients with 
a positive family history for Ll syndrome and having three or more clinical characteristics -
resulted in a detection rate of 85%. 
The OR of finding a mutation in patients with three or more clinical characteristics was 10.1  
(95% confidence interval (Cl) 3.8 to  27. 1). This increased slightly to  10.4 {95% Cl 3.6 to  30. 1) 
when these patients also had two or more affected family members. 
Applying the same calculations to the whole group of 338 patients (367 minus the 29 who 
were only been analyzed to exclude the presence of Ll syndrome), some lacking relevant 
clinical information (table 2), the mutation detection rate was 18% in patients with fewer than 
three characteristics. In patients with three or more characteristics, but no affected relatives, 
this rate increased to 58%, with an OR of 6. 1 {95% Cl 3.0 to12.7). In the group of patients with 
three or more clinical characteristics and a positive family history, the detection rate increased 
to 79%, with an OR of 8. 1 {95% Cl 3.5 tol8.6} as compared with 85% in the selected group. 
These results are logical, as the second group was less well defined (unselected) and therefore 
showed a lower detection rate, but larger and therefore showed a smaller Cl. 
Interrelationships, as mentioned above, can be seen when the data of the whole group are 
used (figure 3). The chance of having a mutation increased when patients have more clinical 
characteristics, and even more when at least two family members were affected. 
We also determined the positive predictive value of the individual clinical characteristics in 
34 
Table 6. Mutation detection rate 
No of age independent clinical characteristics 
< 3  
� 3  
p<0.001 
No of affected family members 
1 
� 2  
p<0.001 
<3 age independent clinical characteristics 




� 3 age independent clinical characteristics 
No of affected family members 
1 




















/ .. , 
,· , 
-·· , 
, ·  -
- _ __ __ ... -. . ---












.• _,.._ 2 or more 
affected family 
members 




























and number of 
affected family 
members. 
Number of clinical characteristics 
relation to the presence of a mutation (table 7), showing the most predictive to be adducted 
thumbs (50%) and the least predictive to be mental retardation (32%). 
Genotype-phenotype correlation 
A statistical analysis was performed on 33 patients who were carrying a mutation to detect 
any possible genotype-phenotype correlation. Children harboring a truncating mutation were 
more likely to die before the age of 3 (52%) than children with a missense mutation (8%) .  This 
indicates a relationship between the seriousness of the disease and the type of mutation. 
These results are statistically significant (Fisher exact p=0.02) (table 8). 
No significant difference was detected in the occurrence of one of the other c l inical 
characteristics (including macrocephaly) comparing patients carrying a missense mutation 
with patients carrying a truncating mutation (table 9). 
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Table 7. Frequency of the clinical characteristics in a group of patients carrying a mutation compared with a 
group without a mutation in the LlCAM gene and the positive predictive value 
Clinical Mutation negative Mutation positive 
characteristic Presence of the clinical Presence of the clinical Positive 
characteristic characteristic 
Yes No Yes No 
n % n % n % n % 
Hydrocephalus 61 86 10 14 30 100 0 0 
Aqueduct stenosis 28 68 13 32 18 78 s 22 
ACC/DCC 14 45 17 55 10 91 1 9 
Mental retardation 38 73 14 27 18 100 0 0 
Aphasia 23 58 17 42 14 93 1 7 
Adducted thumbs 23 37 40 63 23 85 4 15 
Spastic paraplegia 20 45 24 55 16 84 3 16 
Patients are taken from the selected group. 
"Fisher exact test. 
· ·statistical significant. 
ACC/DCC, agenesis/dysgeneis of the corpus callosum. 
Table 8. Genotype-phenotype correlation 
Died before the age of 3 
No 
M issense mutation 
N umber 11 
% 92 
Truncating mutation 
N umber 10 
% 48 
p=0.02 truncating mutation compared with missense mutation 




0.01 * *  
0.01 * *  
0.01 * *  


















clinical characteristic clinical characteristic 1 
Missense mutation -
-





Presence of the 
J 










--= N� p" 
n % n % n % n % 
Hydrocephalus 10 100 0 0 20 100 0 0 
Macrocephaly 6 60 4 40 9 69 4 31 0.69 . .  
Aqueduct stenosis s 56 4 44 13 93 1 7 0.12 .. 
ACC/DCC 6 100 0 0 4 80 1 20 0.46 . • 
Mental retardation 8 100 0 0 10 100 0 0 
Aphasia 7 78 2 22 7 100 0 0 0.48 .. 
Adducted thumbs 8 73 3 27 15 88 2 12 0.35•• 
Spastic paraplegia 8 89 1 11 8 73 3 27 0.59 .. 
* Fisher exact test 
** Statistical not significant 
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Discussion 
Mutation analysis was carried out on 367 referred cases (that is 320 index patients and 47 
relatives). Seventy-two patients were shown to harbor 67 different mutations. One additional 
mutation was found with the MLPA test, making a total of 73 patients with a disease­
causing mutation. The mutations comprise 23 missense mutations, three in-frame deletions/ 
duplications, 18 splice site mutations, 14 nonsense mutations, eight frame-shift mutations, 
one duplication of exons 2-10, and one deletion of the entire gene. This implies that about 
60% of all mutations are truncating and therefore considered to be disease-causing. This 
is less straightforward for the 23 missense mutations. However, the identified missense 
mutations are mostly considered to be disease-causing, as they often occur in the so-called 
key residues1351 that are important for the structure of the lg domains and the fibronectin 
Ill-like domains of Ll protein. Basically, these conclusions relate to the findings of Holden et 
a/.1361, who determined the three-dimensional structure of telokin, a protein with a specific 
domain similar to the Ll lg domain containing 35 key residues responsible for its structure. The 
structure of the fibronectin lll-like3 domain and its key residues can likewise be derived from 
similarities to those of neuroglian 1371 • Other criteria are whether or not the mutation affects a 
highly conserved amino acid, is de nova in the index patient, or is only found in affected males 
and not in unaffected male family members. 
Fifteen of the 23 ("'65%) disease-causing missense mutations were found to be related to key 
residues, which is comparable to data reported by Michaelis et a/.1381 who detected 52 out of 
78 ("'67%). In contrast with the findings of Michaelis et al . and those of Kamiguchi et a/. 1391, we 
found no difference in the severity of the hydrocephalus in patients with a missense mutation 
in key residues versus surface residues 1351 • In our group changes in a key residue led to severe 
hydrocephalus in 57% of the patients and surface changes in 50% of the patients, compared 
with 67% and 42%, respectively, found by Michaelis et a/. 1381 and 78% and 28% determined by 
Kamiguchi et a/. 1391, indicating no correlation between the severity of the hydrocephalus and 
the location of the missense mutation in either the key residues or the surface residues. 
In five of the 73 patients carrying a mutation ("'7%), the mutation was shown to be de nova or 
a maternal germ cell mosaicism. The latter was confirmed in one case (c.645C>T), as a second 
male fetus was found to have the same mutation. Germline mosaicism of L1CAM mutations 
had previously been reported127• 401 • Du et a/.1271 described an unaffected male with a somatic 
and germline mosaicism of an L1CAM mutation and his two daughters carrying the mutation. 
The mutation c.645C> T proved to be a special silent mutation that influences the RNA splicing 
process: a splice donor site arises within exon 6 of the gene. As a consequence, 51 bp or 17 
amino acids are deleted. These deleted amino acids are important for the structure of the lg2 
domain and therefore this mutation is considered to be disease-causing. 
When no DNA material is available from the index patient the diagnosis has to be carried out on 
a close relative, usually the mother. In this study, this was the case in 38 of the 367 patients. In 
25 of these 38 mothers, no mutation was detected. Testing the mother has problems because 
we have shown that 7% of the mutations detected are de nova or a germline mosaicism. 
Another striking finding is the very high ("'10%) occurrence of de nova mutations in mothers or 
a germ cell mosaicism in one of the grandparents of index patients. This and the 7% de nova 
mutations in the index patients means that at least one-fifth of L1 syndrome families have 
evolved rather recently. 
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As a mutation in the UCAM-encoding DNA sequence was found in 20% of referred cases, 
the mutation analysis was broadened by analyzing 100 patients for potential mutations in 
the regulatory sequences of the LlCAM gene. This generated no extra mutations, leading to 
a potential detection rate in these regions of less than 1%. Screening for mutations in the 3' 
region was not performed because of this finding and also because too little is known about 
the function of specific sequences of this region. An MLPA test was used to investigate the 
same 100 patients for large duplications in the L1CAM gene. Only one duplication, exons 2-10, 
was detected, suggesting a very low prevalence of this type of mutation. The same seems 
to be true for large deletions, since, in 73 mutation-carrying patients, only one showed a 
deletion of the entire gene1181 , which is in accordance with previously published results. To 
date, 169 different L1CAM mutations have been published: 164 small point mutations and 
five large deletions or duplications including one deletion of the entire gene1181, one deletion 
of the promoter region and exon 11171, one deletion of 2 kb at the distal part of the gene 
c.3543_?del2kb1411, one deletion of exons 2-5 and part of exon 61161 and one duplication of 
1.3kb c.3543_?dup1.3kb1421 • From these results, it can be concluded that broadening the DNA­
screening procedure to include regulatory sequences analysis is not worthwhile. Screening for 
deletions and duplications may be beneficial, especially in clear clinical cases, although this 
does not seem to greatly influence the detection rate. 
In contrast with this, the combination of clinical data and the number of affected relatives, 
obtained via a questionnaire, shows a clear correlation with the mutation detection rate 
as shown in figure 3. Our findings are therefore of importance for clinicians and genetic 
counselors, since they may be used to predict the chance of finding a mutation. Besides, the 
positive predictive value showing adducted thumbs to be the most predictive may also be 
quite useful. 
Finally, it should be noted that a genotype-phenotype correlation has been identified for the 
LlCAM gene and its associated syndrome in our group of patients. As previously reported143A4l 
we also found that children with a truncating mutation were more likely to die before the age 
of 3, than children with a missense mutation. This illustrates that the type of mutation has an 
important effect on the severity of the Ll syndrome. 
Conclusions 
Our study shows that the mutation detection system is efficient for detecting mutations. 
Using this system, we have clearly shown a correlation between the number of clinical 
characteristics, the number of affected family members and the chance of finding a mutation. 
Moreover, we found a genotype-phenotype correlation for L1 syndrome. This study provides a 
comprehensive tool for genetic counseling. 
Acknowledgements 
We thank all clinicians for filling out the questionnaires and sending us materials for DNA 
analysis (notably Gert Matthijs), Annet Vrieling-Kooistra for technical assistance, and Margaret 
Burton for editing the manuscript. 
38 
A guide for genetic counseling and mutation analysis 
References 
(1) Weller S, Gartner J. Genetic and clinical aspects of X-linked hydrocephalus (Ll disease): Mutations in 
the LlCAM gene. Hum Mutat 2001;18(1):1-12. 
(2) Fransen E, Van CG, Vits L, Willems PJ. Ll-associated diseases: clinical geneticists divide, molecular 
geneticists unite. Hum Mal Genet 1997;6(10):1625-32. 
(3) Schrander-Stumpel C, Legius E, Fryns JP, Cassiman JJ. MASA syndrome: new clinical features and 
linkage analysis using DNA probes. J Med Genet 1990 Nov;27(11):688-92. 
(4) Fryns J P, Spaepen A, Cassiman JJ, van den Berghe H. X linked complicated spastic paraplegia, MASA 
syndrome, and X linked hydrocephalus owing to congenital stenos is of the aqueduct of Sylvius: variable 
expression of the same mutation at Xq28. J Med Genet 1991 Jun;28(6):429-31. 
(5) Moos M, Tacke R, Scherer H, Teplow D, Fruh K, Schachner M. Neural adhesion molecule Ll as a 
member of the immunoglobulin superfamily with binding domains similar to fibronectin. Nature 1988 
Aug 25;334(6184):701-3. 
(6) De Angelis E, Watkins A, Schafer M, Brummendorf T, Kenwrick S. Disease-associated mutations in Ll 
CAM interfere with ligand interactions and cell-surface expression. Hum Mal Genet 2002 Jan 1;11(1):1-
12. 
(7) Simonati A, Boaretto F, Vettori A, Dabrilli P, Criscuolo L, Rizzuto N, Mostacciuolo ML. A novel missense 
mutation in the LlCAM gene in a boy with Ll disease. Neural Sci 2006 Jun;27(2):114-7. 
(8) Senat MV, Bernard J P, Delezoide A, Saugier-Veber P, Hillian Y, Roume J, Ville Y. Prenatal diagnosis of 
hydrocephalus-stenosis of the aqueduct of Sylvius by ultrasound in the first trimester of pregnancy. 
Report of two cases. Prenat Diagn 2001 Dec;21(13):1129-32. 
(9) Sztriha L, Vos YJ, Verlind E, Johansen J, Berg B. X-linked hydrocephalus: a novel missense mutation in 
the LlCAM gene. Pediatr Neurol 2002 Oct;27(4):293-6. 
( 10) Rodriguez CG, Perez AA, Martinez F, Vos YJ, Verlind E, Gonzalez-Meneses LA, Gomez de TS, I, Schrander-Stumpel 
C. X-linked hydrocephalus: another two families with an Ll mutation. Genet Couns 2003;14(1):57-65. 
(11) Silan F, Ozdemir I, Lissens W. A novel LlCAM mutation with Ll spectrum disorders. Prenat Diagn 2005 
Jan;25(1):57-9. 
(12) Bott L, Baute 0, Mention K, Vinchon M, Boman F, Gottrand F. Congenital idiopathic intestinal pseudo­
obstruction and hydrocephalus with stenosis of the aqueduct of sylvius. Am J Med Genet A 2004 Sep 
15;130(1):84-7. 
(13) Okamoto N, Del MR, Valero R, Monros E, Pao P, Kanemura Y, Yamasaki M. Hydrocephalus and 
Hirschsprung's disease with a mutation of LlCAM. J Hum Genet 2004;49(6):334-7. 
(14) Hubner CA, Utermann B, Tinschert S, Kruger G, Ressler B, Steglich C, Schinzel A, Gal A. lntronic 
mutations in the LlCAM gene may cause X-linked hydrocephalus by aberrant splicing. Hum Mutat 
2004 May;23(5):526. 
(15) Moya GE, Michaelis RC, Holloway LW, Sanchez JM. Prenatal diagnosis of Ll cell adhesion molecule 
mutations. Capabilities and limitations. Fetal Diagn Ther 2002 Mar;17(2):115-9. 
(16) Panayi M, Gokhale D, Mansour S, Elles R. Prenatal diagnosis in a family with X-linked hydrocephalus. 
Prenat Diagn 2005 Oct;25(10):930-3. 
(17) Tegay DH, Lane AH, Roohi J, Hatchwell E. Contiguous gene deletion involving LlCAM and AVPR2 causes 
X-linked hydrocephalus with nephrogenic diabetes insipidus. Am J Med Genet A 2007 Mar 15;143(6):594-8. 
(18) Knops NB, Bos KK, Kerstjens M, van Dael K, Vos YJ. Nephrogenic diabetes insipid us in a patient with L1 
syndrome: a new report of a contiguous gene deletion syndrome including LlCAM and AVPR2. Am J 
Med Genet A 2008 Jul 15;146A(14):1853-8. 
(19) Griseri P, Vos Y, Giorda R, Gimelli S, Beri S, Santamaria G, Mognato G, Hofstra RM, Gimelli G, Ceccherini I. 
Complex pathogenesis of Hirschsprung's disease in a patient with hydrocephalus, vesico-ureteral reflux 
and a balanced translocation t(3;17)(p12;q11). Eur J Hum Genet 2009 Apr;17(4):483-90. 
(20) Nakakimura S, Sasaki F, Okada T, Arisue A, Cho K, Yoshino M, Kanemura Y, Yamasaki M, Toda S. 
Hirschsprung's disease, acrocallosal syndrome, and congenital hydrocephalus: report of 2 patients and 
literature review. J Pediatr Surg 2008 May;43(5):E13-E17. 
(21) Wilson PL, Kartman BB, Mulvihill JJ, Li S, Wilkins J, Wagner AF, Goodman JR .  Prenatal identification of 
a novel R937P LlCAM missense mutation. Genet Test Mal Biomarkers 2009 Aug;13(4):515-9. 
(22) Kanemura Y, Okamoto N, Sakamoto H, Shofuda T, Kamiguchi H, Yamasaki M. Molecular mechanisms 
39 
Chapter 2 
and neuroimaging criteria for severe Ll syndrome with X-linked hydrocephalus. J Neurosurg 2006 
Nov;105(5 Suppl):403-12. 
(23) Hofstra RM, Elfferich P, Osinga J, Verlind E, Fransen E, Lopez Pison J, Die-Smulders CE, Stolte-Dijkstra I, 
Buys CH. Hirschsprung disease and LlCAM: is the disturbed sex ratio caused by LlCAM mutations? J 
Med Genet 2002 Mar;39(3):Ell. 
(24) Kallunki P, Edelman GM, Jones FS. Tissue-specific expression of the Ll cell adhesion molecule is 
modulated by the neural restrictive silencer element. J Cell Biol 1997 Sep 22;138(6):1343-54. 
(25) Meech R, Kallunki P, Edelman GM, Jones FS. A binding site for homeodomain and Pax proteins is 
necessary for Ll cell adhesion molecule gene expression by Pax-6 and bone morphogenetic proteins. 
Proc Natl Acad Sci U S  A 1999 Mar 2;96(5):2420-5. 
(26) Sztriha L, Frossard P, Hofstra RM, Verlind E, Nork M. Novel missense mutation in the Ll gene in a child 
with corpus callosum agenesis, retardation, adducted thumbs, spastic paraparesis, and hydrocephalus. 
J Child Neural 2000 Apr;15(4):239-43. 
(27) Du JS, Bason L, Woffendin H, Zackai E, Kenwrick S. Somatic and germ line mosaicism and mutation origin for a 
mutation in the Ll gene in a family with X-linked hydrocephalus. Am J Med Genet 1998 Jan 13;75(2):200-2. 
(28) Gu SM, Orth U, Zankl M, Schroder J, Gal A. Molecular analysis of the LlCAM gene in patients with 
X-linked hydrocephalus demonstrates eight novel mutations and suggests non-allelic heterogeneity of 
the trait. Am J Med Genet 1997 Aug 22;71(3):336-40. 
(29) Jouet M, Mancia A, Paterson J, McKeown C, Fryer A, Carpenter N, Holmberg E, Wadelius C, Kenwrick 
S. New domains of neural cell-adhesion molecule Ll implicated in X-linked hydrocephalus and MASA 
syndrome. Am J Hum Genet 1995 Jun;56(6):1304-14. 
(30) MacFarlane J R, Du JS, Pepys ME, Ramsden S, Donnai D, Charlton R, Garrett C, Tolmie J, Yates JR, Berry 
C, Goudie D, Mancia A, Lunt P, Hodgson S, Jouet M, Kenwrick S. Nine novel Ll CAM mutations in 
families with X-linked hydrocephalus. Hum Mutat 1997;9(6):512-8. 
(31) Ruiz JC, Cuppens H, Legius E, Fryns JP, Glover T, Marynen P, Cassiman JJ. Mutations in Ll-CAM in two families 
with X linked complicated spastic paraplegia, MASA syndrome, and HSAS. J Med Genet 1995 Jul;32(7):549-52. 
(32) Finckh U, Schroder J, Ressler B, Veske A, Gal A. Spectrum and detection rate of LlCAM mutations in 
isolated and familial cases with clinically suspected Ll-disease. Am J Med Genet 2000 May 1;92(1):40-6. 
(33) Fransen E, Vits L, Van CG, Willems PJ. The clinical spectrum of mutations in Ll, a neuronal cell adhesion 
molecule. Am J Med Genet 1996 Jul 12;64(1):73-7. 
(34) Saugier-Veber P, Martin C, Le Meur N, Lyonnet S, Munnich A, David A, Henocq A, Heron D, Jonveaux P, 
Odent S, Manouvrier S, Monda A, Morichon N, Philip N, Satge D, Tosi M, Frebourg T. Identification of 
novel LlCAM mutations using fluorescence-assisted mismatch analysis. Hum Mutat 1998;12(4):259-66. 
(35) Bateman A, Jou et M, MacFarlane J, Du JS, Kenwrick S, Chothia C. Outline structure of the human L1 
cell adhesion molecule and the sites where mutations cause neurological disorders. EMBO J 1996 Nov 
15;15(22) :6050-9. 
(36) Holden HM, Ito M, Hartshorne DJ, Rayment I. X-ray structure determination of telokin, the (-terminal 
domain of myosin light chain kinase, at 2.8 A resolution. J Mal Biol 1992 Oct 5;227(3):840-51. 
(37) Huber AH, Wang YM, Bieber AJ, Bjorkman PJ . Crystal structure of tandem type I ll fibronectin domains 
from Drosophila neuroglian at 2.0 A. Neuron 1994 Apr;12(4):717-31. 
(38) Michaelis RC, Du YZ, Schwartz CE. The site of a missense mutation in the extracellular lg or FN domains 
of L1CAM influences infant mortality and the severity of X linked hydrocephalus. J Med Genet 1998 
Nov;35(11):901-4. 
(39) Kamiguchi H, Hlavin ML, Yamasaki M, Lemmon V. Adhesion molecules and inherited diseases of the 
human nervous system. Annu Rev Neurosci 1998;21:97-125. 
(40) Jouet M, Strain L, Bonthron D, Kenwrick S. Discordant segregation of Xq28 markers and a mutation in 
the Ll gene in a family with X linked hydrocephalus. J Med Genet 1996 Mar;33(3):248-50. 
(41) Vits L, Van Camp G, Coucke P, Fransen E, De Bou lie K, Reyniers E, Korn B, Poustka A, Wilson G, Schrander­
Stumpel C, . MASA syndrome is due to mutations in the neural cell adhesion gene L1CAM. Nat Genet 
1994 Jul;7(3):408-13. 
(42) Van Camp G, Vits L, Coucke P, Lyonnet S, Schrander-Stumpel C, Darby J, Holden J, Munnich A, Willems PJ. A 
duplication in the L1CAM gene associated with X-linked hydrocephalus. Nat Genet 1993 Aug;4(4):421-5. 
(43) Yamasaki M, Thompson P, Lemmon V. CRASH syndrome: mutations in L1CAM correlate with severity of 
the disease. Neuropediatrics 1997 Jun;28(3):175-8. 
(44) Fransen E, Van Camp G, D'Hooge R, Vits L, Willems PJ. Genotype-phenotype correlation in L1 associated 
diseases. J Med Genet 1998 May;35(5):399-404. 
40 
Appendix chapter 2 
Additional DNA testing resu lts 
Ll syndrome in females 
Yvonne J. Vosa, Ulrike Dunkhase-Hein lb, 
Gretel G. Oudesluijsc, Carsten A. Brandtd, Annelies M. ten 
Berge", Krista K. van Dijk-Bosa, Gunnar Houge•, Robert 
M.W Hofstra• 
0 Department of Genetics, University Medical Centre 
Groningen, University of Groningen, the Netherlands 
h Department of Pediatrics, Hospital Li/lebaelt-Kolding, 
Denmark 
c Department of Clinical Genetics, Erasmus University 
Medical Centre, Rotterdam, the Netherlands 
d Department of Clinical Genetics, Hospital Lillebaelt­
Vejle, Denmark 
" Center for Medical Genetics and Molecular Medicine, 
Hauke/and University Hospital, Heise Bergen, Norway 
Manuscript in preparation 
Appendix chapter 2 
Introduction 
So far, female carriers of an L1CAM mutation have been described in the literature as being 
sometimes mildly affected, with slightly adducted thumbs and a cognitive level significantly 
lower than their non-carrier sister(s). Girls with severe hydrocephalus are very rarely seen. 
In fact, almost everyone refers to the scientific work from 1994 by Kaepernick et a/. l11 • They 
reported a large family with eight, more or less affected women: two showing adducted 
thumbs, three with mild mental retardation (two of these women were obligate carriers), and 
three who reportedly died because of a neonatal hydrocephalus. This diagnosis was confirmed 
by autopsy in one case. Thus, based on the current literature, Ll syndrome in females 
is believed to be very rare. This has important consequences, the major one being that in 
prenatal diagnostics, female fetuses carrying a mutation are considered to be healthy. 
Results 
Recently a girl with aqueduct stenosis, adducted thumbs and mild mental retardation was 
referred to our laboratory for diagnostic L1CAM testing. We detected a pathogenic mutation, 
c.1267C>T, p.Gln423X and were able to demonstrate skewed X-inactivation in the gir l .  To 
the best of our knowledge this is the first time that a pathogenic L1CAM mutation has been 
detected in an affected girl without a positive family history. 
In a second girl, suffering from severe hydrocephalus and down syndrome, we detected the 
likely disease-causing mutation c.1156C> T, p.Arg386Cys. This had been detected earlier in her 
brother, who also suffered from severe hydrocephalus. We were also able to demonstrate 
skewed X-inactivation in this gir l .  Furthermore, a maternal germline mosaicism was shown, as 
the mother did not carry the mutation. 
In a third girl, with spastic paraplegia, severe learning difficulties and epilepsy, we found the 
same UV as had been detected in her two affected brothers (hydrocephalus, mental retardation 
and spastic paraplegia): c.516G>A, p.Met1721 1e. In this case skewed X-inactivation could not 
be demonstrated. 
Conclusion 
Our results clearly show that female carriers do have a risk of developing Ll syndrome and this 
therefore has important consequences for diagnostic testing for Ll syndrome. Although we 
cannot yet give an accurate risk estimation of how high the chance is that a mutation carrier 
will be clinically affected (a figure that is important for prenatal diagnostics), it will probably 
be around 3-5% since we have only detected mutations in 78 patients to date. We plan to 
investigate the chance of having an affected girl in a family harboring a proven pathogenic 
mutation more precisely and we will extend our diagnostic testing for L1CAM in girls suspected 
of having Ll syndrome. 
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Chapter 3 
Abstract 
X-linked hydrocephalus is associated with mutations in the Ll neuronal cel l  adhesion molecule 
gene. L1 protein plays a key role in neurite outgrowth, axonal guidance, and pathfinding during 
the development of the nervous system. A male is described with X-linked hydrocephalus 
who had multiple small gyri, hypoplasia of the white matter, agenesis of the corpus cal losum, 
and lack of cleavage of the thalami. Scanning the L1 neuronal cel l adhesion molecule gene 
in Xq28, revealed a novel missense mutation: transition of a guanine to cytosine at position 
1,243, which led to conversion of alanine to praline at position 415 in the lg4 domain of the Ll 
protein. It is likely that the X-linked hydrocephalus and cerebral dysgenesis are a result of the 




Cell adhesion molecules are cell surface proteins, which mediate differential adhesion, 
signal transduction, and physical/mechanical effectsr11 • The following three major classes 
of cell adhesion molecules have been identified in the developing central nervous system: 
the integrins, the cadherins, and the immunoglobulin superfamilyf11 • Ll belongs to the 
immunoglobulin superfamily rz,3J _ Its encoding gene, L1CAM, is located near the telomere of 
the long arm of the X chromosome in the Xq28 region f41 • 
Mutations in the L1CAM gene are responsible for an X-linked recessive neurologic disorder 
that has been described as X-linked hydrocephalus (hydrocephalus as a result of stenosis of 
the aqueduct of Sylvius [HSAS]; MIM 307000), MASA syndrome (mental retardation, aphasia, 
shuffling gait, and adducted thumbs; MIM 303350), X-linked corpus callosum agenesis (ACC; 
MIM 304100), and spastic paraplegia type 1 (SPGl; MIM 303350)141 • The varying nomenclature 
is a reflection of extremely variable presentation within and between families. The most 
consistent features in affected boys are hydrocephalus/ventriculomegaly with or without 
macrocephaly, abnormal gyrification, reduced white matter volume, lack of cleavage of 
the thalami, hypoplasia or agenesis of the corpus callosum, hypoplasia or absence of the 
corticospinal tract, lower limb spasticity, underdevelopment of the cerebel lar vermis, mental 
retardation, and adducted thumbsrs-si. A single acronym, CRASH (corpus callosum hypoplasia, 
retardation, adducted thumbs, spastic paraplegia, hydrocephalus), was proposed for the 
syndrome in 1995r4l , and Ll disease has been suggested recently191 . 
Few reports have been published on the neuroimaging and neuropathologic features of patients 
with L1CAM mutations15-81 • We describe the magnetic resonance imaging characteristics of the 
cerebral dysgenesis in a male with X-linked hydrocephalus who had a missense mutation in 
the L1CAM gene. 
Case report 
The proband was a male who was born at term by cesarean section to consanguineous (first 
cousin) Pakistani parents. His birth weight was 4,770 gm, and Apgar scores were 6 and 8 at 1 and 
5 minutes, respectively. He had congenital hydrocephalus with an occipitofrontal circumference 
of 48.5 cm at birth. Computed tomography revealed enlarged lateral and third ventricles; the 
size of the fourth ventricle was normal. A ventriculoperitoneal shunt was placed shortly after 
birth. The mother had nine pregnancies. Of these pregnancies, three males with congenital 
hydrocephalus died in the neonatal period, and one female, who did not have hydrocephalus or 
any dysmorphic features, died during labor. Four females are healthy (figure 1). 
Figure 1. The pedigree of the family . 
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Figure 2. Axia l  Tl­
weighted (TR = 736 
ms, TE = 14 ms) 
magnetic resonance 
image revea ls multiple 
small gyri i n  the 
occipital regions. There 
i s  a lack of cleavage 
of the thalami in 
the mid l ine, and the 
corpus ca l losum is 
absent. 
Figure 3. Parasagitta l 
Tl-weighted (TR = 
630 ms, TE = 15 ms) 
magnetic resonance 
image reveals multiple 
sma l l  gyri ma in ly i n  
the parieta l-occipita l 
a reas. 
Development of the patient was delayed. Mental retardation became more and more obvious 
(intelligence quotient was approximately SO at 5 years of age). He could follow a few commands and 
recognize his parents but was unable to speak. On neurologic examination at 4.5 years of age his 
head circumference was 49 cm (twenty-fifth percentile). Ophthalmoscopy examination revealed 
normal results. He had strabismus. Both thumbs were adducted at the metacarpophalangeal joints 
and flexed at the interphalangeal joints. He was not able to move his thumbs. Muscle tone, power, 
and deep tendon reflexes were normal on the upper extremities. He was able to feed himself. 
Severe spastic diplegia with equinovarus deformity of the feet, brisk deep tendon reflexes, and 
positive Babinski reflex were observed on the lower extremities. He was not able to stand or walk 
unsupported. Sensation appeared normal with pain stimulus; other modalities were not assessed 
because of the mental retardation. 
Brain magnetic resonance imaging was performed when the child was 4.5 years of age. Sagittal 
(TR = 630 ms, TE = 15 ms) and axial T1-weighted (TR = 736 ms, TE = 14 ms), coronal T1-weighted 
(TR = 736 ms, TE = 14 ms) and T2-weighted (TR = 6,900 ms, TE = 90 ms), axial proton density (TR = 
5,000 ms, TE = 19 ms) and T2-weighted images (TR = 5,000 ms, TE = 95 ms) were obtained. Parietal­
occipital hypoplasia with reduced white matter volume, multiple small gyri, and thin cortex was 
observed (figure 2 and figure 3). There was an unusual arborization of the cerebral mantle with 
widened deep sulci between fingerlike bunches of white matter covered with gray matter in these 
regions. The T2-weighted images did not reveal high signal intensity in the white matter. Some of 
the gyri on the medial surfaces of the hemispheres had a radiating pattern. The posterior aspect 
of the lateral ventricles had irregular walls. The corpus callosum was absent, and the fornix was 
thick. The thalami lacked cleavage in the midline and the third ventricle was practically filled by 
the large massa intermedia (figure 2). A patent aqueduct and the superior and inferior colliculi 
could not be identified. The fourth ventricle was small and had a relatively high location. The 
cerebellum demonstrated normal structure, although it had a towering high extension of its 
vermis. The posterior fossa was relatively small. The cerebral peduncles and brainstem appeared 
normal. There was a small pituitary gland within a correspondingly small sella turcica. 
Because the clinical findings were highly suggestive of X-linked hydrocephalus, mutation analysis 
of the LlCAM gene was performed as described previously18•101 • Sequencing revealed a transition 
of a G (guanine) to C (cytosine) at position 1,243 (c.1243G>C}. This is a missense mutation 
resulting in an amino acid change of alanine to praline on position 415 (p.Ala415Pro) in the 
fourth immunoglobulin domain { lg4) of the Ll molecule. The same mutation was evident in the 
mother of the male. 
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Discussion 
Multiple small gyri, markedly reduced white matter volume, agenesis of the corpus callosum, 
and lack of cleavage of the thalami were the main magnetic resonance imaging findings after the 
shunt procedure in this patient with X-linked hydrocephalus as a result of a missense mutation in 
the LlCAM gene. A patent aqueduct was not identified. These features demonstrate similarities 
to the previously published magnetic resonance imaging and neuropathologic findings [5-11 • 
Diffuse hypoplasia of the cerebral white matter associated with ventriculomegaly, hypoplasia/ 
agenesis of the corpus callosum, and lack of cleavage of the thalami were common findings in all 
patients. Neuropathology revealed multiple small gyri (polymicrogyria) similar to those described 
in this study [61 • There were six cortical layers with sparse cells and poorly organized lamination [61• 
In addition, neuropathology and diffusion-weighted magnetic resonance imaging demonstrated 
that the corticospinal tracts were hypo plastic or absent[6•71 • The cerebral peduncles and brainstem 
appeared normal in our magnetic resonance imaging study; however, they were demonstrated 
to be hypoplastic in other studies [5,11 , a finding that is consistent with the hypoplasia of the 
corticospinal tracts. The aqueduct of Sylvius was previously described as patent with or without 
stenosis[5-11, and therefore the pathogenesis of the severe progressive hydrocephalus remained 
poorly understood. The outcome was poor in X-linked hydrocephalus because of the widespread 
cerebral abnormalitiesl5-71 _ 
The cerebral dysgenesis, found by neuroradiologic and neuropathologic techniques among 
the various clinical presentations of LlCAM gene mutations or CRASH syndrome, is the result 
of disrupted Ll structure and function[4,111 • Information processing performed by the brain is 
determined by an intricate network of connections between neurons [121 • Neuronal connections 
form during embryonic development when each differentiating neuron sends out an axon that 
projects through the embryonic environment to its synaptic targets. Pathfinding is directed by 
the coordinate action of short- and long-range attraction and short- and long-range repulsion [121 • 
A large number of molecules have been identified that mediate the guidance mechanisms1121 • 
Ll, a member of the immunoglobulin superfamily is the best studied among the cell adhesion 
molecules participating in the development of the nervous system[2,3,121 . 
Ll is a transmembrane glycoprotein with six immunoglobulin-like and five fibronectin type Ill 
domains on the extracellular surface[2·31 • The extracellular part is linked to a short cytoplasmic 
tail by a transmembrane domain. Both the extracellular and cytoplasmic domains of the Ll 
molecule are involved in several interactions[31 • The extracellular interactions include Ll itself 
(Ll-Ll homophilic binding) or other members of the lg superfamily, integrins, extracellular 
matrix proteins, such as laminin, and a variety of proteoglycans (heterophilic binding) [3,131 , 
There is growing evidence that the homophilic interactions promote both neurite outgrowth 
and cell adhesion, which are relevant to both axon growth and fasciculation (axon bundling) 
[3,121 • Extracellular Ll ligands are also linked to intracellular signaling pathways, and it is likely that 
the axonal growth is initiated through the activation of tyrosine kinase-associated receptors of 
fibroblast growth factors13•121 • The complexes formed by heterophilic interactions may also be 
required for the Ll-Ll-mediated regulation of neurite outgrowth131 • The cytoplasmic domain 
interacts with the cytoskeleton. It has a binding site for ankyrin, and ankyrin-mediated tethering 
of Ll to the spectrin cytoskeleton can stabilize L1 within the axon[141 • 
The LlCAM gene spans 16 kb and has 28 coding exons. Exons 3-14 encode the six immunoglobulin 
domains with two exons for each domain. Exons 15-24 encode the five fibronectin domains, 
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exon 25 the transmembrane domain, and exons 26-28 form the cytoplasmatic domainl41. As 
of January 2001, 137 different L1CAM mutations have been described in 146 families (http:// 
dnalab-www.uia.ac.be/dnalab/Ll/index.html)l15l _  The mutations are dispersed throughout 
the entire L1CAM gene and include missense, nonsense, splice site mutations, deletions, and 
insertionsl91. 
The mutations can be classified into three classesr111. The first class of mutations includes 
mutations that affect only the cytoplasmic domain of L1 at the C-terminal end of the protein. 
In these cases, binding with the intracellular cytoskeleton and signal transduction might be 
impaired, whereas the extracellular and transmembrane domains remain intact. The second 
class consists of missense point mutations in the extracellular domain. In these cases the 
mutant protein is still an integral membrane protein with a normal transmembrane and 
cytoplasmic domain. However, the binding capacities of the Ll protein toward its ligands might 
be distorted because the structure of the extracellular domains is altered at one amino acid 
position. Indeed, studies on mutated L1 molecules provide evidence that missense changes 
in the extracellular domains have variable effects on homophilic and heterophilic binding 
of the moleculel131. The third class of mutant L1 proteins has a premature stop codon in the 
extracellular part. In these cases the transmembrane protein is absent, and the mutant protein 
could be secreted into the extracellular space. Obviously such a protein loses its function 
because its contact with the nerve cell is lostl 111. 
A correlation between the type of mutation and the severity of the disease has been 
demonstrated by Yamasaki et a/. l111. Mutations that produce truncations in the extracellular 
domain (class 3) are more likely to produce severe hydrocephalus, grave mental retardation, 
or early death than point mutations in the extracellular domain or mutations affecting only the 
cytoplasmic domain of the protein. Although less severe than extracellular truncations, point 
mutations in the extracellular domain (class 2) produce more severe neurologic problems than 
mutations in only the cytoplasmic domain (class 1). 
In our patient the mutation-the G to T transition at position 1,243-affects exon 10 of the 
L1CAM gene. This missense mutation has not been described previously and represents a form 
of class 2 mutation on the basis of the classification suggested by Yamasaki et at. r111. Exons 9 
and 10 encode the fourth immunoglobulin domain (lg4)12I, and this mutation in exon 10 leads 
to a change of alanine to praline in position 415 (A415P). Alanine 415 is a key residue that is 
important for the conformation of the domain: change of an alanine to praline likely causes 
disruption of a beta sheet hydrogen bond121. 
The key role of alanine at position 415 can explain the severe clinical manifestations of X-linked 
hydrocephalus in this family despite the fact that the p.Ala415Pro change is a class 2 mutation. 
Because the mother also carries the same mutation, it is likely that the three brothers who 
died of hydrocephalus in the neonatal period had the same mutation. Evidence has been 
provided that missense mutations in key residues tend to produce more severe hydrocephalus 
than mutations in surface residues121. In vitro studies confirmed that mutations in key residues 
of all lg domains result in the diminution of both homophilic and heterophilic binding 1131. It is 
likely, therefore, that the abnormal binding properties of the mutated Ll in our patient led to 
the cerebral dysgenesis because of abnormal neurite outgrowth and pathfinding. 
We can conclude that further studies on the effect of normal and abnormal function of Ll and 
other cell adhesion molecules will allow deeper insight into the pathogenesis of a group of 
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Abstract 
The Ll syndrome is an X-linked recessive disease caused by mutations in the L1CAM gene. To 
date more than 200 different mutations have been reported, scattered over the entire gene, 
about 35% being missense mutations. Although it is tempting to consider these missense 
mutations as being disease-causing, one should be careful in drawing any firm conclusions, 
unless there is additional supporting information. This is in contrast to truncating mutations, 
which are always considered to be disease-causing, unless they involve truncations close 
to the gene stop codon. In order to allow conclusions to be drawn on the disease-causing 
nature of L1CAM (missense) mutations, we have updated and upgraded our LICAM mutation 
database with more pathogenicity data and clinical information collected from the literature or 
generated by our own research. As a result, the renewed database offers condensed scientific 
information, allowing conclusions to be drawn on the pathogenicity and severity of LICAM 
mutations based on multiple factors. 
The L1CAM Mutation Database is at: www.llcammutationdatabase.info. 
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Introduction 
Ll syndrome is an X-l i nked recessive disorder with an incidence of 1 : 30,000 newborn 
males. I t  comprises four neuro logical syndromes, a l l  associated with mutations i n  the 
LlCAM gene 11-31 • The most severe of the four different forms, is X-linked hydrocephalus, also 
referred to as hydrocephalus, due to stenosis of the aqueduct of Sylvius (HSAS, M IM 307000}. This 
syndrome was first described in the 1940s and is the most frequent genetic form of congenital 
hydrocephalus 141 • Other clinical characteristics are adducted thumbs, mental retardation, and 
lower l imb spasticity. In most families, the affected boys die before, during, or soon after birth151 • 
A less severe form of the disease has been published under the acronym MASA syndrome (MIM 
303350). This syndrome consists of  light to moderate mental retardation, £phasia, �huffling gait 
and £dducted thumbs. Occasional ly, phenotypic variation ranging from the severe, X-linked 
hydrocephalus type, to the less severe MASA syndrome can be found in the same family !5, 71 • 
X-linked complicated hereditary spastic paraplegia type 1 (SPGl, M IM 303350} and X-l inked 
complicated corpus callosum agenesis (X-linked ACC, M IM 304100} are also parts of the L1 
syndrome, but are seen much less frequently. The complicated forms may be combined with 
mild to moderate mental retardation. 
The LlCAM gene, coding for the neural cel l  adhesion molecule Ll, is located on the X-chromosome 
at Xq28. The human L1CAM gene consists of 29 exons: the first exon of 125 bp is non-coding and 
was only discovered later181 • Therefore, in contrast to common practice, the first exon, which is 
located 10 kb upstream of the ATG containing exon 1, is known as exon A and not exon 1. 
The L1CAM gene is primarily expressed in the nervous system and encodes a protein of 1,257 
amino acids, comprising a signal peptide of 19 amino acids and a functional L1 protein of 1,238 
amino acids. I n  non-neural tissue, alternative RNA splicing generates mRNA, which lacks exons 
2 and 27 of the gene 19•101 and leads to a protein that is 9 amino acids shorter. 
Ll is a transmembrane glycoprotein belonging to the immunoglobulin superfamily cel l adhesion 
molecules [nJ and contains thirteen distinct domains, i.e . six immunoglobulin- (lg) and five 
fibronectin (Fn) I l l - l ike domains at the extracel lular surface, one single-pass transmembrane 
domain, and one short cytoplasmic domain . Ll may mediate axon growth during development 
and axon bundling (fasciculation) [12, 131 • It is also involved in interactions between Schwann 
cel ls and axons, neuronal cel l  migration, and neuronal cel l  survival [14, 151 • The activity is known 
to be mediated by homophilic and heterophilic interactions and transduction of a variety of 
signaling events through associated proteins[151 _ 
To date more than 200 different L1CAM mutations have been published: 130 of these were 
reviewed in 2001[171 and another 41 were published subsequently[1s-35l_ Moreover 52 novel 
mutations have been detected in our laboratory and were published recently1361 • Most mutations 
have been compi led in the L1CAM Mutation Database, original ly constructed by Van Camp et 
a/. !371 and later continued by our group. Since the amount of additional information is growing 
rapidly and it is important to researchers, clinicians and genetic counselors to have access to 
these new data in a fast and simple way, we decided to renew and update the L1CAM Mutation 
Database quite drastically. New information compi led in the upgraded database comprise: (1) 
e lements which co-determine the possible pathogenicity of a mutation, (2) clinical data, (3) 
family histories, (4) reported clinical classification, and (5) effect of a mutation on molecular 





All mutations known from the old database were transferred to the new version of the database 
and all new mutations, either recently found in our laboratory or published by others, were 
added; all were described according the nomenclature of the Human Genome Variation Society 
(www.hgvs.org/mutnomen)r3s. 391 and numbered according to the reference sequence (+l = A 
of ATG translation initiation codon), as listed in GenBank: NM_000425.3. Next we checked 
all the original publications for extra information related to the mutations, to upgrade the 
database not only with a direct link to the publication but, more importantly, in order to add 
the extra information about the mutations. We added information to the truncating mutations, 
which are considered to be pathogenic, such as mutation history (inherited or de nova), the 
family history of the patient, and clinical information on the occurrence of hydrocephalus 
(HC), adducted thumbs (AT), mental retardation (MR), aphasia (Aph), spastic paraplegia (SP), 
agenesis/dysagenesis corpus callosum (ACC/DCC), or hypotonia (HP), which are the most 
predominant characteristics related to Ll syndrome. 
For missense mutations, which in general correlate much less directly to disease-causing, 
we have upgraded the database moreover with information on the mutation, like any 
published classification, i.e. disease-causing, likely disease-causing, likely non-disease-causing, 
polymorphism, or unknown. For this category of mutations we have also added whether the 
mutation is present in affected or non-affected male relatives, as far as could be derived from 
the original publications. Next we investigated other parameters which could influence the 
mutation pathogenicity, such as (1) the difference in physical and chemical characteristics 
between the two amino acids, (2) the degree of conservation of the amino acid mutated, and 
(3) the mutation versus protein function relationship. Consequently, our new LICAM Mutation 
Database includes the SIFT1401 and Polyphenr411 predictions, and whether the mutations might 
affect a key or a surface residue, as defined by Bateman142I, because these residues are supposed 
to maintain the structure of the lg and Fnlll domains in the Ll protein and hence its function. 
As an illustration, we have summarized the results obtained with these kinds of predictions on 
the series of new missense mutations detected and studied in our laboratory in table 1 (table 
1 and the LlCAM database). 
Data base features 
To date 240 different LlCAM mutations have been reported, scattered over the entire gene: 204 
disease-causing, 11 likely disease causing, 6 likely non disease-causing, 12 non disease-causing, 
and 7 of unknown pathogenicity. Most LlCAM mutations are unique for each family, i.e. they 
appear to be private mutations. Out of the 215 (likely) disease-causing mutations recorded in 
the database, 1 appears in 6 different families (p.Val752Met), 1 appears in 4 different families 
(c.807-6G>A), 8 appear in three different families, and 17 appear in two families. About 58% 
of all mutations are truncating and therefore considered to be disease-causing. Out of the 
102 remaining mutations, 66 are reported as disease-causing, 11 likely diseases-causing, 6 
likely non-disease-causing, 7 unknown and 12 non-disease-causing/polymorphisms. These 
102 mutations, predominantly missense mutations, also include 6 silent mutations and 15 
intronic mutations. 
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Figure 1. Page 1 of the LlCAM mutation database with 10 variants. 
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Figure 2. The "details" page of the p.Gly121Ser variant. 
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The database contains only a few large deletions or duplications that involve more than one 
exonl2s, 43-45l, and only one case of a deletion of the entire L1CAM genel29l. In the new L1CAM 
mutation database, you can screen for mutations per exon or intron and select for reported 
classification and type (figure 1). Mutation-specific information can be obtained by clicking the 
"details" button (figure 2). 
The L1CAM database will be updated monthly with newly published data. We will search for 
this, but other researchers are encouraged to submit their new mutation data via the online 
submission form. The submission will be checked by the curator and completed if necessary. 
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I Exon Remarks Consequence 
1 
• Domain 
ID change re atives Ii 
Bateman 
292 c.110T>A 3 p.lle37Asn 4 lg1 Not detected in one unaffected Key residue 
male relative 
89 c.536T>G* 6 p.lle179 Ser >1 lg2 Previously, linkage analysis Key residue 
confirmed a locus on Xq28 
56 c.550C>G 6 p.Arg184Gly 10 lg2 Key residue 
235 c.551G>A* 6 p.Arg184Gln 1 lg2 Previously described as pathogenic Key residue 
27 c.604G>T 6 p.Asp202Tyr 1 lg2 Surface 
164 c.761C>A 7 p.Ala254Asp 4 lg3 Present in two affected males Key residue 
Absent in one unaffected male 
348 c.826T>C 8 p.Trp276Arg 1 lg3 De novo in mother of index patient Key residue 
35 c.938T>C 8 p.Leu313Pro 1 lg3 De nova Surface 
187 c.1003T>C* 9 p.Trp335Arg 1 lg4 Previously described as pathogenic Key residue 
184 c.1107C>A 9 p.Asn369Lys 3 lg4 Index patient with an affected Key residue 
brother and nephew 
91 c.1243G>C 10 p.Ala415Pro 4 lg4 Index patient with three affected Key residue 
uncles (maternal line) 
36 c.1438G>A 12 p.Gly480Arg 2 lgS Two affected brothers, their Key residue 
mother is a carrier 
208 c.1933A>T 15 p.lle645Phe 1 Fnl De nova Key residue 
23 c.2140C>T 17 p.Pro714Ser 1 Fn2 Key residue 
80,156, c.2254G>A* 18 p.Val752Met 7, 4, 2  Fn2 3 families Key residue 
336 Previously described as pathogenic 
275 c.2260T>A 18 p.Trp754Arg 3 Fn2 Familial history Key residue 
162 c.3239T>A 24 p.Leu1080Gln 2 FnS The mutation was detected in two Key residue 
affected brothers 
* Previously found by other groups, ** 1 probably damaging, 2 possibly damaging, 3 benign, 4 unknown 
,i 
11 
In silico data 
SIFT II Poly-h ** Conserved �· e, en JI 
Not tolerated 1 Highly 
Not tolerated 1 Highly 
Not tolerated 1 Highly 
Not tolerated 1 Highly 
Not tolerated 1 Highly 
Not tolerated 2 Highly 
Not tolerated 1 Highly 
Not tolerated 2 Moderately 
Not tolerated 1 Highly 
Not tolerated 1 Highly 
Not tolerated 1 Highly 
Not tolerated 1 Highly 
Not tolerated 1 Highly 
Not tolerated 1 Highly 
Not tolerated 2 Highly 
Not tolerated 1 Highly 












ID change relatives 
11 
The mutation was detected in 
366 c.516G>A 5 p.Metl 72I Ie  3 lg2 two affected brothers and one 
affected sister 
De nova in mother 
200 c.1546G>A 12 p.Asp516Asn 1 lg6 
Affects RNA splicing most likely 
302 c.1546G>T 12 p.Asp516Tyr 1 lg6 Affects RNA splicing most likely 
320 c.1880C>T 15 p.Thr627Met 1 Fnl 
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Poly-SIFT 
h 
*"' , Conserved 
p en 
"'- -
Not tolerated 1 Highly 
Low 
Tolerated 3 (in frog 
Asn516) 
Not tolerated 1 Low 












Recently the contribution of modifiers to the severity of X-linked hydrocephalus in mouse 
models has been describedl461 • Furthermore, also in animal models, some 10 genes causing 
hydrocephalus have been detectedl45, 471, but to date in humans only the L1CAM gene has 
been identified to be associated with the Ll syndrome. Therefore, and since hardly any 
polymorphisms occur in the L1CAM gene, it is tempting to consider the missense mutations, 
detected in the group of patients suffering from Ll syndrome, as disease-causing. However, 
without any further supporting information, we should be careful in drawing any firm 
conclusions about the missense mutations, in terms of their being disease-causing. This is in 
contrast to the truncating mutations, which, in general due to their nature, are always likely to 
be disease-causing unless they involve truncations close to the gene stop codon. In order to 
allow firmer conclusions as to the pathogenicity of missense mutations, we have upgraded our 
LICAM mutation database with additional information collected from the literature. As a result, 
we have been better able to indicate the disease-causing nature of many of the missense 
mutations in the L1CAM gene, thereby providing researchers, clinicians and counselors with 
a more useful tool for drawing conclusions. Next, by adding information to the database, like 
the live span of patients suffering from Ll syndrome (i.e. age at early death), the database 
offers background information that allows the correlation of genotypes to phenotypes, i.e. 
links the severity of disease to the type of mutation, essentially according to Fransen et a/. 1481 
and Yamasaki et a/. 1491 and more recently Vos et al. l35J _  
In conclusion, this updated and upgraded version of the L1CAM mutation database offers more 
scientific information to enable conclusions to be drawn on the pathogenicity and severity of 
L1CAM mutations based on multiple factors. 
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Chapter 5 
Abstract 
Ll syndrome, characterized by hydrocephalus, aqueduct stenosis, mental retardation, 
adducted thumbs, agenesis/dysgenesis of the corpus callosum, aphasia and spastic paraplegia 
is caused by mutations in the LlCAM gene. We analyzed 367 patients suspected of having Ll 
syndrome and referred to our laboratory for diagnostic testing. Of these, 73 patients were 
found to harbor one of 68 different mutations, 61 of which are considered to be disease­
causing and seven of which are unclassified variants (UVs). For some of these UVs we have in 
silica evidence that they might be involved in aberrant splicing of the pre-mRNA. In order to 
prove an effect on splicing for three of these UVs, c.76+5G>A, c.1546G>A (Asp516Asn) and 
c.1546G>T (p.Asp516Tyr), we used an ex vivo RNA splicing assay and were able to show that 
all three were pathogenic. A previously proven splice mutation, c.645C>T (p.=), was used as a 
positive control in the assay. 
The number of disease-causing DNA variants increased from 61 to 64. Thus our analysis 
showed that not only is this number higher than previously thought, but also that UVs might 
well cause RNA splicing problems and should therefore be studied carefully. 
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Introduction 
Ll syndrome is an X-linked recessive neurological disorder caused by mutations in the L1CAM 
gene[1, 21, a gene coding for the neural cell adhesion molecule Ll. The phenotypic spectrum 
associated with these mutations includes four different neurological syndromes: X-linked 
hydrocephalus, also referred to as hydrocephalus due to stenosis of the aqueduct of Sylvius 
(HSAS; MIM 30700), the MASA syndrome (MIM 303350), standing for mental retardation, 
§.phasia, �huffling gait and §.dducted thumbs, X-linked complicated hereditary spastic paraplegia 
type 1 (SPGl, MIM 303350) and X-linked complicated corpus callosum agenesis (X-linked 
ACC, MIM 304100) 131 • The seven most important clinical characteristics of Ll syndrome are 
hydrocephalus, aqueduct stenosis, mental retardation, adducted thumbs, agenesis/dysgenesis 
of the corpus callosum, aphasia (delayed speech development) and spastic paraplegia. 
To date more than 200 different LlCAM mutations have been published!41 • We detected 68 of 
these in a large group of patients (n=367) who were referred to our laboratory for diagnostic 
testing. These 68 different mutations were found in 73 patients[51, 61 of the mutations are 
considered to be disease-causing and seven variants have an unknown pathogenic status 
and are therefore called unclassified variants (UVs) . These seven UVs consist of five missense 
mutations and two intronic mutations (table 1) . Based on in silica data these UVs are believed 
Table 1. Unclassified variants 
Nucleotiae change Exon7 
intron 
c.76+5G>A intron 1 ? 
c.516G>A exon 5 p.Met172lle 
[c.523+9_523+10delinsGA; intron 5 ? 
c.523+ 12delC] 
c.1546G>A exon 12 p.Asp516Asn 
c.1546G>T exon 12 p.Asp516Tyr 
c.1574G>A 
c.1880C>T 
exon 13 p.Arg525His 




site of intron 




site of intron 5 
is weakened 
2** Splice donor 
site of intron 
12 is very 
weakened 
Splice donor 
site of intron 
12 is very 
weakened 
*1. The mutation was detected in two affected brothers and one affected sister 
**2. De nova in mother 
In sllico data 
Polyphen Coi,served 
Not Probably H ighly 
tolerated damaging -
Tolerated Benign Low 
(in frog 
Asn516) 
Not Probably Low 
tolerated damaging 
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Figure 1. 
Principle of ex vivo splicing assay. In the pSPL3 vector 
two (non-Ll) exons have been cloned separated by 
an intron with a multiple cloning site. PCR-amplified 
wild-type and mutant exons from the LlCAM gene, 
including flanking intronic sequences, are cloned 
into this multiple cloning site. After transfection into 
HEK293 cells total RNA is extracted and amplified 
to synthesize cDNA. cDNA is amplified using pSPL3 
specific primers and the PCR products are analyzed 
by gel electrophoresis and direct sequencing. If a 
wild-type exon and flanking intronic sequences are 
cloned into the vector, the L1 exon will be present in 
the synthesized cDNA (lower right site of the figure). 
The Ll exon (or part of it) will be absent when a 
splice site affecting mutation is present in the cloned 
sequence (lower left part of the figure). 
to be "likely disease causing" (table 1), but further research is needed to determine their 
status accurately. 
Four out of the seven likely disease-causing mutations most probably influence correct pre­
mRNA splicing. These comprise a mutation in intron 1, a mutation in intron 5 and two mutations 
in exon 12. Both mutations in exon 12 affect the last nucleotide of the exon and according to 
three out of four splice site prediction programs tested, the splice site at the beginning of 
intron 12 is not, or almost not, being recognized. Due to the mutations in intrans 1 and 5, it is 
predicted that the origina l splice donor sites of intrans 1 and 5 will be weakened. 
To prove that these possibly splice mutations are indeed disease causing, we decided to 
investigate three mutations in terms of their involvement in RNA splicing. Since it was not 
possible to isolate and analyze RNA from the patients, we used an ex vivo RNA splicing assay 
(figure 1). The c.645C>T mutation in exon 6 of the LlCAM gene, a silent mutation we have 
proved to be pathogenic by influencing the RNA splicing [51, was used as a positive control. 
The mutation in intron 5 has not been examined yet. 
Materials and methods 
Constructs for ex vivo splicing assay 
Wild-type and mutant LlCAM exons 1, 6 and 11 and 12, including 60-200 bp of 5'- and 3' 
flanking intronic sequences, were amplified from control and patient genomic DNA (table 2: 
primers) . The PCR was carried out using Phusion High-Fidelity DNA polymerase (NEB) in the 
following steps: denaturation at 98°C for 30 seconds, followed by 35 cycles of denaturation 
at 98°C for 10 seconds, annealing at 63°C for 30 seconds, elongation at 72°C for 30 seconds, 
and a final step at 72°C for 10 minutes. The products were analyzed on, and extracted from, 
an agarose gel (Qiagen kit). To obtain 3' A-overhangs, 7 µI of purified PCR product, 1 µI Taq 
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CT AT-Ba m H 1,5' -TGTCCCTGGTGCTGAAATCG-3' 
CTTA-EcoRl,5' -GGGAGCAGGGAAGCAAGAT-3' 
CTAT-BamH 1,5' -TGCGTGGGGAGTCACTCT-3' 
CTTA-EcoRl,5' -CTCGTGGGGTCGGGGTGTTA-3' 




11 & 1 2  
11 & 1 2  
6 
6 
polymerase, 1 µI l0xRB and 1 µI dNTPs were incubated at 72°C for 15 minutes and put on 
ice for 2 minutes. 4 µI of this product was added to 1 µI pCR2.1 TOPO plasmid (lnvitrogen) 
and 1 µI salt and incubated for 5 minutes at room temperature. The pCR2.1 TOPO constructs 
were then transformed to DH Sa competent cells, according to the manufacturer's protocol for 
"Transforming One Shot Machl-TlCompetent Cel ls". 40 µI of X-gal (20 mg/ml) was spread over 
ampicillin-containing agar plates. Then the transformed DHSa cells were plated and incubated 
for 16 hours at 37°C. White colonies were picked and grown in Low Broth medium for 16 hours 
at 37°C and 225 rpm. The DNA constructs isolated from these cells using the Machery-Nagel 
kit were checked by BamHI and EcoRI restriction enzyme analysis and direct sequencing . Then 
the correct plasmids and the exon trapping vector pSPL3 { lnvitrogen) were digested, loaded on 
and extracted from an agarose gel (Qiagen) . 100 ng pSPL3 and 50 ng insert were put together 
with 3 µI lOx ligation buffer (Biolabs) and 1 µI T4 Ligase (Biolabs) in a total volume of 30 µI. 
Ligation was performed overnight at 16°C and 2 µI of the product was transformed to DHSa 
competent cel ls as described. The final DNA constructs were checked by restriction enzyme 
analysis and direct sequencing. 
Trans/ection of HEK 293 cells and RT-PCR 
Human embryonic kidney (HEK) 293 cells were plated in 6-well plates containing 6 x 105 
cel ls/well and cultured in DEMEM supplemented with glutamine, 10% foetal bovine serum 
(FBS), 1% penicillin/streptomycin (penicil l in 10000 U/ml, streptomycin 10000 µg/ml) and 
incubated at 37°C in air with 5% CO2 • After 24 hours the cells were transfected with 1 µg 
plasmid DNA using polyethylenimine according the manufacturer's instructions (Polyscience 
INC} .  The pSPL3 plasmid containing the wild-type UCAM sequences and the pSPL3 vector, 
as such (without an LlCAM insert), were used as controls. After 48 hours the cells were lysed 
and RNA was isolated according the manufacturer's instructions (Qiagen) .  4.5 µg total RNA 
was used as a template to synthesize cDNA using the cDNA primers pd(N)6 (GE Healthcare). 
Then PCR was performed using the primers (SD6) 5'-CTGAGTCACCTGGACAACC-3' and (SA2) 
5'-ATCTCAGTGGTATTTGTGAGC-3' and the fol lowing amplification program: 5 minutes at 94°C, 
followed by 35 cycles of 1 minute at 94°C, 1 minute at 60°C and 5 minutes 72°C, and a final 
elongation time of 10 minutes at 72°C. The PCR products were analyzed by gel electrophoresis 
and direct sequencing. 
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Splice site prediction 
The Alamut Splicing prediction module from Interactive Biosoftware was used to predict 
the influence of a mutation on the pre-mRNA splicing. This module integrates four different 
prediction methods: SpliceSiteFinder, MaxEntScan, NNSplice and GeneSplicer. 
(www.interactive-biosoftware.com). 
Results 
Silent mutation c.645C>T 
The c.645C> T mutation in exon 6 was used as a positive control. Previously research on RNA 
isolated from patient's blood has demonstrated that a new splice donor site created by the 
mutation is recognized rather than the original splice donor site at the beginning of intron 6, 
resulting in a 51 bp deletion at the 3' site of exon 6 (figure 2A). The c.645C>T mutation gave in 
the ex vivo RNA splicing assay exactly the same result (figure 2B). The cDNA fragment obtained 
is 51 bp shorter than that of the wild type, which could be confirmed by sequence analysis of 
the fragments recovered from the agarose gel. 
A 
c.645C>T Deletion of 51 bp 
exon 6 intron 6 
650 660 670 680 694 
TCCCAGGTACCAGGACCATCATTCAGAAGGAACCCATTGACCTCCGGGTCAAGCCC gtgagt 
Splice donor site mutant splice donor site wild type 
B cDNA fragments 
pSPL3 exon 6 pPSPL3 
Pos 383 bp 
pSPL3 263 bp 
Figure 2. 
(A) Sequence of the 3' site of exon 6 of the L1CAM gene. A new splice donor site is created due to the c.645C> T 
mutation. 
(B) Analysis of the PCR products of the different cDNA samples: 
B = no template control, M = marker, 
WT = wild type :  pSPL3 containing wild type exon 6, 
Pas = positive control: pSPL3 containing mutated exon 6 (c.645C>T), 
pPSPL3: pSPL3 plasmid without an L1CAM insert. 
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A 
59 base pairs c.76+5G>A 
20 30 40 50 60 76 t 
CTGCGGTACGTGTGGCCTCTCCTCCTCTGCAGCCCCTGCCTGCITATCCAGATCCCCGAGGAAT gtgaatagc 




pSPL3 exon 1 pPSPL3 
Patl 388 bp 
pSPL3 263 bp 
Original splice donor site 
(A) Sequence of the 3' site of exon 1 of the LlCAM gene. The potential 5' splice donor site in exon 1 is used 
instead of the original splice site due to the c. 76+5G>A mutation. 
(B) Analysis of the PCR products of the different cDNA samples: 
B = no template control, M = marker, 
WT = wild type: p5PL3 containing wild type exon/intronl, 
Patl = patientl, p5PL3 containing mutated exon/intronl (c.75+5G>A), 
pPSPL3:  p5PL3 plasmid without an Ll CAM insert. 
lntron l variant c. 76+5G>A 
The c.76+5G>A variant in intron 1 of the LlCAM gene caused a shorter cDNA fragment than 
generated from the wild-type construct (figure 3B). Sequence analysis of the recovered 
fragments showed a deletion of 59 bp at the 3' site of exon 1. The original splice donor site 
was weakened by the mutation at +5 such that the potential splice donor site present in exon 1 
of the LlCAM gene was being used rather than the weakened original splice donor site (figure 
3A). This was also predicted by at least three prediction programs. The cDNA sample of patient 
1 (Patl) contains a second fragment (figure 3B) that turned out to be pSPL3 without an insert. 
Probably the splice donor site of pSPL3 itself competes with the splice donor site in exon 1. 
Exon 12 variants p.Asp516Asn and p.Asp516Tyr (c. 1546G>A and c. 1546G>T) 
Both the c.1546G>A (present in patient 2) and the c.1546G> T (present in patient 3) variants 
at the end of exon 12 completely eliminated the splice donor site, such that RNA splicing 
had to occur at the splice donor site of exon 11, thus inducing complete skipping of exon 12 
(figure 4A, Pat2 and Pat3). Since this was predicted by various prediction programs, we cloned 
a fragment containing exon 11 and exon 12, with and without one of the variants, in pSPL3. 
Sequence analysis of the largest cDNA fragment of the wild type (figure 4A) confirmed the 
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Pat 2 + 3 375  bp  
pSPL3 263 bp 
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Figure 4. cDNA analysis of the c.1546G>A (p.Asp516Asn) and c.1546G> T (p.Asp516Tyr) variants. 
(A) Analysis of the PCR products of the different cDNA samples: 
B = no template control, M = marker, 
WT = wild-type: pSPL3 containing wild-type exonll-intronll-exonl2, 
Pat2 = patient2, pSPL3 containing the c.1546G>A variant 
Pat3 = patient3, pSPL3 containing the c.1546G>T variant 
pPSPL3: pSPL3 plasmid without an LlCAM insert. 
(B) Sequence analysis of the cDNA fragment obtained with the c.1546G>A variant. 
(figure 4A) confirmed the absence of exon 12 (figure 4B). As can be concluded from figure 
4A, the 5' splice site at the beginning of intron 12 is rather weak anyway, since the wild-type 
cDNA also showed some cDNA lacking exon 12. Probably the splice donor site of pSPL3 itself 
competes with the other splice donor sites, since the cDNA fragment of pSPL3 was detected 
in all the cDNA samples. 
Conclusion 
Ex vivo RNA splicing analysis is a fast and reliable method to determine the effect of mutations 
on RNA splicing, as demonstrated with a comparable system for mutations in MLHl and M5H2f61 
and BRCAl and BRCA2171 • Here we confirm the reliability of our ex vivo RNA splicing assay with 
the LlCAM c.645C> T mutation, since it generated the same result as found in vivo in the RNA of 
the patient 151 • Also, as we assumed from the in silica data, the other three variants analyzed by 
this method, c.76+5G>A, c.1546G>A (Asp516Asn) and c.1546G>T (p.Asp516Tyr), were shown to 
disturb the correct splicing. These UVs are therefore considered as disease causing. 
Now we have shown the three UVs to be pathogenic, the number of disease-causing mutations 
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has increased from 61 to 64 in the group of 68 mutations found in 367 patients. Consequently 
the number of UVs judged to be likely disease-causing drops from 7 to 4. 
In conclusion, our analysis shows that unclassified variants (intronic variants as well as silent 
and missense mutations) might well cause RNA splicing problems and should therefore be 
studied carefully. We suggest pre-screening via splice site prediction methods such as used by 
Alamut (Interactive Biosoftware), followed by ex vivo RNA splicing assaying. 
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We report on an infant boy with congenital hydrocephalus due to Ll syndrome and polyuria 
due to diabetes insipidus. We initially believed his excessive urine loss was from central 
diabetes insipidus and that the cerebral malformation caused a secondary insufficient pituitary 
vasopressin release. However, he failed to respond to treatment with a vasopressin analogue, 
which pointed to nephrogenic diabetes insipidus (NDI). Ll syndrome and X-linked NDI are 
distinct clinical disorders caused by mutations in the L1CAM and AVPR2 genes, respectively, 
located in adjacent positions in Xq28. In this boy we found a deletion of 61,577 basepairs 
encompassing the entire L1CAM and AVPR2 genes and extending into intron 7 of the ARHGAP4 
gene. To our knowledge this is the first description of a patient with a deletion of these three 
genes. He is the second patient to be described with L1 syndrome and NOi. During follow-up 
he manifested complications from the hydrocephalus and NOi  including global developmental 
delay and growth failure with low IGF-1 and hypothyroidism. 
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Introduction 
Ll syndrome is a spectrum of X-linked syndromes caused by mutations in the L1CAM gene. 
The LlCAM protein plays an important role in the central nervous system development. 
One manifestation of Ll syndrome is congenital hydrocephalus with aqueduct stenosis. 
Approximately half of affected children show adduction and flexion of the thumbs, probably 
reflecting corticospinal tract compression. Other, often milder, clinical forms of Ll syndrome 
have been described as MASA syndrome (mental retardation, aphasia, shuffling gate and 
adducted thumbs; OMIM 303350), Complicated Spastic Paraplegia type 1 (SP-1), and Agenesis 
of the corpus callosum (ACC). 
Nephrogenic diabetes insipidus (NDI) is characterized by the excessive loss of dilute urine 
caused by the inability of the renal collecting tubules to respond to vasopressin. Mutations in 
the vasopressin receptor gene (AVPR2) are responsible for 90% of patients with NDI. The genes 
for these disorders are adjacent on Xq28. Here we report a patient with a contiguous gene 
deletion leading to Ll syndrome and NOi.  
Clinical report 
The baby's mother was 35 years old and she had one healthy 2-year-old daughter. She had 
no history of miscarriages or abortion. Family history revealed no specific abnormalities. The 
current pregnancy was without complications and a fetal sonogram in the third trimester 
showed no structural defects. Labor began after 40 weeks of pregnancy, a caesarean was 
performed for cephalopelvic disproportion. A boy was born with APGAR scores of 7 and 9 after 
1 and 5 min, respectively. He weighed 3,470 g (+1.3 SD) and had a head circumference of 46 cm 
(+11.1 SD). Physical examination revealed bulging fontanelles with separated sutures, sunset 
phenomenon, bilateral adducted thumbs with single palmar creases (figure 1), hypertonia of 
the legs, and glandular hypospadias. Cranial MR imaging showed hydrocephalus with a thin 
layer of cortex and a relatively small fourth ventricle due to an aqueduct stenosis (figure 1) . 
Initially, a third ventriculostomy was performed, but due to persisting increased intracranial 
pressure, a ventriculoperitoneal shunt was inserted. Ll syndrome was suspected due to the 
combination of hydrocephalus with adducted thumbs in a boy. 
In the third week he became less active and lost weight, despite an adequate intake for his 
age. Laboratory investigation revealed a hypernatremia of 158 mmol/L and increased serum 
osmolality of 330 mOsm/kg. A relative polyuria was found with urinary osmolality of 89 
mOsm/kg. An ultrasound of the kidneys and urinary tract was normal. The initial working 
diagnosis was diabetes insipid us, probably of central origin due to the cerebral malformations 
and insufficient vasopressin release. Treatment with extra fluid intake and desmopressin was 
initiated. However, the baby persistently needed a high fluid intake, which led to the suspicion 
of NOi. A diagnostic challenge with desmopressin had no effect on urine or serum osmolality 
and confirmed the diagnosis of NOi (maximum urinary osmolality 200 mOsm/kg). Diuretic 
treatment (hydrochlorothiazide and amiloride) was started at age 5 months, after which he 
required less fluid. Further evaluation revealed secondary/tertiary hypothyroidism (at age 2 
months: FT4 9.2 pmol/L; TSH 0.86 mE/L), but MRI revealed no structural abnormalities of 




A: Adduction and flexion 
of thumb. B: Magnetic 
resonance image of 
the brain showing 
hydrocephalus with 
aqueduct stenosis (arrow). 
percutaneous gastrostomy was insta l led because of feeding difficu lties and  stunting (height 
80 cm (-3.8 SD); ta rget height: 164 cm (-0.5 SD ); weight 11 .2  kg (weight for height: +0.2  SD) ) .  
Height SD scores d id not improve despite adequate nutrition and  flu id i ntake. A stimu lation 
test demonstrated a growth hormone deficiency and supplements were sta rted . During fol low­
u p  the boy suffered from globa l developmenta l de lay: smi l ing responsive ly at 6 months, ab le  
to  s i t  unsupported at 2 years, wa lk ing  at  3 yea rs. He is now 5 years o ld and  is just ab le to  make 
two word combinations.  
The combination of Ll syndrome and  N Oi, with the correspond ing genes LlCAM and AVPR2 
located close to each other on the long arm of the X chromosome, led to the hypothesis of a 
contiguous gene deletion syndrome and genetic ana lysis was performed. 
Materials and methods 
D NA was isolated from peripheral b lood by the h igh salt/chloroform extraction method 111 • To 
a nalyze the LlCAM and AVPR2 gene, the first a nd last exons of both genes were ampl ified us ing 
a s ingle PCR program and the products were ana lyzed on a 2% agarose gel .  The M LPA kit  "Sa lsa 
M LPA POlSc MECP2 kit" from M RC-Hol land,  conta in ing one p robe for exon 4 of the LlCAM 
gene (personal commu nication and  product information from the M RC-Hol land website www. 
m rc-hol land .com), was used to determine the nu mber of LlCAM a l le les in the DNA of the 
boy's mother. The ana lysis was performed accord ing to the man ufacturer's instructions. To 
p rove that the mother is the boy's b iological parent, we performed microsatel l ite ana lysis with 
five polymorphic markers. 
Primers a round the LlCAM and AVPR2 gene were designed to map the deletion breakpoints by 
the presence or absence of fragments (tab le 1 ) .  Ampl ification was carried out using a standard 
PCR protocol at the anneal ing tem perature given in table 1. F ina l ly, the deletion junctions were 
characterized by sequence ana lysis of the PCR product obtained after amp l ification, by us ing 
p rimer pair LlCAMdel2 F (4F) and l ntron7C R (11R) .  Sequence ana lysis was performed us ing 
the ABI B ig Dye Terminator K it  and  the ABI Pr ism 3 100 Genetic Ana lyzer. 
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Table 1. Primers to map the deletion breakpoints 
# Primer name Primer sequence Location AT PCR product 
in proband 
LlCAM locus {GenBank U52112.2) 
l F  Exon 1 F GTGGCTGTGCTGCGCGGTGC Around exon 1 58 No 
l R  Exon 1 R {40GC)CATAGCGGCGAAGGTAGGCG LlCAM gene 
2 F  Exon 28 F {40GC,8T)TTCATTGGCCAGTACAGTG Exon 28 58 No 
2 R  Exon 28 R GAGAGGGAGGGGCCTGGATC LlCAM gene 
3 F  LlCAMdell F TTGCTGTTCCGCCATCCTCAACG 11967-11989 57 No 
3 R  LlCAMdell R TGAGATGGAGTCTCGCTCGATCAC 12344-12367 57 
4 F  LlCAMdel2 F AGGGCTAACAGTGCTAAATC 9447-9466 51  No 
4 R  LlCAMdel2 R GGGAGTTAGGACTCTTCAAACA 9934-9955 51  
S F  DXS7065 F GGGATGGATATAACATTGG 9160-9178 60 Yes 
S R  DXS7065 R ATAGGCTGTTAGAGTCAC 9069-9085 60 
AVPR2 gene {GenBank NC_000023.9) 
6 F  Exon 1-2 P AGTCCGCACATCACCTCCA Exon 1 and 2 65 No 
6 R  Exon 1-2 R TGTCCAGTGGCCTCTCCTG 65 
7 F  Exon 3 P TCTATGTGCTGTGCTGGGCA lntron 2 59 No 
7 R  Exon 3 R CTGAGCTTCTCAAAGCCTCT Exon 3 57  
ARHGAP4 gene {GenBank NC_000023.9) 
S F  Exon 10-11  F CAAGACACCTCCTGCTCCTCCTTGT 
Exons 10 and 
68 No 
11• 
S R  Exon 10-11  R CAGGAGTATCTGAGTGGACGGAGCAT 68 
9 F  lntron 7A F CTGTACTCCAGCCTGGACAAC lntron 7 53 No 
9 R  lntron 7A R GGGCTTGGTCCTGGATTGGATG 53 
10 F lntron 7B F TGTAGTCCCAGCTACTTG lntron 7 50 No 
10 R lntron 7B R TCTCTTGCCTCAGGAATG 50 
11  F lntron 7C F CAGCTGTGACGCCATCGG lntron 7 54 Yes 
ll R lntron 7C R CCGCAATGGCCAAGGAGG 
12 F Exon 6-7 F TCGAGAACCTTGGCTTTGTC Exons 6 and 7 55 Yes 
12 R Exon 6-7 R TCAACGCTGCTGTCAGTAAC 55 
• See Demura et al. [10] 
Results 
The first and last exons of the LlCAM gene and the first and last exons of the AVPR2 gene 
were amplified and the PCR products were analyzed by agarose gel electrophoresis. None of 
the four fragments could be detected, indicating that both genes could have been deleted. In 
addition, several X chromosomal polymorphic markers were amplified. In all cases clear PCR 
products were seen, indicating the good quality of the DNA sample. To determine the exact 
size of the deletion, different primer pairs at both sites of the genes were used to amplify the 
DNA. We obtained clear fragments with the primers 5, 11, and 12 (see table 1 and figure 2) 
and none with the other primer pairs. In addition to the LlCAM and AVPR2 genes, part of the 
ARHGAP4 gene (figure 2) was found to be deleted. The breakpoint was sequenced with the 4F 
and llR primers. 
The deletion appears to span 61,577 basepairs and an insertion of one basepair, a Thymidine, 
was also identified. We showed that the boy's mother does not carry the deletion by using the 
MLPA technique (see figure 3). Polymorphic marker analysis had proved that the DNA was of 
the biological mother of our patient. 
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TGC'!'A'l'CAGCCA A'!'C'I'GA'l'CAGG aagtagaaagg gacagctcctccc 
TGCTATCAGCCAGG ,ATCTGATCAGGtGGGGTGGGTTA I GGGAGCAGCTGTGA 
tctgggggtgggagctgggaacggga GGGGTGGGTTA GGGAGCAGCTGTGA 
Figure 2. Determination of the deletion. Solid arrows indicate primer pairs (1, 2, 3, 4, 6, 7, 8, 9, 10) that 
did not amplify. Broken arrows indicate primer pairs (5, 11, 12) that did amplify. WT L: Wild-type sequence 
downstream the LlCAM gene, WT R: Part of the ARHGAP4 sequence around the breakpoint site. MT junction: 
The breakpoint sequence of our patient. 





Figure 3. MLPA analysis. The DNA was amplified with the specific probes and the fragments obtained were 
analyzed on an ABI 377 sequencer. The peak area is a measure for the number of alleles. C: control probes for 
two alleles. Cx control probes located on the X-chromosome. 1. LlCAM probe (arrow). 2. MECP2 probe. No 
signal was obtained with the LlCAM probe and the patient's DNA, as expected. The control male gave a peak 
half as high as those in a control female and the boy's mother. 
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Discussion 
Ll syndrome and NOi are two distinct clinical disorders caused by mutations in genes located 
in the same area of the X-chromosome. In the present patient, we found a deletion of 61,577 
basepairs encompassing the entire L1CAM and AVPR2 genes and extending into the ARHGAP4 
gene, located telomeric to AVPR2. To our knowledge, this is the second patient to be described 
with Ll syndrome and X-linked NOi. 
Tegay et a!Y1 described an infant boy with the same combination and found a 32.7 kb deletion 
from L1CAM intron 1 to AVPR2 exon 2. The boy also suffered from Hirschsprung's disease. The 
child died at 89 days. His asymptomatic mother was found to carry the same microdeletion. 
Hirschsprung's disease has been reported in patients with L1CAM mutationsl31. In contrast, 
the present patient has a larger deletion but a milder phenotype and does not show any signs 
of Hirschsprung's disease. Patients with NDI need a high fluid intake, and often suffer from 
vomiting and feeding difficultiesl41• The combination with Hirschsprung's disease could further 
compromise intake and uptake of adequate amounts of nutrition. There is one other report 
of a patient with the possible combination of Ll syndrome and NDI, a 15-week-old girl with 
a combination of congenital hydrocephalus and NDl l51• No follow up data or family history 
were reported and it was not possible to detect mutations in the L1CAM and AVPR2 genes 
at that time. Symptomatic female heterozygotes have been described for both AVPR2 and 
L1CAM mutations. The X-chromosome with the normal allele was found to be preferentially 
inactivated by methylation in the women with the disease phenotypel6·81. 
To our knowledge, the present patient is the only person described with a deletion of both 
L1CAM and AVPR2 with part of the ARHGAP4 gene. The ARHGAP4 protein is a signaling 
protein, involved in the regulation of GTP-binding proteins of the RAS superfamily. It is 
predominantly expressed in hematopoietic cells, but also in the placenta and lung and 
during fetal development. Contiguous gene deletions of AVPR2 and the ARHGAP4 have been 
described, but these patients only showed signs of NDI and not hematopoietic disorders or 
other symptoms19·111 • A boy has been described with a 34.4 kb deletion encompassing the 
AVPR2 and ARHGAP4 gene, extending further into a highly conserved DNA segment between 
ARHGAP4 and AR01A 1121.This chromosomal segment is believed to contain regulatory elements 
for hematopoietic cells. That patient also suffered from severe combined immunodeficiency. 
Similar to the patients described by Schoneberg et af.l91 and Demura et a/. 1101 the patient in the 
present report showed no hematologic abnormalities. 
In addition to neural tissue, the L1CAM adhesion protein is expressed in the urogenital tract. 
Ll activity has been found in epithelial cells of different regions including the epididymal tail, 
deferent duct, ejaculatory duct, seminal vesicles, bladder, and urethra1131• The Ll protein is also 
expressed throughout collecting duct development in the mesonephric duct and mesonephros. 
Mice with a targeted deletion of the L1CAM gene show various renal malformations including 
duplex kidneys and malformed or an incorrectly positioned outer medullaf141 • In humans, only 
one patient with Ll syndrome has been described with congenital abnormalities of the kidney 
and urinary tract (i.e., duplex kidneys)I151_ The present patient showed normal renal anatomy 
on ultrasound but had mild hypospadias. 
We observed secondary/tertiary hypothyroidism, low IGF-1 and growth retardation in the 
patient reported here. We believe this to result from both the NDI and the treatment of 
hydrocephalus. These endocrine abnormalities are common in patients with hydrocephalus 
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after third ventriculostomy and are possibly related to the perforation of the third ventricle 
floor (part of the hypothalamic-pituitary neuronal network) or unphysiological intracranial 
pressure profiles developed after a shunt procedurel16• 171• These patients have a higher 
incidence of growth failure1181, which has also been described in NDl[41. 
We did not find any possible mutational mechanisms at the breakpoints of deletion delineated 
in this report. Chromosome rearrangement breakpoints predominate in pericentromeric and 
subtelomeric regions and low copy repeats (LCR), Alu elements, AT-rich palindromes and 
pericentromeric repeats are often found at these sites[191 • Tegay et a/Y1 identified short direct 
repeat homology between the junctional insertion fragments and the flanking segments at the 
breakpoints in their patient with Ll syndrome and NDI. As they state, a common predisposing 
mechanism for this particular contiguous gene syndrome seems unlikely, given the rarity of the 
genomic disorder described. 
In conclusion, we here report a second patient with contiguous gene deletion syndrome with 
Ll syndrome and NDI due to haploinsufficiency of the LlCAM and AVPR2 genes. In contrast to 
the patient described previously [21 the patient reported here displays a milder clinical course, 
possibly due to the absence of Hirschsprung's disease. In addition to the typical features of Ll 
syndrome and NDI, he demonstrates severe growth failure with growth hormone deficiency 
and hypothyroidism. We regard these as secondary features of the hydrocephalus. Glandular 
hypospadias could be related to the LlCAM mutation. The deletion discovered in this patient 
was found to extend into a third gene: ARHGA P4. However, mutations in this gene are not 
associated with a clearly defined clinical phenotype. 
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Chapter 7 
Abstract 
Hirschsprung's disease (HSCR), a congenital complex disorder of intestinal innervation, is often 
associated with other inherited syndromes. Identifying genes involved in syndromic HSCR 
cases will not only help understanding the specific underlying diseases, but it will also give an 
insight into the development of the most frequent isolated HSCR. The association between 
hydrocephalus and HSCR is not surprising as a large number of patients have been reported 
to show the same clinical association, most of them showing mutations in the L1CAM gene, 
encoding a neural adhesion molecule often involved in isolated X-linked hydrocephalus. L1 
defects are believed to be necessary but not sufficient for the occurrence of the intestinal 
phenotype in syndromic cases. In this paper, we have carried out the molecular characterization 
of a patient affected with Hirschsprung's disease and X-linked hydrocephalus, with a de nova 
reciprocal balanced translocation t(3;17) (p12;q21) . In particular, we have taken advantage 
of this chromosomal defect to gain access to the predisposing background possibly leading 
to Hirschsprung's disease. Detailed analysis of the RET and L1CAM genes, and molecular 
characterization of MY018A and TIAF1, the genes involved in the balanced translocation, 
allowed us to identify, besides the Ll mutation c.2265delC, different additional factors related 
to RfT-dependent and -independent pathways which may have contributed to the genesis of 
enteric phenotype in the present patient. 
88 
HSCR disease in a patient with an LlCAM mutation 
Introduction 
Hirschsprung's disease is the major congenital defect affecting the enteric nervous system 
(ENS). It is characterized by the absence of enteric ganglion cells along a variable length of the 
intestine. Mutations of the RET proto-oncogene, encoding a tyrosine kinase receptor mainly 
involved in neural crest cells development, were identified in 1994 as being responsible for the 
disease, and are still considered as the most frequent cause of intestinal aganglionosis (7-35% 
of sporadic patients)r11• Besides RET, nine other HSCR susceptibility genes have been identified, 
most of them found by studying pedigrees with the recurrence of intestinal aganglionosis in 
association with other clinical signs (syndromic HSCR forms)r2-41• The greatest proportion of 
these genes has been shown or supposed to be related to three specific pathways that are 
involved in different cellular programmes crucial for the normal development of the enteric 
nervous system: the RET pathway (RET, GDNF, NTN, SOXlO, PHOX28), the endothelin pathway 
(EDN3, EDNRB, SOXlO} and, to a lesser extent, the TGF-6 signalling pathways {ZFHXlB). 
However, the great proportion of unexplained cases, incomplete penetrance and the variable 
expressivity suggest that the disease is the result of complex interactions between known and/ 
or unknown modifier genes. Additional evidence supporting this model is the existence of 
other genetic syndromes such as trisomy 21, Smith-Nemli-Opitz, and cartilage-hair hypoplasia 
which show an association with HSCR to a variable extent. All these data suggest that studying 
syndromic families showing an association of HSCR with other congenital abnormalities might 
be worthwhile. 
In this paper, we have carried out the molecular characterization of a patient affected with 
HSCR disease, X-linked hydrocephalus, and vesico-ureteral reflux showing a de nova structural 
chromosome anomaly t(3;17)(p12.11;q11.21). 
X-linked hydrocephalus has an incidence of 1/30 000 male births and it is characterized by 
severe mental retardation, spastic tetraplegia and bilateral adducted thumbs, with major 
additional phenotypes including agenesis of corpus callosum and/or corticospinal tract. The 
great proportion of cases is ascribed to loss of function mutations of LlCAM, a neural cell 
adhesion molecule located in Xq28 and involved in the development of the ventricular system, 
axonal tracts and the cerebellumrsi . 
The association between hydrocephalus and HSCR is not surprising as brain development 
is largely controlled by the same neural growth factors acting in the ENS161 • Until now, 
mutations of the LlCAM gene have been found in seven out of eight patients reported to 
show association of X-linked hydrocephalus with HSCR diseaser7-9l _  These results suggest that 
mutations in LlCAM may be involved in HSCR development in association with a predisposing 
genetic background. 
Taking advantage of the chromosomal rearrangement t(3;17)(p12.11;q11.21) detected in 
our patient, we have identified genes encompassing the breakpoints and evaluated their 




Materials and methods 
Cytogenetics investigations 
Fluorescent in situ hybridization (FISH) was carried out using genomic BAC clones spanning the 
chromosomal 3p12 and 17qll, two regions selected from the human library RPCl-11 according 
to the UCSC Human Genome Assembly (March 2006 freeze) . Array-CGH was performed using 
the Agilent Human Genome CGH Microarray Kit 44B (Agilent Technologies) r101 • 
Gene analysis and profile expression 
Screening of LlCAM and RET coding regions was performed as already describedl6,111 • The 
expression profile of Myosin XV IIIA (MY018A} and TGF-81-induced antiapoptotic factor 
l (TIAF1) in human tissues was performed on a human cDNA commercial panel (Origene 
technology Inc., Rockville, MD, USA; www.origene.com). Sequence primers are available under 
request. 
Gene expression levels 
Analysis of SNP rs2320786, corresponding to the synonymous substitution p.A1470A of the 
MY018A gene, was performed on the patient's genomic DNA and corresponding cDNA. 
Quantitative determination of MY018A, TIAF1 and RET expression levels was performed 
using the ABI Prism 7500 Sequence Detection System in combination with TaqMan chemistry 
(SYBR Green PCR Master Mix. PE Biosystems), according to the manufacturer's guidelines. PCR 
conditions and primer sequences are available under request . 
Results 
Clinical report 
The boy (NF, 10 years) is the first child of healthy non-consanguineous parents. He was 
electively delivered at 38 weeks of gestational age by cesarean section, with a birth weight of 
3620 g, length of 52 cm, and macrocephaly (OFC=39.5 cm). Ultrasound examination revealed 
marked ventriculomegaly with reduction of the brain cortex and a shunt was inserted at 8 days 
after birth. At 16 months he was evaluated for chronic constipation and abdominal distention. 
Rectal suction biopsy and histological examination confirmed the diagnosis of a short form of 
HSCR with absence of ganglion cells in the rectosigmoid colon. At 20 months, he underwent 
a laparoscopic colectomy for short-segment disease. At the age of 9 years, bilateral spastic 
paraplegia, adducted thumbs and mental retardation were present. He interacts exclusively 
with a social smile and eye contact, whereas speech is limited to a few words. The patient 
was also diagnosed with a severe vesico-ureteral reflux (VUR) associated with recurrent 
urinary infections. For the last 2 years the patient has been treated with continuous low-dose 
antibiotic prophylaxis. 
Karyotype analysis 
Standard karyotype performed on peripheral blood lymphocytes from the patient showed a de 
nova reciprocal balanced translocation 46,XY, t(3;17)(pl2.l;qll.21} (figure 1). The karyotype 
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Figure 1. Cytogenetics and F ISH results 
obtained from the patient's lymphocytes. 
(a) Cut-out and (b) ideogram of the normal 
and derivative chromosomes 3 and 17. (c) 
FISH with BAC RP11-331K15 (black signals) 
shows the chromosome 3 breakpoint on 
the short arm. Arrowhead indicates the 
signal on normal chromosome 3 and the 
arrows indicate the der(3) and der (17) 
derivative chromosomes. (d) F ISH with 
BAC RP11-321Al 7 demonstrates that the 
chromosome 17 breakpoint is within this 
clone. Signals on normal chromosome 17 
is indicated by arrowhead whereas der(3) 
and der(l 7) derivative chromosomes are 
indicated by arrows . 
Figure 2. Sequence analysis of patient's DNA, showing the c.2265delC (p. Pro756fs) mutation in the LlCAM 
gene. The sequence of the parental DNAs demonstrates that the mutation is inherited from the heterozygous 
mother. 
Molecular screening of L1CAM and RET genes 
LlCAM is a cell adhesion molecule responsible for X-linked hydrocephalus affected males. 
Molecular testing of the gene revealed a single nucleotide deletion in exon 18 in the patient's 
DNA, inherited from the healthy mother, which leads to a premature stop codon causing 
the protein truncation at the level of the third fibronectin type Ill domain (c.226SdelC, 
p.Pro756Leufs9SX) (figure 2). This kind of mutation is commonly associated with the most 
severe phenotype of X-linked hydrocephalus151 • In the attempt to explain the intestinal 
phenotype of the patient, we performed the mutation analysis of the RET gene. Analysis of 
the 21 exons of the gene did not reveal any mutation in the coding region or in the intron-exon 
junctions. Interestingly, the patient showed a heterozygous result for the RET predisposing 
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haplotype, a specific combination of genetic variants located between the promoter and 
the second exon of the gene, largely reported to be over-represented in HSCR patients with 
respect to controls1121 • This haplotype has been associated with reduced gene expression 
and, accordingly, demonstrated in strong linkage disequilibrium with an intronic nucleotide 
substitution which has been shown to impair an RfT transcriptional enhancer in vitro1131 • 
The molecular analysis of LlCAM and RET genes is fully in agreement with the previous 
screening performed on eight patients with the association of hydrocephalus and HSCR 
disease, most of which showed severe LlCAM defects but no RET coding mutations17-91 • The 
presence of an LlCAM mutation fully accounts for the neurological phenotype, whereas the 
molecular defect causing HSCR disease remains unknown. The main hypothesis proposed to 
explain the co-occurrence of the two diseases is that the LlCAM mutation itself may confer a 
predisposing background on which additional factors may act causing the disease phenotype. 
Breakpoint characterization 
To define the translocation at the molecular level, we constructed two genomic contigs with BACs 
covering the region containing the breakpoints on both chromosomes. For chromosome 3p12.1, 
the breakpoint mapped to the RP11-331K15 clone, giving signals on normal chromosome 3, on 
derivative der(3), and on derivative der(17). 
Using a similar strategy, we were also able to map the chromosome 17q11.2 breakpoint to the 
BAC clone RP11-321A17 (AC024619). Comparative genomic hybridization (CGH) array analysis of 
patient DNA allowed us to exclude the presence of further deletions or duplications elsewhere in 
the genome with a resolution of about 75 Kb. 
Somatic cell hybrids from the patient's lymphoblasts were generated to separate the normal 
chromosomes 3 and 17 and the two derivative chromosomes der(3) and der(17). DNA from these 
hybrids was used in a PCR-based strategy with selected non-polymorphic markers spanning the 
region defined by BAC clones (not shown) . We therefore localized both breakpoints, amplified 
and sequenced both junction fragments thus providing the exact molecular definition of the 
translocation (figure 3) . The breakpoint on der{3) lacks one nucleotide from each parental 
chromosome, whereas the der(17) breakpoint contains seven additional bases, probably derived 
from a partial duplication of a nearby sequence (figure 3) . There is no apparent homology 
between the two sequences, and no repeats are involved 
The chromosome 3 breakpoint is located at 390 kb far from the 3'UTR of the CADM2{/GSF4D) 
gene and 480 kb far from the 3' terminal of the VGLL3 gene. Comparative genomic analysis 
performed with the Genome Vista browser ((http://pipeline.lbl.gov/index.html) did not reveal 
any significant homology with the mouse sequence, thus making unlikely the presence of a 
regulatory region in this genomic fragment. 
On chromosome 17 the breakpoint occurred in a region containing two genes, MY018A and 
TIAFl . Myosin XVIIIA is encoded by 40 exons with the production of two alternative isoforms. 
The protein has recently been demonstrated as a high affinity receptor (SP-R210) for surfactant 
protein A {SP-A), a highly versatile immune molecule, which contributes significantly to surfactant 
homeostasis and pulmonary immunityl141 _ 
TGF-81-induced antiapoptotic factor 1 (TIAFl) is an intronless gene, which resides within the 3' 
untranslated region of the MY018A gene. Identified and cloned in 1998, TIAFl was shown to 
participate in the transforming growth factor Bl-mediated growth regulation by both increasing 
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Figure 3. Map of the tran51ocated regions. The breakpoint on chromosome 3 is located between the 
CADM2(1GSF4D) and VEGL3 genes. The breakpoint on chromosome 17 interrupts the MY018A and TIAFl 
genes. The sequences at the breakpoints are reported in the table at the bottom. 
altering TGF-81-mediated Smad2/3 phosphorylation[15,15J _  It has also been shown that TIAFl and 
p53 functionally interact in regulating apoptosis, and TIAFl is likely to participate in the nuclear 
translocation of activated pS3[17J _  
The role of TIAFl in preventing cellular apoptosis is  very intriguing in the light of the patient's 
HSCR phenotype as it has been hypothesized that one of the causes of HSCR pathogenesis is a 
defect in normal survival of enteric neurons and/or premature apoptosis[1l. 
The expression profile of the MY018A and TIAF genes performed on a panel of 24 human tissues 
is in agreement with literature data, showing a quite ubiquitous presence of the two genes with 
a preferential expression in the muscle (data not shown). 
Considering the role of TIAFl as an antiapoptotic factor, we decided to carry out a genetic 
analysis of this gene to determine if it may affect the survival of enteric neurons, playing a role 
in the normal development of the intestine. To this end, we screened the gene in four additional 
patients showing the association of X-linked hydrocephalus with HSCR disease. An analysis of 
1256 bp of the MY018A 3'UTR of gene, containing the whole coding region of TIAFl, did not 
show any alteration in these individuals, with the exception of a silent polymorphism (rs1049848) 
in one patient. To further investigate the role of TIAFl in favouring the intestinal phenotype in 
syndromic HSCR, we analysed a selected group of 17 HSCR patients showing aganglionosis in 
association with other clinical symptoms (six multiple malformations, five limb defects, three 
dismorphisms, one renal hypoplasia, one mental retardation, and one cardiopathy). We did not 
find any mutation or polymorphic variant of the TIAFl gene in these patients, a circumstance 
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Figure 4. Expression profile of the patient. (a) Monoallelic expression at an informative polymorphic marker 
locus of the MY018A gene, determined by comparing the sequence of the patient's genomic DNA with his 
corresponding lymphoblasts cDNA. (b) Quantitative determination of the expression levels of MY018A and 
TIAFl in patient's lymphoblast mRNA. Data are normalized on the control's gene expression levels. 
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Expression profile of the patient 
Figure 5. RET expression in lymphoblastoid cells. RET 
expression levels are reduced in the patient carrying 
one copy of the predisposing haplotype compared 
with a normal wild-type control. 
After investigating the presence of informative alleles of single nucleotide polymorphisms (SNPs) 
of the MY018A and TIAF1 genes among those reported in the SN P database (http://www.ncbi. 
nlm.nih.gov/SNP/), the patient showed a heterozygous result CIT for rs2320786 (p.A1470A) 
in the coding region of MY018A. RT-PCR performed on patient lymphoblasts mRNA could 
confirm the presence of the only C allele at the SNP rs2320786 locus, suggesting a monoallelic 
expression of the MY018A gene as a likely result of the translocation (figure 4a). To exclude 
a physiological monoallelic expression of this gene, we checked if the MY018AITIAF1 gene(s) 
and the 17q21 region have previously been implicated in imprinting (http://igc.otago.ac.nz/home. 
html), finding negative results. Moreover, we also performed Real-time RT-PCR for the two genes 
involved in the translocation, testing the gene expression level in the patient compared with a 
normal control individual (figure 4b). MY018A and TIAF1 show a reduction in their expression of 
approximately SO% in patient's mRNA with respect to the double expression dose detected in the 
control, thus confirming a monoallelic expression because of the translocation. 
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It has been proposed that the presence of a RET predisposing haplotype can increase the risk of 
aganglionosis above the threshold. For this reason, we performed real-time RT-PCR on the RET 
gene using lymphoblasts' mRNA of our patient, who carries one copy of the RET predisposing 
S'haplotype, and compared results to that obtained using mRNA from a control homozygote for 
a wild-type version of the RET gene. Our patient showed a marked reduction of RET mRNA (58 vs 
100% of the control, P-value=0.019) (figure 5), a finding in agreement with previous data showing 
an impaired RET expression associated with this haplotype1181 • 
Our data support the hypothesis of a major role played by the association of L1CAM mutation and 
the RET predisposing haplotype in the occurrence of the two phenotypes, as previously reported 
in eight patientsl7-9l _ Moreover, based on present results, the hypothesis that the impaired 
expression of the MY018AITIAF1 genes represents an additional risk factor, acting together with 
LlCAM and RET defects in our patient to the occurrence of the Hirschsprung's phenotype, cannot 
be excluded. 
Discussion 
In this paper we describe a patient associated with HSCR and X-linked hydrocephalus, who 
shows a mutation in the L1CAM gene, a decreased RET expression and haploinsufficiency of 
two genes involved in a balanced translocation (3;17)(p12;q21) . 
Of eight patients reported so far with co-occurrence of HSCR and hydrocephalus, seven showed 
mutations in the L1CAM gene, which was proposed as a candidate HSCR gene. 
L1CAM may be implicated in HSCR for several reasons. First of all, the 4:1 male/female bias in 
the incidence of HSCR has suggested, for a long time, a role of an X-linked gene in the disease 
aetiology; however, linkage studies have failed to yield any X chromosome locus and, to date, 
L1CAM is the only X-linked gene known to associate with HSCR.l191.Second, L1CAM expression 
has been shown to be under tight regulation in mouse ret k-/k- intestine t201 and a selective 
deficit in L1CAM immunostaining has been reported in sections of bowel from patients with 
HSCR 1211 • Third, L1CAM is expressed exclusively by neural crest-derived cells in the developing 
mouse gut and L1CAM-deficient mice showed a small but significant reduction in enteric 
neural crest cell migration throughout the developing gut1221 • 
Although these observations suggest an important role for L1CAM in the migration of neural 
crest cells in the developing gut, the low incidence of HSCR disease in patients with L1CAM 
mutations (about 3%) and the absence of L1CAM mutations in males affected with isolated 
HSCR suggest that L1CAM is not an HSCR causative gene but provides a predisposing genetic 
background, likely acting as an X-linked modifier gene for the development of HSCR 17-91 • 
Additional factors may act on this background promoting the occurrence of Hirschsprung's 
disease, among which the RET predisposing haplotype, found in our infant affected with HSCR 
and hydrocephalus and carrying a L1CAM mutation. In agreement with the presence of one copy 
of this low-expressed RET haplotype, we found a marked decrease of the RET gene expression 
in our patient compared with a normal control. Though still in need of further validation in a 
larger number of patients, these data seem fully in agreement with the model proposed for 
other syndromes also showing association with HSCR disease, such as the congenital central 
hypoventilation syndrome (CCHS), Bardet-Biedl Syndrome and Down syndrome, and sharing 
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Figure 6 . Hypothetical model of Hirschsprung pathogenesis in our patient. The three major pathways involved 
in the normal development of the enteric nervous system are shown. RET decreased expression and TIAF 
haploinsufficiency can concur together with LlCAM mutation to HSCR pathogenesis. 
With respect to the de nova balanced translocation carried by the patient, we considered two 
different scenarios: (i) the de nova balanced translocation can be non-pathogenetic and only 
by chance associated with the disease phenotype; ii) the genes involved in the translocation 
may a ct as modifier genes in HSCR and/or in other phenotypes observed in the patient. 
MY018A, encoding for the receptor of collectin SP-A, seems not to be involved in HSCR 
disease but may play a pivotal role in the immunity response of the lung. However, with the 
exception of a hospitalization for bronchiolite at 9 months of age, until now our patient does 
not show any susceptibility to recurrent pulmonary infections or asthma and allergic reactions. 
More interestingly, the second gene involved in the translocation, TIAF1, may play a role as 
predisposing HSCR factor by acting in the TGF-8-signalling pathway as an antiapoptotic factor. 
One of the known HSCR genes, ZFHX1B, is also involved in the TGF-8/BMP/Smad-mediated 
signalling cascade as a transcriptional repressor of smad proteins. Indeed, mutations of the 
ZFHX1B gene results in Mowat-Wilson syndrome, a multiple congenital anomaly characterized 
by mental retardation, microcephaly and, at variable extent, Hirschsprung's disease, congenital 
heart disease, genitourinary anomalies and hypospadiasl51 . 
The patient described here shows haploinsufficiency for T/AF1, but further molecular 
analyses allowed us to detect mutations neither in four patients showing hydrocephalus 
and HSCR disease nor in 17 additional HSCR patients characterized by different syndromic 
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associations; therefore, no definitive conclusion can be drawn regarding the role of TIAF1 in 
HSCR. Nonetheless, in the present patient, we hypothesize that TIAF1 haploinsufficiency may 
have perturbed an alternative, RET-independent HSCR pathway, namely the TGF-8-signalling 
pathway, thus increasing not only the risk of developing intestinal aganglionosis but also, based 
on the control that TGF-8 variants seem to exert on the pathogenesis of urinary tract infection 
and vesico-ureteral refluxl241,the risk of developing VUR. In particular, we propose a complex 
mechanism in which one copy of the RET predisposing haplotype and the L1CAM mutation play 
a critical role affecting the RET-mediated cellular program, whereas TIAF haploinsufficiency 
may concur to HSCR disease and VUR pathogenesis by altering a RET-independent-signalling 
pathway (figure 6). However, the pathogenetic mechanism we have postulated in the present 
patient, while confirming the complex genetic etiology of syndromic HSCR, cannot be easily 
generalized to other cases. 
Interestingly, both the pathways mediated by TGF-8 and Ret may concur to the development 
of the VUR observed in our patient. VUR has often been reported to be associated with TGF-8 
signal-dependent Mowat-Wilson syndrome (38%) and TGF-81 polymorphisms have been 
recently shown to be associated with the susceptibility to VURls, 241 _ 
On the other hand, the RET gene plays a critical role in kidney development and it has been 
found involved in isolated congenital anomalies of the kidneyl25I • Considering that, like HSCR, 
vesico-ureteral reflux is a genetically heterogeneous trait which may occur as a result of the 
complex inheritance, we suggest that contemporary defects in the two pathways (decreased 
RET expression and TIAF1 haploinsufficiency) may be critical for the onset of vesico-ureteral 
reflux in our proband and that these different pathways may be involved in other cases of 
either syndromic or isolated vesico-ureteral reflux or renal malformations. 
Further screening of the TIAF1 gene in other HSCR patients with association of vesico-uretral 
reflux or other renal malformations may be helpful to better understand the molecular basis 
of the disease. 
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Ll syn d rome is an X- l i nked recessive d isorder caused by mutations in  the L1CAM gene.  Because 
only 20% of the patients c l in ica l ly suspected of having Ll syndrome carry a mutation in  the 
L1CAM gene, we hypothesize that other genes must be involved. We searched for a second 
gene on  the X-chromosome by screening for de letions i n  60 patients using a high density 
X-chro mosomal array. 
Ana lysis of the resu lts revealed e leven candidate d isease-causing deletions in twelve patients, 
i nvolving e leven cand idate genes: DGAT2L6, POU3F4, GD/1, ASMTL, ATP6AP1, M/01, FRMPD4, 
MAP3K15, TGIF2LX, DDX53, and  TMEM27. Sequence ana lyses of five of these genes in  95 Ll 
syndrome patients showed only one gene, GD/1, to be involved : in addition to the deletion 
found we detected one mutation, c.153-3C>T (probably pathogenic) .  
From the low deletion and m utation frequency fou nd, we conclude that at least the five 
selected genes do not appear to be major p layers in Ll syndrome, but our  find ings do not 
exc lude a role for these in the d isease deve lopment. 
Not fi nd ing a frequently i nvolved second L1 syndrome gene m ight be caused by the selection 
of the ca ndidate genes (maybe, one or more of the remai n ing six genes do harbor more 
mutations) or by the in itia l  screen ing method searching for micro de letions (>2kb) .  By using this 
method, genes that on ly have point mutations or  sma l l  deletions cou ld have been missed .  
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Introduction 
Ll syndrome is an X-linked recessive neurological disorder, caused by mutations in the LlCAM 
gene 11· 21, a gene located on the X-chromosome at Xq28. The phenotypic spectrum associated 
with mutations in LlCAM includes four different neurological disorders: X-linked Hydrocephalus, 
also referred to as Hydrocephalus due to stenosis of the Aqueduct of Sylvius (HSAS, MIM 
#307000), MASA syndrome standing for Mental Retardation (MR), Aphasia, Shuffl ing gait 
and Adducted thumbs (MIM #303350) 131, X-linked complicated hereditary Spastic Paraplegia 
type 1 (SPGl, MIM # 303350) and X-linked complicated Corpus Callosum Agenesis (X-linked 
ACC, MIM # 304100) 14·51 • The seven most important characteristics of these four disorders are 
hydrocephalus, aqueduct stenosis, mental retardation, adducted thumbs, agenesis/dysgenesis 
of the corpus callosum, aphasia and spastic paraplegia. 
We conducted an LlCAM mutation analysis study in our lab with 367 patients, most of whom 
were suspected to have L1 syndrome. We were able to detect a mutation in almost 20% of 
these patients. This rate increased to 85% for patients showing at least three of the seven 
major Ll syndrome characteristics mentioned above and with at least one affected relative16I. 
These results indicate that the chance of detecting an LlCAM mutation increases with the 
number of characteristics supporting the Ll syndrome diagnosis. However, this also raises the 
question of whether there are other, not yet identified, genes involved in Ll syndrome and 
whether they might explain part, if not all, of the remaining 80% of the patients who do not 
have a mutation in the LlCAM gene. To exclude potentially overlooked mutations in the non­
coding regions of the LlCAM gene, we analyzed the promoter region, the Neural Restrictive 
Silencer Element (NRSE) and the Homeodomain and Paired Domain Binding s ite (HPD), but 
found no mutations [61. 
To date, the possibility of heterogeneity in Ll syndrome has not been studied in detail, partly 
because the results from a linkage study in a number of families with congenital hydrocephalus 
and MASA syndrome[7I revealed a clear 1.5 Mb region at Xq28[8I that harbors the LlCAM gene. 
Shortly afterwards, the LlCAM gene was shown to be responsible for the disorder 11, 9•111. The 
search for new genes involved in the Ll syndrome has so far been limited to animal models. 
Recently it was reported112I that, in mice, apart from a mutation in the LlCAM gene, a so-called 
Llcam hydrocephalus modifier 1 locus [Llhydrol] had been found that might have an effect on 
the severity of the hydrocephalus. This modifier locus is located on chromosome 5 and harbors 
a few candidate genes that could be an Ll modifier. The human homologues have not yet been 
associated with hydrocephalus 1121 . 
It is known from animal models that abnormal brain development, caused by abnormal cellular 
signaling and functioning during early development, can lead to congenital hydrocephalus. In 
animals (rat, mouse and zebrafish), at least 43 loci and 14 genes have been linked to hereditary 
hydrocephalus to date 112·131, coding for cytokines and growth factors, in addition to molecules 
active in the cellular signal pathways during early brain development, and those involved in 
ciliary function. Thus, different groups of genes may be involved in congenital hydrocephalus 
in animals. 
We cannot exclude the possibility that more than one gene might be involved in the development 
of the Ll syndrome or congenital hydrocephalus in humans. To test this hypothesis we have 
focused on the X chromosome, since 95% of all Ll syndrome patients (with and without an 
LlCAM mutation) are males and familial cases mostly show an X-linked recessive inheritance. 
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We searched for small deletions using a new, high density, X-chromosomal oligonucleotide 
array, with one oligonucleotide every 1.9 Kb on average. Our analysis was performed mainly 
on male patients, but also included a few females diagnosed with ll syndrome. We included 
them because a few female Ll syndrome patients have been shown to have a mutation in the 
LlCAM gene 114• 151 (Chapter 2, appendix) . 
The best candidate genes detected with this method were then analyzed for possible point 
mutations in a cohort of 95 patients suspected of having Ll syndrome. 
Materia ls  and  methods 
Patients used for array CGH 
About 370 patients had been referred to our laboratory for diagnostic LlCAM testing. We selected 
60 patients without a mutation in their LlCAM gene; these included 8 patients with a strong 
suspicion of L1 syndrome (they had at least three characteristics of Ll syndrome and one or more 
affected family members161, and 52 patients belonging to a less stringent group (table 1). 
The study included 49 males and 11 females; 7 unaffected females who were related to 
male index patients for whom we had no DNA (mother n=5 or sister n=2) and 4 females with 
characteristics of ll syndrome. 
Table 1. Patients 
lA. Number of affected family members and number of clinical characteristics in eight patients belonging 
to the group highly suspected of having Ll syndrome 
No. of affected family members No. of features* No. of patients in this group 
2 3 2 
2 4 2 
2 5 2 
3 4 1 
6 3 1 
1B. Number of affected family members and number of clinical characteristics in the 52 patients 
belonging to the less stringent group 
No. of affected family members No. of features* No. of patients in this group 
Index patient: male 
1 2 14 
1 3 6 
1 4 5 
1 5 5 
1 6 1 
2 1 7 
2 2 5 
3 1 2 
5 1 2 
6 1 1 
Index patient: female 
1 4 3 
2 (including one male} 1 1 
* Features: hydrocephalus (HC), aqueduct stenosis (AqS), adducted thumbs (AT}, a/dysgenesis corpus callosum 
(ACC/DCC), mental retardation (MR), aphasia (Aph), spastic paraplegia (SP), hypotonia (HP) 
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Patients used for sequence analysis of candidate genes 
From the approximately 370 patients, we selected a group of 95 patients to sequence the 
candidate genes; they did not have a mutation in their LlCAM gene, but were suspected of 
having L1 syndrome. From these 95 patients 27 were also included in the array experiments. 
X-chromosome-specific array-based comparative genomic hybridization (array CGH) 
An 8-plex 60K array was custom-designed using eArray. The array (1 0_023317, Agilent 
Technologies Inc., Santa Clara, CA, USA) contains 48,325 probes evenly distributed over 
the X chromosome, with an average distance of 1.9 Kb between the probes. All the probes 
were selected from the groups present in the catalogue for lM and 400K arrays { 10_021529 
and 10_021850, respectively, Agilent). In addition, the array contains 10,178 probes from 
chromosome 22. 
Mixes of either 40 healthy male or female DNA samples were used as a reference. 500 ng 
DNA samples were labeled using the genomic DNA enzymatic labeling k it (Agilent). After 
hybridization and washing (procedures carried out according to the manufacturer's protocols), 
the slides were scanned at 2 �tm resolution (microarray scanner, Agilent), and the resulting 
Tiff images were processed with Feature Extraction (FE) software V.9.1 (Agilent). The output 
tiles from FE were imported into DNA analytics V.4.081 (Agilent). Next 2 IogR data from all the 
arrays were exported from DNA analytics into Excel for further analysis. Chromosome-X oligo's 
deleted in males and homozygously deleted in females were identified in Excel by a 2 IogR value 
< -1.5. A sensitivity and specificity of at least 95% is reached with two consecutive probes. 
Sequence analysis of candidate genes 
Mutation analysis of all the coding exons and flanking intronic sequences of the genes DDX53, 
POU3F4, DGAT2L6, GD/1 and TGIF2LX genes was carried out using flanking intronic primers 
(primer sequences available upon request) . PCR was performed in a total volume of 15 µI 
containing 10 µI AmpliTag Gold ®Fast PCR Master Mix (Applied Biosystems), 1.5 pmol/µI of each 
primer (Eurogentec, Serian, Belgium) and 2 µI genomic DNA. The samples were PCR amplified 
on a Perkin-Elmer (ABI) Geneamp 9700 using the following program: an initial denaturation 
at 94°C for 1 minute, followed by 5 cycles of denaturation at 94°C for 5 seconds, annealing 
starting at 65°C for 30 seconds with a stepdown of 1 °C every cycle, and elongation at 72°C 
for 1 minute, followed by 20 cycles of denaturation at 94°C for 5 seconds, annealing at 60°C 
for 30 seconds, and elongation at 72°C for 1 minute, followed by 15 cycles of denaturation 
at 94°C for 5 seconds, annealing at 55°C for 30 seconds, and elongation at 72°C for 1 minute 
with a final step at 72°C for 5 minutes, after which the samples were cooled down to 20°C. 5 
µI of the PCR products were loaded with 5 µI loading buffer and run on a 2% agarose gel with 
a FastRuler Low Range DNA Ladder (Fermentas) for comparison. The remaining PCR products 
were purified with ExoSAP-IT (Amersham Pharmacia Biotech, Biscataway, NY) and subjected to 
direct sequencing on an ABI 3730 automated sequencer, using the specific primers. 
Constructs for Ex Vivo Splicing Assay 
Wild type and mutant GD/1 exon 3 and exon 9, including approximately 80 bp of 5' and 
3'flanking intronic sequences, were amplified from control and patient genomic DNA, 
using the primers GCCGCC-EcoRl,5'-CACAGGGTGGAAGTAGCTC-3', and GGGCGC-BamHl,5'­
CAACATCAGCACGGCTCTC-3' for the intron 2 mutation and the primers GCCGCC-EcoRl,5' -
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GTAGCCACCACAACTTGGAG-3' and GGGCGC-BamHI, 5'CCTCACAATGGGCCATGCC-3' for the 
intron 8 mutation. The PCR was carried out using Phusion High-Fidelity DNA polymerase 
(NEB) in the following steps: denaturation at 98°C for 30 seconds, followed by 35 cycles of 
denaturation at 98°C for 10 seconds, annealing at 63°C for 30 seconds, and elongation at 
72°C for 30 seconds, and a final step at 72°C for 10 minutes. The products were analysed 
on, and extracted from, an agarose gel (Qiagen kit) . To obtain 3'A-overhangs, 7 µI of purified 
PCR product, 1 µI Taq polymerase, 1 µI l0xRB and 1 µI dNTPs were incubated at 72°C for 15 
minutes and put on ice for 2 minutes. 4 µI of this product was added to 1 µI pCR2.1 TOPO 
plasmid (lnvitrogen) and 1 µI salt and incubated for 5 minutes at room temperature. The 
pCR2.1 TOPO constructs were then transformed to DHSa competent cells, according to the 
manufacturer's protocol: "Transforming One Shot Machl-TlCompetent Cells". 40 µI of X-gal 
(20 mg/ml) was spread over ampicillin- containing agar plates. Then the transformed DH5a 
cells were plated and incubated for 16 hours at 37°C. White colonies were picked and grown 
in Low Broth medium for 16 hours at 37°C and 225 rpm. The DNA constructs isolated from 
these cells using the Machery-Nagel kit were checked by BamHI and EcoRI restriction enzyme 
analysis and direct sequencing. Then the correct plasmids and the exon trapping vector pSPL3 
(lnvitrogen) were digested, loaded on and extracted from an agarose gel (Qiagen) .  100 ng 
pSPL3 and 50 ng insert were put together with 3 µI l0x ligation buffer (Biolabs) and 1 µI T4 
Ligase (Biolabs) in a total volume of 30 µI. Ligation was performed overnight at 16°C and 2 µI of 
the product was transformed to DH5a competent cells as described. The final DNA constructs 
were checked by restriction enzyme analysis and direct sequencing. 
Transfection of HEK 293 cells and RT-PCR 
Human embryonic kidney (HEK) 293 cells were plated in 6-well plates containing 6 x 105 
cells/well and cultured in DEMEM supplemented with glutamine, 10% fetal bovine serum 
(FBS), 1% penicillin/streptomycin (penicillin 10,000 U/ml, streptomycin 10,000 µg/ml) and 
incubated at 37°C in air with 5% CO2 • After 24 hours the cells were transfected with 1 µg 
plasmid DNA using polyethylenimine according the manufacturer's instructions (Polyscience 
INC). The plasmid containing the wild-type GOil sequences and the pSPL3 vector, as such, 
were used as controls. After 48 hours the cells were lysed and RNA was isolated according the 
manufacturer's instructions (Qiagen) . 4.5 µg total RNA was used as a template to synthesize 
cDNA using the cDNA primers pd(N)6 (GE Healthcare). Then PCR was performed using the 
primers (SD6) 5' -CTGAGTCACCTGGACAACC-3' and (SA2) 5' -ATCTCAGTGGTATTTGTGAGC-3' and 
the following amplification program: 5 minutes at 94°C, followed by 35 cycles of 1 minute at 
94°C, 1 minute at 60°C and 5 minutes 72°C, and a final elongation time of 10 minutes at 72°C. 
The PCR products were analyzed by gel electrophoresis and direct sequencing. 
Non random X-inactivation 
A possible pathogenic mutation in the GOil gen was detected in a female patient, so we 
were interested whether this patient showed non random X-inactivation. HPAll-digestion of 
the DNA sample was performed overnight at 37°C in a total volume of 20 µI, containing 2 
µg DNA, 2 µI Hpall (l0U/µI, New England Biolabs), 2 µI l0x restriction buffer. The next day 
a PCR was performed in a total volume of 20 µI, containing 2 µI l0xPCR buffer (Amersham 
Biosciences), 0.1 µI rTaq polymerase (5 U/µI, Amersham Biosciences), 0.5 µI of 20 pmol of 
Forward Androgen Receptor (AR) primer (5' -GCTGTGAAGGTTGCTGTTCCTCAT) and 0.5 µI of 
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20 pmol of Reverse AR primer (5'-TCCAGAATCTGTTCCAGAGCGTGC) (Eurogentec) 2 µI 4x2mM 
dNTP's (Amersham Pharmacia Biotech), 3 µI digested DNA (or a non-digested sample) and 
MilliQ water. The samples were PCR amplified on a Perkin-Elmer (ABI) Geneamp 9700 using 
the following protocol: an initial denaturation at 95°C for 5 minute, followed by 32 cycles of 
denaturation at 95°C for 30 seconds, annealing at 60°C for 1 minute, elongation at 72°C for 1 
minute with a final step at 72°C for 5 minutes, after which the samples are cooled down to 
20°C. 1 µI of each PCR-product is used in a formamide dilution and analyzed on an ABI 3130x/ 
(Applied Biosystems). 
Results 
X-chromosome-specijic array-based comparative genomic hybridization (array CGH) 
Deletions encompassing at least two consecutive oligonucleotides 
After screening the DNA of 49 male patients suspected of having Ll syndrome by array-CGH 
and analyzing the data obtained, we detected 74 deletions that encompassed at least two 
consecutive oligonucleotides. Several of these were either known polymorphisms (CNVs listed in 
the Database of Genomic Variants at http://projects.tcag.ca/variation) or deletions not including 
all or part of a known gene (CCDS or RefSeq track, UCSC genome browser at http://genome.ucsc. 
edu/, build 36.1). These deletions were excluded from further analysis. In this way we ended 
up with 8 candidate disease-associated deletions. We also identified two single-copy deletions 
in pseudo-autosomal regions, which included the TG/21X/Y gene and part of the ASMTL gene, 
respectively. We decided to include these two deletions in our further analysis, making a total 
of 10 candidate disease-associated deletions (table 2). In the group of 11 females, we identified 
one deletion, resulting in the loss of one copy of part of the ASMTL gene. This deletion was also 
found in one of the male patients (patient 4). 
In the deletions we identified 11 genes that could be involved in the Ll syndrome (table 2) in 12 
different patients. The candidate genes were divided over four groups (table 2): Group A contains 
the most likely candidate genes based on the known characteristics of the gene product and/ 
or their expression in brain/neuronal tissue; Group B contains candidate genes for which it is 
unknown whether they are expressed in brain/neuronal tissue; Group C comprises candidate 
genes selected because the gene is expressed in neuronal tissue and the deletions, comprising 
several probes in an intron, may extend into an exon of the gene (because the flanking probe 
is positioned in, or downstream of, the adjacent exon); and Group D contains those candidate 
genes selected using the same criteria as for Group C but which are not extending into an exon. 
We selected only those deletions which comprised more than one probe, but if several patients 
showed a deletion in the same region of a gene, we deviated from this criterion (patients 
121, 44), giving 11 candidate disease-associated deletions (table 2). In three DNA samples, 
we detected more than one deletion (patients 4, 6 and 44). Two candidate genes were found 
in patients belonging to the highly suspected group; these were DGAT2L6 (patient 207) and 
M/D1 (patient 121). Deletions in the ASMTL gene, the M/Dlgene, and the MAP3K15 gene were 
detected in several patients. 
Deletions encompassing only one oligonucleotide 
In addition to the 74 deletions that encompassed at least two consecutive oligonucleotides, we 
identified 319 deletions in 46/49 male patients that comprised only one oligonucleotide (162 
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,- -- �� . - �-- - 'i'Jr- �-_:_ I ------ --- -- -- ·-.. ,�-� ----. 
Patient Sex Phenotype # Affected Gene Start - end # Kb Deleted Remarks � 
relatives Probes 
.., 
II I ___ _J 
Group A* 
prom, 
Diacylglycerol Opacyltransferase 2-like 
207 M HC, AqS, AT 2 DGAT2L6 69310516 - 69315731 3 5.2 protei n  6. Expressed i n  brain,  among other 
exon 1 
tissues. 
Neural transcription factor. Expressed during 
397 M M R, AT 1 POU3F4 823477751 - 82669656 so 321.9 whole gene embryonic development in  bra in .  Disease 
gene:  X-linked deafness. 
prom, 
Expressed primarily in neural and sensory 
4 M HC, MR, Aph, H P  1 GDll 153316250 - 153320060 2 3.8 tissue. Mutations in this gene have been 
exon 1 
linked to non-specific M R. 
Group B* 
Also called CAGE gene (Cancer associated 
31 M HC, AT 1 DDX53 22867019 - 23018419 53 151 .4 whole gene gene), expressed i n  a variety of cancers and 
i n  testis. 
Exclusively expressed in kidneys, not in adult 
44 M HC, MR, Aph, DCC 1 TMEM27 15574355 - 15634089 31 59.7 exons 1-3 bra in .  Is detectable at day 13 of gestation i n  
mice mRNA (Zhang et  al. 2001} .  
Transcription factor. Testis-specific 
71 M H C  3 TGI F2LX 88943182 - 89400685 69 457.5 whole gene expression. mRNA from bra in  tissue has 




289 F 2 ASMTL 1528326 - 1530474 4 2.1 protein. Expressed in brain,  among other 
Son : HC exonl? 
tissues. 




Vacuolar ATPase. Expressed in many tissues, 
4 M HC, MR, Aph, H P  1 ATP6AP1 153316250 - 153320060 2 3.8 
exons? 
including foetal brain. Many functions such 
as fibroblast growth factor receptor binding. 
Patient Sex Phenotype # Affected Gene Start - end # Kb Deleted Remarks 
relatives 11 II 'Probes -
Group D* 
--,;--- --- - ----- --- ------ -lf  Mid line 1 ,  member of  the tripartite 
i1 motif family. Mutations in this gene have 
367 M HC 2 MIDl 10654513 - 10663078 3 8.6 intronl  
been associated with Opitz syndrome. 
Expressed in brain, among other tissues. 
121 M HC, M R, SP 2 M IDl 10486705 - 10492151 1 5.4 intron2 
44 M HC, M R, Aph, DCC 1 I� I MIDl 10486705 - 10492151 I 1 5.4 intron2 
FERM and PDZ domain containing 4.  It's in  
6 M HC, ACC, AT 1 FRMPD4 12343603 - 12349210 2 5.6 intronl  vivo function is yet unknown. Expressed in 
brain, among other tissues. 
Member of the mitogen-activated 
protein-kinase kinase kinases. In contrast 
44 M HC, M R, Aph, DCC 1 MAP3K15 19375526 - 19381726 2 6.2 intronS to some members, the function of 
MAP3K15 is still unknown. Expressed in 
nervous system, among others. 
6 M HC, ACC, AT 1 MAP3K15 idem 2 6.2 intron 5 
392 M HC, MR, ACC, SP, AT 1 M AP3K15 idem 2 6.2 intron 5 
79 M HC, DCC 1 MAP3Kl5 idem 2 6.2 intron 5 
Legend. The deletions groups are based on several criteria: 3 
0 
Group A 0 
- Deletions comprising several probes covering all or part of a coding area of a gene. The gene is expressed in neurons and/or in the brain.  3 
Group B t 
- Deletions comprising several probes covering all or part of a coding area of a gene. The gene is probably not expressed in neurons and/or in the brain. 
Group C r, 
Cl 
- Deletions comprising several probes in an intron or the promoter area of a gene. Probably, the deletion also comprises coding regions of the gene. The gene is 
expressed in neurons and/or in the brain. "f 
Group D:  
- Deletions comprising several probes i n  an intron of a gene or deletions comprising only one probe i n  an intron of a gene but the deletion has been found in more than 
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53 M HC, AqS, M R  1 WWC3 10059340 - 10063447 4107 
138 M HC, MR, Aph, DCC, SP 1 MAP3K15 19383842 - 19386854 3012 
110 M HC, AqS, ACC, AT 2 SH3KBP1 19634524 - 19637815 3291 
121 M HC, M R, SP 2 FAM47C 36939186 - 36947481 8295 
391 F 
Normal, carrier 
2 WNK3 54267613 - 54274012 6399 
Son: HC 
41 M HC, AT 1 LOC554203 73081201 - 73086192 4991 
178 M HC, M R, AT 1 BCORLl 128943192 - 128946728 3536 
109 M HC, MR, Aph, ACC 1 F8 153781200 -153783605 2405 
mapped within a tra nscribed sequence, representing 65 d iffe rent loci ) .  S ince the l i ke l i hood 
of fa lse-positives is rather h igh in  this group of 3 19 one probes de letions, we app l ied the 
fol lowing fou r, rather stringent, selection criteria :  (1) only resu lts with a h igh qua l ity score were 
inc luded; (2) we excluded deletions that were frequently lost homozygously or heterozygously 
in  a control group of 17 hea lthy females; (3 )  we excl uded deletions that were known CNVs or  
that  mapped with in  segmenta l dup l ications.  Th is reduced the group from 319 to 97 deletions; 
and (4) we further  refi ned this group by selecting only those de letions that partly over lapped 
with an  exon of a gene (UCSC genome browser, CCDS or RefSeq track) .  For this, the size of 
the deletion was ca lcu lated as the segment between the two fla n king (non-deleted) ol igos. 
Our fina l  l ist conta ined on ly 8 possib le cand idate deletions associated with Ll syndrome for 8 
ind ividua l  ca ndidate genes in 7 patients and in 1 mother of a deceased patient (tab le 3 ) .  The 
ol igo of one of the deletions was found i n  an exon (WNK3 gene)  and another deleted ol igo 
was nearby an exon - the ol igo comprised the conserved spl ice s ite of the intron - (WWC3 
gene) .  I n  one patient, a de letion was found in  the MAP3K15 gene, giving a tota l of 5 patients 
with a deletion in this gene  (ta bles 2 and 3 ), and  thus making it a very promising candidate 
gene for Ll syndrome. Two other candidate genes were found in patients belonging to the 
highly suspected group, i .e .  SH3KBP1 ( patient 1 10), and FAM47C (patient 121) .  I n  the latter, a 
deletion in the M/01 gene was a lso found (tab le 2) .  
Sequence analysis of candidate genes 
In order to determine whether these genes play a more genera l  role in patients suspected of 
having Ll syndrome, we sequenced the coding and flanking intronic regions of five candidate 
genes from Groups A and B, i .e. DGAT2L6, POU3F4, and GD/1 (Group A), and DDX53 and TGIF2LX 
(Group B) in a group of 95 patients suspected of having Ll syndrome. 
In the genes from Group A no mutations were detected in  the DGAT2L6 gene or the POU3F4 gene. 
I n  the GD/1 gene two variants were detected :  c. 154-3C>T on one a l lele in  i ntron 2, in a young girl 
with Ll syndrome and c.992-lOC>T in  intron 8 in  an affected boy. These variants are no known 
SNPs according to the NCBI SNP database and were not detected in  100 healthy male controls. 
I n  G roup B we detected one varia nt in  the DDX53 gene, c .185T>C, implying an amino acid 
su bstitution from va l ine  to a la n ine, p.Va l62Ala .  However, as this variant is mentioned in  the 
NCBI SNP database, it is considered to be a polymorphism. 
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A. Principle of exon trapping. SA = splice acceptor site, SD = splice donor site. 
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B. cDNA from wild type and mutated intron2/exon3. M = marker DNA, WT = wild-type intron2/exon 3, Mut = 
c.154-3C>T mutation in intron 2, pSPL3 = empty vector, Bl = blank. 
In the TGIF2LX gene, we found the variant, c.421T>C, at the protein level resulting in the 
replacement of a serine by a praline (p.Ser141Pro), a missense mutation of unknown 
pathogenicity. This variant is no known SNP according the NCBI SNP database. Prediction 
programs do not indicate a high likelihood of pathogenicity for proline141 due to the moderate 
physicochemical difference between serine and praline (Grantham score: 74) and the moderate 
conservation of serine 141 and its flanking amino acids. 
Ex Vivo Splicing assay intronic GD/1 mutation 
Because RNA from the girl carrying the c.154-3C> T variant in the GOil gene was not available, 
we investigated the possible influence of this variant on RNA splicing using an exon trapping 
system (figure lA). We cloned exon 3 of the GOil gene, including its flanking intron regions, 
both with and without the mutation in pSPL3. RNA isolated from transfected HEK93 cells was 
converted, using reverse transcriptase, to cDNA. After PCR of this cDNA with pSPL3 specific 
primers, we got two fragments in both cases (figure lB) . Based on the sizes of these fragments 
we concluded that one fragment lacked exon 3 and the other one contained exon 3 (figure 
lB), which was then confirmed by sequence analysis of the fragments eluted from the agarose 
gel. So, from figure lB, which shows a clear difference in intensity of the bands, it may be 
concluded that the wild-type RNA represents mainly correctly-spliced RNA, while in case of the 
c.154-3C>T variant, mainly incorrectly-spliced RNA, skipping exon 3, is being formed. 
Based on these findings which were reproduced in independent experiments, we concluded 
that the patient with this c.154-3C> T variant in intron 2 of the GOil gene was mainly producing 
the shortened mRNA and this might well be the cause of her clinical phenotype. 
The c.992-l0C>T variant did not influence the proper RNA splicing using the ex vivo RNA 
splicing assay and is considered non-disease-causing. 
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Non random X-inactivation 
In order to confirm the relevance of the c.154-3C> T mutation in the GOil gene in a female 
patient suspected of having L1 syndrome, we investigated DNA from her blood for non random 
X-inactivation. We could not detect non random X-inactivation. 
Discussion 
Because almost 20% of the patients suspected of having Ll syndrome carry a mutation in the 
LlCAM gener61 we started to search for one or more potentially disease associated gene(s) 
on the X chromosome. We choose for the X chromosome since 95% of all Ll syndrome 
patients reffered to us are male and because familial cases mostly show X-linked recessive 
inheritance. 
In our screening of 60 patients using a high density X-chromosomal array, we identified eleven 
candidate deletions containing eleven candidate genes (table 2). These deletions encompassed 
at least two consecutive oligonucleotides to prevent false positive results (or only one probe, 
when the deletion was found in more than one patient). In our laboratory the Agilent system 
is validated for diagnostic purposes. A sensitivity and specificity of at least 95% is reached with 
two consecutive probes. 
We classified the eleven genes into four groups and hypothesized that genes involved in Ll 
syndrome should be expressed in the brain or neurons in an early stage of fetal development. 
As shown in table 2, at least 8/11  genes are being expressed in the brain or in neurons indeed 
(OGAT2L6, POU3F4, GOil, ASMTL, ATP6AP1, M/01, FRMPO4, and MAP3K15} (Groups A, C 
and D) and at least 3/8 were expressed in an early stage of development (POU3F4, GOil, 
and ATP6AP1). The other three candidate genes were less easily to categorize. Nonetheless 
we selected OOX53 and TMEM27 (Group B), as they harbored distinct, non-CNV deletions in 
patients who certainly had Ll syndrome and TGIF2LX, because brain cDNA clones have been 
described (BI830352 and BC029920). 
The candidate genes are found in patients belonging to the stringent group as well as in 
patients from the less stringent groups. 
From the literature it is known that three out of these eleven candidate genes are disease­
causing when mutated, i.e. the POU3F4 gene r161, M/01 gener171 and GOil genel181. 
The POU3F4 gene 
Mutations in the POU3F4 gene cause X-linked non-syndromic deafness 1161 • In one family 
patients have been described with X-linked non-syndromic deafness and MR1191 . Their disease­
causing mutation turned out to be a deletion of at least 200 kb, lying between 300 and 700 kb 
upstream of the POU3F4 gene. The deafness in this family might be explained by the deletion 
as it likely affects a regulatory region controlling POU3F4 expression. As the POU3F4 gene 
could not directly explain the MR in the family, it was hypothesized that within this 200 kb­
sized DNA sequence a gene should reside that could explain the MR, although a causative gene 
was not identified 1191 . As our deletion overlapped with the deletion found in this family, the 
MR in our patients might be explained by the same genetic aberration. There is some doubt 
as to whether this is a gene since analysis of the region revealed no genes. We reduced the 
region to approx 300 kb upstream of the POU3F4 gene, as a result of the upstream border 
of the deletion in our patient. Hildebrand's 1191 and our data can also be seen as an indication 
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that the POU3F4 gene itself might be involved in mental retardation, which was reason for 
us to sequence the POU3F4 gene in 95 patients suspected of having Ll syndrome. However, 
we found no mutations. Thus, the POU3F4 gene does not seem to be part of the cause of Ll 
syndrome or of an atypical appearance thereof, except for very seldom cases, as might be the 
case with our patient with the deletion. 
The M/01 gene 
The M/01 gene is involved in Opitz syndrome, as demonstrated by approximately 80 mutations 
reported for this gene1171 . These mutations are scattered over the entire gene and consist of 
missense, nonsense and splice site mutations, small insertions and deletions, and deletions 
of either single exons or the entire M/01 coding region. They did not report intronic deletions 
in patients having Opitz syndrome, as we detect in our patients (table 2). This can explain 
why the three patients in our study do not have Opitz syndrome. Some minor characteristics 
of this syndrome show overlap with Ll syndrome, notably MR, developmental delay and 
agenesis of the corpus cal losum1171. 98% of the patients carrying a mutation in M/01 suffer 
from hypertelorism1171, but this is not seen in patients suspected of having Ll syndrome, so 
it seems unlikely that mutations in the M/01 gene would be involved in causing Ll syndrome 
or an atypical appearance thereof. This was the reason we did not sequence the cohort of 
95 patients suspected of having Ll syndrome for mutations in this gene. However, since 
3/60 patients did show a deletion in this gene (twice in intron 2 and once in intron 1), some 
involvement in Ll syndrome as a result of these deletions cannot be excluded. 
The GD/1 gene 
In contrast, the GD/1 gene, identified as being one of the non-syndromic MR genes11s1, was 
thought to be an attractive candidate second Ll syndrome gene. It codes for a protein, involved in 
the neuronal differentiation during brain development, neurite extension and neurotransmitter 
release1201. So far, only three mutations in the GD/1 gene have been detected1181; two mutations 
in large families from linkage data mapping to Xq28 by D'Adamo et al. 1201, and a third in a study 
of 164 patients suffering from non-syndromic MR1211 . We sequenced this gene in our group 
of 95 patients suspected of having Ll syndrome and we detected two different mutations in 
two different L1 syndrome patients: c.153-3C>T in intron 2 and c.992-lOC>T in intron 8. Both 
mutations are no known SNPs according the NCBI SNP database and could not be detected 
in 100 male healthy controls. Although, the c.992-lOC> T variant is considered non-disease­
causing, since it did not influence the proper RNA splicing. 
Ex vivo RNA splicing analysis of the mutation in intron 2 showed two distinct splice forms 
(figure 18), one with exon 3 present and one with exon 3 lacking. The splice form without exon 
3 proved to be the most pronounced band. In contrast the splice form with exon 3 proved the 
main product for the wild type construct. As we did see a quantitative difference between the 
transcripts of the wild type and mutant constructs we concluded that the c.153-3C> T mutation 
might be considered pathogenic. This mutation was found in a newborn girl suffering from 
hydrocephalus, aqueduct stenosis, agenesis of the corpus callosum and adducted thumbs. As 
this heterozygous mutation was found in a female patient, non-random X-inactivation in the 
nerves and brain would be needed for this mutation to be causative, but this can obviously 
not be confirmed experimentally. In blood we did not detect non-random X-inactivation. It is 
interesting to note that in one of the two families described by D'Adamo, carrier females were 
also affected1221. We conclude that the GD/1 gene could well be involved in generating non­
UCAM mediated Ll syndrome. 
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For the other 8 candidate genes no disease associated mutations are described yet. 
DGAT2L6 gene 
The DGAT2L6 gene encodes a diacylglycerol O-acyltransferase 2-like protein 6 and is expressed 
in many different types of tissues, including the brain 1231 • Studies with this gene, cloned in 
yeast revealed its role in triacylglycerol synthesis1231 • The DGAT2L6 protein shows significant 
homology with a large number of acyl-CoA diacyl-glyceroltransferases. If DGAT2L6 has 
a comparable function (acyltransferase), it could be a candidate (early stage membrane 
synthesis?). However, detailed DNA analysis of 95 patients suspected of having Ll syndrome 
did not reveal any mutations in this gene. Besides the possible involvement of the mutated 
gene in the disease of the patient of this study (patient 207), we do not foresee an important 
role for the DGAT2L6 gene in typical or atypical Ll syndrome development. 
The DDX53 gene 
The DDX53 gene, which codes for a protein with possibly helicase activity and plays a role in 
cell proliferation1241, was the only gene in the 150 kb deletion seen in one of our Ll syndrome 
patients and we therefore considered it to be a potential candidate gene. However, the analysis 
of the DDX53 gene in the 95 patients did not reveal any mutations. Besides its possible role in 
the patient with the deletion, the DDX53 gene does not appear to play a key role in typical or 
atypical Ll syndrome development. 
The TGIF2LX gene 
The TGIF2LX gene codes for one of the so-called TG-interacting factors (TGIFs) belonging to 
the family of TALE-homeodomain proteins. This family includes TGIF, TGIF2, and TGIF2LX/Y, 
which play an important role in the developmental stage of various tissues. TGIF and TGIF2 
are transcriptional repressors1251 • Mutations in hTGIF, a close family member of TGIF2LX, 
have been associated with holoprosencephaly, a birth defect involving malformation of the 
anterior ventral midline, including forebrain and facial structures1261 • The function of TGIF2LX/Y 
is unknown. In a Drosophila model system it was shown, that human TGIF2LX inhibits cell 
division and cell growth, in fat body cells, epithelial cells and neuronal cells, amongst others. 
It is unknown whether these findings are relevant in humans1251 , but we thought it sufficient 
reason to sequence this gene in our group of 95 patients. We found one variant in this gene, 
c.421T>C (p.Ser141Pro), but this variant is probably non-pathogenic. Thus, the relevance of 
TGIF2LX as a second gene related to the Ll syndrome is judged to be limited. The testis specific 
expression of the gene is in line with this conclusion. 
The MAP3K15 gene 
This gene is a member of the apoptosis signal-regulating kinase (ASK) family and, more 
specifically, of the mitogen-activated protein kinase kinase kinases (MAP3K) subfamily. These 
MAP3Ks phosphorylate and activate MAPK kinases, which in turn phosphorylate and activate 
MAPKs during signaling cascades, which are important in mediating cellular responses to 
extracellular signals. Although the function of MAP3K5 (ASKl) and MAP3K6 (ASK2) is known, 
it is unknown for the MAP3K15 gene. However, if we assume a role in signal transduction 
for MAP3K15 as well, this makes it an attractive candidate for involvement in Ll syndrome 
development, since Li-mediated neurite outgrowth involves intracellular signaling1271 • A role 
for the MAPK cascade in the Ll-guided activation has been described1281 • We identified five 
deletions in five different patients suspected of having Ll syndrome: four patients had a 
deletion in intron 6 of the MAP3K15 gene, and one patient had a deletion in intron 5 (one 
probe). Intrans 5 and 6 are part of the non-coding segment of the MAP3K15 gene (the first ten 
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exons of the gene are non-coding, according to RefSeq track UCSC genome browser). Thus, 
although it is clear that these mutations do not cause an altered gene product as such, they 
might disturb the proper processing of the primary transcript and might therefore be relevant 
to Ll syndrome development. It is noteworthy that neither MAP3K15 deletions were present 
in our control group, nor are they described as known CNVs. However, in a study concerning 
X-linked mental retardation (XLMR) ([29], Tarpey et al. found two truncating mutations in the 
coding sequences of the MAP3K15 gene in male controls (p.Arg611X (2/272) and p.Arg597X 
(1/243)), making the MAP3K15 gene an unlikely candidate in Ll syndrome development. 
Although these data do not implicate MAP3K15, the identified deletions might still be involved 
by influencing the expression of other gene(s) on the X-chromosome and thereby contributing 
to Ll syndrome development. 
TMEM27. FRMPD4. ASMTL. and ATP6AP1 
The other four genes TMEM27, FRMPD4, ASMTL, and ATP6AP1, were not analyzed further, 
since we judged them to be less likely candidate genes due to their (tissue) specific function 
or because the deletion may not comprise coding regions of the gene (table 2). We also did 
not examine candidate genes detected by only one probe any further. It is obvious that these 
deletions will need independent confirmation by an independent approach, prior to a final 
decision about their relevance. 
Based on the low deletion- and mutation frequency found in our group of respectively 60 and 
95 patients, we conclude that at least the five genes we selected for mutation analysis do not 
appear to be major players in the development of Ll syndrome. However, our findings cannot 
exclude a certain role for these genes in the disease phenotype, because in all cases we have 
found a deletion of (or part of) these genes in at least one patient and six genes have not been 
screened for mutations yet. The high frequency of deletions found in the MAP3K15 gene (in 5 
out of 60 patients) is striking, and it was not detected in controls . However, the gene as such 
is not a likely candidate due to the finding of truncating mutations in male controls by Tarpey 
et al. l291• 
For one candidate gene, GD/1, however, the potential involvement in the typical or atypical 
Ll syndrome is more likely, since we could relate Ll syndrome phenotypes with GD/1 gene 
abnormalities in 2 patients .  In one patient we found a deletion in the gene and in a second 
patient we found a splice site mutation (c.153-3C>T in intron 2) that likely is pathogenic. This 
makes the GD/1 gene the strongest candidate gene that emerged from this study. 
We also conclude that a putative, second Ll syndrome gene on chromosome X is apparently 
not characterized by deletions (>2 kb) in a considerable proportion of the patients. Novel 
techniques that allow the detection of smaller aberrations, including X-chromosome-specific 
exome resequencing approaches, are thus needed to further elucidate the role of these and 
other genes in Ll syndrome development. 
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Discussion and future 
perspectives 
Chapter 9 
This thesis has addressed different aspects of genetic analysis in patients clinically suspected 
of having L1 syndrome and it set out to resolve various questions: Who should be analyzed for 
mutations in the LlCAM gene? Is there a correlation between the disease phenotype and the 
mutations identified in LlCAM? How should missense mutations be interpreted in terms of 
their potential disease-causing effects and what about variants influencing the RNA splicing? 
Are genes other than the LlCAM gene involved in Ll syndrome or an atypical form of it? In this 
chapter, I discuss these issues and the results of my research. 
PART I 
Mutation analysis of the L1CAM gene in patients 
suspected of having Ll syndrome 
We performed mutation analysis of the LlCAM gene in a large group of patients (n=367) 
suspected of having Ll syndrome and referred to our laboratory for diagnostic LlCAM testing. 
To date, LlCAM is the only gene that has been clearly shown to be involved in L1 syndrome 11-51 • 
In this group of patients, only �20% harbored a mutation in LlCAM, implying that 80% did not 
have a mutation in this gene; this raised several questions. Had we overlooked any mutations? 
Were the patients referred to us truly suspected of having Ll syndrome or was the test 
requested to exclude this possibility? Are there more genes involved in Ll syndrome or an 
atypical form of it? 
Had we overlooked any mutations? 
The mutation analysis we performed was based on a prescreening method called denaturing 
gradient gel electrophoresis (DGGE), followed by direct sequencing of any fragments showing 
an aberrant DGGE pattern. We might have overlooked some mutations using this technique. 
However, the DGGE technique had been validated by testing 175 BRCAl and BRCA2 gene 
mutations with a sensitivity of 100%l61• Such validation for the LlCAM DGGE system was 
not possible due to the limited number of mutations available when we started this work. 
Nevertheless, all the known LlCAM mutations detected by other techniques could be detected 
using our DGGE system. A full sequence analysis of the gene in 15 patients not showing a 
mutation by DGGE but who were clinically very likely to have a mutation in the LlCAM gene did 
not produce any missed mutations, corroborating that we had not overlooked many mutations 
by using DGGE. 
Since we analyzed only the coding sequences and the exon-intron boundaries, we were not 
able to exclude mutations residing in regions regulating gene expression. Searching 100 
patients for mutations in the LlCAM promoter and two other regulatory regions, namely the 
neural restrictive silencer element (NRSE) and the homeodomain and paired domain-binding 
(HPD) site, did not reveal any additional mutations (Chapter 2). The probability of mutations in 
these regions being responsible for the Ll syndrome in our group of 367 patients was therefore 
judged to be very low. Thus, the low frequency of mutation detection could not be explained 
by mutations overlooked in these regulatory sequences. 
To check whether we had overlooked the possibility of large duplications in the LlCAM gene 
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(this analysis is no standard procedure in our diagnostic DNA screening) as a cause of Ll 
syndrome, we analyzed a subgroup of 98 patients for this type of genetic aberration. We found 
a duplication in only one of these patients and concluded that this type of mutation could also 
not explain the low frequency of detection (Chapter 2). 
Sometimes we analyzed DNA from the mother instead of from the index patient. We cannot 
exclude missing a mutation in 1 or 2 index patients by doing this (see Germ line mosaicism), but 
again, this does not explain why so many patients did not have an L1CAM mutation. 
One region we did not screen for possible mutations was the 3' part of the gene. Apart from 
the AAUAAA element, which signals 3' cleavage for most mRNAs, it is known that microRNAs 
(miRNAs) regulate gene expression post-transcriptionally by pairing with the 3' UTR of target 
mRNAs171 • Some genetic variants in this region, which alter miRNA recognition sites, may play 
a pathogenic role in human diseases181 as demonstrated for two point mutations in the 3'UTR 
of the REEP1 gene, which is associated with spastic paraplegia type 3119• 101 . Thus, we cannot 
fully exclude possible mutations being located in this region of the L1CAM gene. We will look 
for this type of mutation in the near future, but at the moment we assume the likelihood of 
finding anything will be rather low. 
In conclusion we are confident that it is very unlikely that we have overlooked many mutations 
in the L1CAM gene. 
Does the mutation detection rate depend on the pre-selection of patients? 
We concluded from a questionnaire sent to clinicians that approximately 20% of the patients 
who were analyzed were referred to us in order to exclude a diagnosis of Ll syndrome (Chapter 
2). These patients most probably do not have an L1CAM mutation. If we exclude such patients 
from our analyses, the mutation frequency becomes 25% instead of 20%. 
The Ll syndrome diagnosis is based on specific clinical characteristics. The seven most 
important are hydrocephalus, aqueduct stenosis, mental retardation, adducted thumbs, 
agenesis/dysgenesis of the corpus callosum, aphasia and spastic paraplegia. We showed 
that the chance of detecting a mutation is positively correlated with the number of clinical 
characteristics (Chapter 2). Besides these clinical characteristics, a positive family history also 
proved to be a powerful criterion. A combination of these two characteristics - that is, patients 
with a positive family history for Ll syndrome and with three or more clinical characteristics -
resulted in a higher detection rate of 85% in a well documented subgroup of 106 patients (OR 
10.4, 95%CI 3.6 to 30.1) (Chapter 2). Thus, the mutation detection rate does depend on the 
pre-selection of cases. 
This finding is in line with the results of two other studies, although it is more pronounced. 
Finckh et a/Y11 reported a rather low mutation frequency (30%) in an unselected group of L1 
syndrome patients. Much higher frequencies of 46% and 74% were reported in pre-selected 
groups with a positive family history for L1 syndrome by Kanemura et a/. 1121 and Finckh et a/. f11l, 
respectively. This supports our own finding that pre-selection of patients raises the mutation 
frequencies. Our mutation detection rate increased even more, from 20% (unselected group) 
to 85% when we selected for patients more stringently, that is with three or more clinical 
characteristics in addition to a positive family history. Indirectly this also corroborates our 
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Figure 1. M utation detection rate versus number of age- independent c l inical cha racteristics and number of 
affected fa mi ly members.  
A mutation determination model 
Using these data - the mutation ana lysis resu l ts, the c l in ica l data and  the fami ly anamneses 
- we were a ble to develop a powerfu l tool for c l i n ic ians and genetic cou nselors (Cha pter 2)  to 
determine the chance of find ing a mutation in  a ta rget patient before DNA diagnostic testing, 
see figu re 1 .  Since d iagnostic DNA ana lysis is time consuming and costly, it is im porta nt to be 
wel l  i nformed prior to requesting a DNA test. 
Figu re 1 shows the mutation detection rate in re lation to the number of age-independent 
c l in ica l  characteristics and the nu mber of affected fami ly members.  These i nterrelationsh ips 
were d etermined from data from 338 patients suspected of having Ll syndrome (338 = 367 
minus  29 patients who were only ana lyzed to excl ude Ll syndrome) .  
Despite the relevance of this tool, it is important to rea l ize that mutations might a lso be 
detected i n  patients with on ly one or two c l in ical  characteristics and with a negative fami ly 
anamnesis, as seen in our data and from the l iteratu re 111• 13• 141 . 
Genotype-phenotype correlations 
In trying to identify genotype-phenotype corre lations in a group of patients (n=33) (Chapter 
2),  we demonstrated that ch i ldren with a truncati ng mutation were more l ikely to d ie  before 
the age of 3 yea rs (52%) than ch i ldren with a m issense mutation (8%}. These resu lts a re 
statistica l ly  significant and  re levant for genetic cou nsel ing re lated to prenatal DNA diagnostics. 
They correspond with previous reports by F ransen et af. 1151 and Yamasaki et al_ l161 • Fransen et al. 
reported early death percentages of 100% (truncating) versus 58% (m issense) before the age 
of 2 and  Yamasaki et al. reported 50% (tru ncating) versus 32% (m issense) before the age of 1. 
I n  our group of patients we did not detect a corre lation between the severity of hydrocepha lus 
and the location of the m issense mutation in e ither the key resid ues or the surface res idues 
of the Ll protein, in  contrast to what Michael is et al.f171 and Kam iguch i et alY81 detected. Key 
residues a re amino acid res idues crucial for the structura l  bu i ld  up of the p rotein domains and 
122 
Discussion and future perspectives 
a surface residue occurs at the surface site of a protein and is important for intermolecular 
interactions. We determined that severe hydrocephalus is due to key residue changes in 57% 
of the patients and due to surface residue changes in 50% of the patients, which are much 
closer rates than the 67% and 42%, respectively, reported by Michaelis et a/.l171, or the 78% 
and 28%, respectively, determined by Kamiguchi et a/Y81• This discrepancy may be explained 
by differences in the sizes of the target groups (Michaelis' group was three times larger than 
ours). 
Another explanation for the genotype-phenotype differences might lie in the relevance of 
genetic modifiers. The contribution of modifiers to the severity of X-linked hydrocephalus in 
mouse models has recently been describedr41 • Likewise the differences in the occurrence and 
severity of hydrocephalus, which has been documented among related males r19, 201 carrying the 
same LlCAM mutationr151, might also be explained by the action of different modifiers. 
Germline mosaicism 
Most mutations found in the LlCAM gene are private mutations, occurring only in a single 
family. In this thesis (Chapter 2) we have described 58 private mutations out of the 68 mutations 
identified and shown that 7% of all mutations detected in our index patients occurred de nova, 
which is in the same range as that published by others, e.g. 4%r111 and ll%r211 • For one of 
the patients with a de nova mutation, we detected a germline mosaicism in the mother, a 
phenomena that has already been described for L1 syndrome r11, 21• 221 • Although the frequency 
of germline mosaicism in the mothers of index patients is not precisely known, we estimate 
it to be 5-10% based on our own screening and data from the literature, assuming all de nova 
mutations are germline mosaicisms. This relatively high percentage is important, because it 
is the frequency of germline mosaicism in the mother that determines the risk of having an 
affected child in a next pregnancy (if no mutation is detected in DNA isolated from the mother's 
blood) and therefore warrants prenatal DNA diagnostics. 
In addition, based on the frequency of de nova mutations/germline mosaicism to be 7% in 
our group of 367 patients, we determined that we may have overlooked 1 or 2 index patients 
whose mothers (n=25) were analyzed due to lack of DNA from the index patient and found 
negative for a mutation, thus leading us to assume that the index patient did not have a 
mutation, whereas in fact it had. 
The occurrence of de nova mutations in mothers of index patients or a germline mosaicism 
in a grandparent of the index patient has also been described r23, 241 and was determined to be 
about 10% in our study. This and the 7% de nova mutations in the index patients means that 
at least one-fifth (20%) of the mutations causing the Ll syndrome in our group has arisen 
recently. This was also reported by Finckh et a1.r111, who showed that eight mutations out 
of 46 (17%) emerged recently: originating maternally (n = 2), in a grandfather (n = 4), in a 
grandmother (n = 1) and in a great-grandfather (n = 1). 
Mutations disturbing proper RNA splicing 
lntronic but also silent and missense mutations might disturb proper RNA splicing and thereby 
explain the phenotype. In order to study this possibility we selected four variants (2 missense, 
1 silent and 1 intronic mutation) for which it was unclear whether they were disease causing, 
to check for potential involvement in pre-mRNA splicing. 
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Figure 2. RNA splicing prediction by four different methods: Splice Site Finder-like, Max Ent Scan, NNSPLICE 
and Gene Splicer, comparing the wild-type sequence with the mutant sequence (c.645C>T). The strength of 
the S'splice site is expressed on different scales, 0-100, 0-12, 0-1 and 0-15, respectively. The new splice donor 
site is much stronger according to GeneSplicer, 9 .7 instead of 4.6. 
silent mutation, c.645C>T in exon 6 of the LlCAM gene was indeed pathogenic, because this 
mutation generates a new splice donor site (Chapter 2). Another silent mutation detected by 
Du et a/Y51 in exon 8 of the LlCAM gene, c.924C>T, was also shown to be a splice site mutation. 
Since RNA research is lengthy and rather costly, it is not part of the standard diagnostic tool kit 
for demonstrating the pathogenicity of a mutation. However, due to our findings and those of 
Du et a/Y51, the possibility that a (silent) mutation might disturb proper RNA splicing and be 
pathogenic should be noted. 
Splice site prediction programs can be a great help in indicating the pathogenicity, as shown 
in figure 2. The c.645C> T mutation is predicted by four different methods to create a splice 
donor site not occurring in the wild-type gene which is much stronger than the splice site at 
the beginning of intron 6 according to one of the methods (figure 2). 
Irrespective of the usefulness of the predictions, final proof should always come from RNA analysis 
(Chapter 2), not in the least because it might lead to RNA splice site mutations not predicted by 
these models. Since it is not always possible to isolate and analyze RNA from patients, a reliable 
alternative might be an ex vivo RNA splicing assay, as described in Chapter 5. 
By applying this assay, we showed that the three other selected variants are now considered 
pathogenic due to disturbance of the correct RNA splicing: two mutations detected in an 
exon, c.1546G>T (p.Asp516Tyr) and c.1546G>A (p.Asp516Asn) and one detected in an intron, 
c.76+5G>A. Consequently, we recommend checking all mutations of unknown pathogenicity 
in both intrans and exons for their influence on RNA splicing. 
The number of mutations detected in our group of 367 patients and considered to be disease­
causing increased with this result from 61 (Chapter 2) to 64 (Chapter 5) and the number of 
likely disease-causing mutations decreased (from 7 to 4). 
Interpretation of missense mutations 
In the 367 patients investigated, we found 73 patients with 68 different disease-causing or 
likely disease-causing mutations. Of these, 40 mutations were truncating and therefore 
considered to be disease-causing. The remaining 28 mutations were missense mutations 
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(n=23), in-frame deletions or duplications (n=3), and intronic variants outside the splice site 
consensus sequences (n=2), of which 24 were considered to be disease-causing and 4 as likely 
disease-causing. 
The missense mutations in the L1CAM gene are considered to be disease causing, for various 
reasons: 
1. In Ll syndrome the number of de nova mutations detected in index patients is very 
high at "'7%. A de nova mutation found in the index patient is always considered to be 
pathogenic while a de nova mutation found in the mother of an affected child is always 
seen as a strong indication. The number of de nova mutations in mothers or a germ l ine 
mosaicism in a grandparent of the index patient is ,.., 10%. 
In silica analysis of the protein plays an important role 
2. The Ll protein is highly conserved. The replacement of a strongly conserved amino 
acid contributes positively to deciding that a missense mutation is considered to be 
pathogenic. 
3. If a mutation influences the protein structure as described by Bateman et a/.!261, notably 
if it involves replacement of key residuesl261, this is seen as a strong indication of 
pathogenicity because disturbance of the protein structure and therefore a change in 
the proper protein functionality are likely to occur. 
Further arguments are: 
4. Co-segregation of the variant in the family is also seen as an indication for pathogenicity. 
In most cases, however, only a few family members are ava ilable so that this is not a very 
reliable tool, although excluding the mutation as pathogenic by finding it in unaffected 
males in the family does help. 
5. M issense and silent mutations shown to be responsible for incorrect RNA splicing are 
considered to be pathogenic. If they are only pinpointed by prediction programs, they 
are considered to be potentially pathogenic. 
6. Loss of function in a functional analysis. If a mutation affects the axon growth or 
influences the Ll protein dimer interaction or disturbs Ll protein interaction with other 
relevant molecules needed for optimal functioning of the L1 protein, this also strongly 
indicates pathogenicity of the mutation. 
Obviously, prior to final ly label ing an L1CAM mutation as pathogenic, it is important to 
determine most of the above issues in order to make the conclusion as strong as possible. 
Several studies concerning changes in protein functionality due to a mutation in the LlCAM 
gene have been describedl27-311 • Figure 3 gives a schematic overview of the protein-protein 
interactions and the pathways activated by the wild-type Ll proteinl321 • 
It was proven that some mutations influence the proper functioning of the L1 protein, since 
they disturb the interaction of the Ll protein with itself or with other proteins such as axonin-1 
and Fll (both cell adhesion molecules) and neurocan, or they disturb the transfer of the 
protein to the exterior of the celll27,291• Others have studied the effect that mutations may have 
on the growth and branching of axonsl30•311 . Although these functional studies seem to be rather 
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Figure 3. The complexity of L1 protein interactions. The protein shows interactions with itself and with other 
proteins to initiate neurite outgrowth (adapted from Kenwrick et al. (32] ). 
Sometimes normal protein interactions occur, irrespective of the pathogenicity of certain 
mutations, as illustrated by mutation p. Lys655Glu[291, a pathogenic mutation segregating with 
the disease in a large X-linked pedigreer331 _ From analyses by De Angelis et al. 1291 it may be 
concluded that this mutant protein still interacts normally with wild-type Ll protein and with 
axonin-1 and is correctly being transported to the exterior of the cell. However, because the 
overall interaction pattern of the Ll protein is quite complex[321 (figure 3), it cannot be ruled 
out that the pathogenicity is caused by disturbance of the interaction with another protein, for 
instance in this example Fll or an unknown protein. 
Basically, these problems also apply to studies that look at the growth and branching of axons. 
Michelson et al.f3°1 seems to outline a nice method to confirm the pathogenicity of missense 
mutations. Four mutations considered to be pathogenic were tested. All four showed a clearly 
reduced outgrowth of neurons, whereas studies by Cheng et alY11 indicate that most of the six 
considered pathogenic Ll mutations they tested did not affect neurite length significantly, but 
rather led to a decrease in branching. 
This clearly demonstrates the need for validated functional assays with known sensitivity and 
specificity, although these are extremely hard to determine. In order to do this one would 
need two sets of unclassified variants (UVs), one very likely to be pathogenic and the other 
very unlikely to be pathogenic, to be selected from all the UVs identified so far and based on 
the criteria mentioned. There is still a long way to go and at this point in time a functional assay 
with 100% reliability to confirm the pathogenicity of certain mutations is not yet available. 
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llCAM database 
Since technologies for detecting mutations are becoming more and more advanced, the n u m ber 
of mutations identified is growing enormously, a lso implying an  increase in  the nu mber of UVs 
identified . As d iscussed, add itional  research and  tool development is needed to cope with 
this. One such tool is our L1CAM mutation database (described in  Chapter 4), which is freely 
accessib le and conta ins not on ly a l ist of m utations but a lso other re levant information.  This 
extra information m ight outl ine c l in ical characteristics of patients, co-segregation in  the fa mi ly, 
and resu lts from fu nctional assays, RNA spl icing experiments, in silico ana lysis and the l i ke .  
Our L1CAM mutation database not only conta ins mutations detected in our  own lab, but a lso 
publ ished mutations inc lud ing any relevant i nformation given and, if necessary, supplemented 
by us with in silica data . As a resu lt this database is a good tool for researchers and cou nselors, 
provid ing access to a l l  the data in a fast and  s imple way and  enab l ing them to draw conclusions 
on the pathogenicity and severity of L1CAM mutations based on mu ltiple factors. 
Other Ll syndrome genes 
Although the frequency of mutation detection in specific well-defined patient groups is 
h igh {85%), a large group of patients clearly suspected of having Ll syndrome sti l l  rema ins 
unexpla ined.  It is  therefore tempting to assume that the L1CAM gene is not the on ly gene 
involved i n  Ll syndrome development. One of the a ims of this thesis was to identify potentia l ly 
new genes, as described in Chapter 8, and  this work wi l l  be further d iscussed in Part I l l  of this 
cha pter. 
Future perspectives 
Although we have been able to improve the diagnostic tool box for patient care, we need to 
upgrade it continuously, for i nsta nce by: 
;,.- Sequencing the 3' end of the L1CAM gene 
Th is region of the L1CAM gene wi l l  be sequenced to look for possible mutations 
which a lter miRNA recognition sites, consequently making them potentia l ly d isease­
causing. 
};;> Functional  assays 
A good functional assay is sti l l  lacking to determine whether a m issense mutation is 
pathogen ic. This needs to be a fast and rel iable assay for standard appl ication in  D NA 
d iagnostics which we feel may be best based on a n  assay to measure the outgrowth 
and debra nching of neurons [3o1 .  
};;> Incorrect pre-mRNA spl ic ing 
l ntronic mutations are found regularly, but we do not know if they are pathogenic .  
After the i ntroduction of next generation sequenci ng tech nology, it is  expected 
that this number wi l l  increase qu ite dra matica l ly  and  there wi l l  be a need for a 
re l iable ex vivo RNA spl ic ing assay. This should a lso be less dependent on the 
ava i la bi l ity of patient RNA. The first experiments we performed look very promis ing 
(described in  Chapter S )  and  fu rther research wi l l  lead to a standard a ppl ication in 
DNA d iagnostics. Furthermore, with this assay, a l l  m utations in  exons of unknown 
pathogen icity wi l l  be checked for their infl uence on RNA sp l icing. 
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PART I I  
Syndromic pat ients including characterist ics of the Ll 
syndrome 
Patients with several congenital abnormalities i n  which the L l  syndrome characteristics 
are part of the phenotype have been described in literature 134·411 • In most of these patients 
a mutation in the LlCAM gene was found, sometimes in addition to another chromosomal 
aberration 136•371 • 
We investigated two such patients, one with Nephrogenic Diabetes lnsipidus (NDI) and Ll 
syndrome (Chapter 6) and one with Hirschsprung's disease (HSCR) and Ll syndrome (Chapter 
7) . The reasons to study these patients were to determine whether the clinical picture caused 
by mutations in the LlCAM gene is broader than thought or that these clinical presentations 
are not (solely) based on a mutation in the LlCAM gene, but due to an aberration in a different 
gene or a large deletion including the LlCAM gene .  If we could detect new genes by such an 
approach it would also be interesting to check whether mutations in these genes could explain  
the clinical features of  some of  the L1 syndrome patients who do not have a mutation in the 
LlCAM gene. 
Can Nephrogenic D i abetes lns ipidus {NO i )  be exp la ined by a mutation in the 
l1CAM gene a lone? 
Two patients have been described suffering from both Ll syndrome and NDI :  one is described 
in Chapter 6 and one was previously reported1361 • ND I  is characterized by the excessive loss of 
dilute urine due to the inability of the renal collecting tubules to respond to vasopressin and it 
is caused by mutations in the AVPR2 gene142A31 _ Since the LlCAM and AVPR2 genes are located 
close to each other on the long arm of the X chromosome, we analyzed our patient for the 
presence of a deletion on the X chromosome including both genes as an explanation for the 
dual phenotype . We found a deletion of 61 .577 kb encompassing the entire LlCAM and AVPR2 
genes, thereby confirming the linked clinical characteristic in our patient. The second patient 
was described as having virtually the same phenotype 1361 and showed a deletion of 32 .7 kb 
from LlCAM intron 1 to AVPR2 exon 2, thus confirming the results for our patient . 
Finding this deletion as an explanation for the linked phenotype led us to conclude that the 
NDI  phenotypic features are caused by the loss of the AVPR2 gene rather than the loss of the 
LlCAM gene .  
Hirschsprung's disease {HSCR) and l1 syndrome 
At least 13 cases concerning patients with joint HSCR a nd Ll syndrome characteristics have 
been reported in literature l22, 36•38·41A4-461 · In 11 of these patients, a mutation in the LlCAM gene 
could be detected122, 36•38·41A4A5l_ No pathogenic mutation in  the RET gene, which is associated 
with HSCR disease, was detected in these patients as far as it was tested for. 
I n  our study (Chapter 7) we carried out the molecula r characterization of a ten-year old 
boy affected with HSCR disease, X-lin ked hydrocephalus and vesico-ureteral reflux. A de 
nova reciprocal balanced translocation, t(3; 17)(p12.l;q11 .21), was found by karyotyping .  
Mutation analysis of the LlCAM gene and the RET gene showed a frame shift mutation in the 
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LlCAM gene, c.2265delC, leading to a premature stop codon in the LlCAM gene, whereas no 
pathogenic mutation could be detected the RET gene. 
Although we cannot exclude an involvement of the translocation being involved in the 
phenotype of our patient, our data in combination with the data presented in the literature 
showed that a large proportion of patients with Ll syndrome in combination with HSCR do 
in fact have an L1CAM mutation. The frequency is far higher than one would expect based 
on random matingl45l, suggesting that there might be a link between LlCAM mutations and 
HSCR. The low incidence of HCSR disease in patients with LlCAM mutations (about 3%} and 
the absence of L1CAM mutations in males affected with isolated HSCRf45l suggest that LlCAM 
is not a causative gene of HSCR, but that it likely acts as a modifier gene in the development of 
HSCRl3s,4s,45l _ Additional factors might promote the occurrence of HSCR, these include the RET 
predisposing haplotype, which is a specific combination of genetic variants located between 
the promoter and exon 2 of the genel471 • Our patient proved heterozygous for this particular 
haplotype. This hypothesis requires further work to prove it valid. 
In conclusion the intestinal aganglionosis of HSCR might be due in part to LlCAM mutations. 
Future perspectives 
We have described the possible modifier role that the L1CAM gene might have in HSCR. It 
would be interesting to prove the gene plays this role by finding evidence for the hypothesis 
that the RET predisposing haplotype contributes to the intestinal aganglionosis under the 
influence of an L1CAM mutation. To prove this we need to demonstrate that the presence 
of the RET haplotype in patients with an LlCAM mutation is significantly higher in those with 
HSCR disease than those without HSCR disease, but as the number of patients available is very 
small, this will be hard to prove. 
PART I l l  
Do other L l  syndrome genes exist? 
Only -20% of all the patients referred to our laboratory for LlCAM testing turned out to harbor 
a mutation in the LlCAM gene, implying that 80% of them did not have a mutation in this gene. 
If we correct for the number of patients that were analyzed to simply exclude the Ll syndrome, 
the number suspected of having Ll syndrome but with no mutation in the LlCAM gene drops 
to 75%. This is still very high. Even when patients are very stringently pre-selected using the 
clinical criteria mentioned, we still do not find mutations in 15-20% of our patients. 
These findings led to the hypothesis that other genes might be involved in L1 syndrome or 
an atypical form of it. In order to test this hypothesis we attempted to find such genes by 
selecting patients without an LlCAM mutation and analyzing them for large deletions using a 
high-density, X-chromosome-specific array-CGH (Chapter 8). 
X-chromosome-specific array-CGH analysis 
An X-chromosome-specific array-CGH analysis was used to detect deletions that could include 
genes potentially involved in Ll syndrome. We focused on the X-chromosome since 95% of all 
referred patients suspected of having L1 syndrome are males and familial cases mostly show 
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an X-linked recessive inheritance. In order to increase the chance of finding a new gene, we 
designed a very dense array. All the deletions found could in principle be associated with the 
Ll syndrome, unless they concerned a polymorphism (Chromosomal Neutral Variant (CNV)). 
Deleted genes were classified as candidate Ll syndrome genes based on different criteria, 
for instance their gene product or their expression in tissues of interest, such as the brain or 
neurons, or their expression in an early stage of fetal development, or because of the features 
of the deletion itself, namely its size and/or localization (within coding or non-coding regions 
of the gene) . 
By screening 60 patients, selected because they were clinical ly suspected of having Ll 
syndrome, we identified 11 candidate deletions containing 11 candidate genes (Chapter 8) . At 
least eight out of eleven genes are expressed in the brain or in neurons (DGAT2L6, POU3F4, 
GD/1, ASMTL, ATP6AP1, M/01, FRMPD4 and MAP3K15}, and at least three out of eight are 
expressed in an early stage of development (POU3F4, GD/1 and ATP6AP1}. The other three 
candidate genes are TGIF2LX, DDX53 and TMEM27. 
As our analysis only detected deletions and no point mutations, which are probably far more 
common, we selected five genes as being the best candidates (based on different criteria, see 
table 2 Chapter 8) for further sequence analysis (POU3F4, DGAT2L6, GD/1, DDX53 and TGIF2LX}. 
The analysis was performed in 95 patients suspected of having Ll syndrome without an LlCAM 
mutation. In three out of the 95 patients we detected a variant : two intronic variants in GD/1, 
c.153-3C>T in intron 2 and c.992-lOC>T in intron 8, and one missense mutation in TGIF2LX, 
c.421T>C (p.Ser141Pro). The c.153-3C> T variant is most likely to be disease-causing, while the 
other two are probably not disease-causing (Chapter 8) . 
We therefore concluded that in these 95 patients the evidence for a second gene involved in 
Ll syndrome is still rather weak, with perhaps the exception of the GD/1 gene which seemed 
to be the most likely candidate. 
The remaining six candidate genes were not further analyzed by sequencing the DNA of the 
95 patients, because they were estimated to be less likely candidate genes. However, at first 
glance the M/01 gene seemed to be of interest, because we detected a deletion in three 
different patients (table 2, Chapter 8), but since the deletions comprised only intrans and 
no coding regions, this gene was also labeled as a less probable candidate for Ll syndrome. 
Basically the same also applied to the MAP3K15 gene. 
These results show that we still lack hard evidence for any gene other than the LlCAM gene 
to explain Ll syndrome in many patients. However, the possible involvement of the candidate 
genes we identified cannot be excluded in patients suspected of having Ll syndrome, because 
of the presence of deletions in or from these genes and for one gene an additional point 
mutation in this gene. 
Future perspectives 
The existence of a second gene explaining Ll syndrome in patients suspected of having Ll 
syndrome has not yet been clearly demonstrated. We might have overlooked putative new L1 
syndrome genes due to the design of our study: we only looked for reasonably large deletions 
and so we would have missed genes that only have point mutations or small deletions. Most 
probably a more advanced technology wil l  be needed to detect other genes involved in L1 
syndrome. We therefore plan to perform X-chromosome-specific exome resequencing of 
patients clinical ly suspected of having Ll syndrome and not carrying an LlCAM mutation. This 
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will allow us to draw better conclusions as to the involvement of other genes in Ll syndrome 
in the near future. 
Finally, we should point out that perhaps it is not a matter of one or two unknown genes but 
rather a whole set of genes each of them explaining the disorder in a few patients suspected 
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Ll syndrome is  an X-l i n ked recessive d isorder with a p reva lence of 1 :30,000 newborn males. 
It comp rises four  neurologica l syndromes, al l associated with mutations i n  the L1CAM gene.  
The most severe of the four  d ifferent forms is X- l i n ked hydrocephalus, a l so referred to as 
hydrocepha lus due to stenosis of the aqueduct of Sylvius (HSAS). Other c l in ica l  characteristics 
are adducted thumbs, menta l retardation, and lower l imb  spasticity. I n  most fami l ies, the 
affected boys d ie before, during, or soon after b i rth .  A l ess severe form of the d isease has been 
publ ished under  the acronym MASA synd rome. This syndrome consists of l ight to moderate 
mental reta rdation, .§.phasia, �huffi ing gait and  .§.dducted thumbs. X-l i nked compl icated 
hereditary spastic paraplegia type 1 and X- l i nked com pl icated corpus cal losu m agenesis 
(X- l inked  ACC) a re a lso parts of the Ll syndrome, but are seen much less frequently. The 
com pl icated forms may be com bined with mild to moderate mental retardation.  Overa l l, the 
seven most important characteristics of Ll synd rome a re hydrocephalus, aqueduct stenosis, 
menta l reta rdation, adducted thumbs, agenesis/dysgenesis of the corpus cal losum, aphasia 
(delayed speech development) and spastic parap leg ia .  
The L1CAM gene, located on the X-chromosome at Xq28,  codes for the neura l  ce l l  adhesion 
molecu le Ll ( Ll protein)  and is primari ly expressed i n  the nervous system.  The gene consists 
of 29 exons and  encodes a protein  of 1,257 amino acids .  The first exon of 125 bp is non-cod ing. 
The Ll protein  is a transmembrane glycoprotein of approximately 200 kDA belonging to the 
immunoglobu l in  su perfami ly ce l l  adhesion molecules and conta ins thirteen d istinct domains, 
i .e .  six i m munoglobu l in - ( lg) and five fibronectin ( Fn )  I l l - l i ke domains at the extrace l l u lar  su rface, 
one single-pass transmembrane domain, and one short cytoplasmic doma in .  The Ll protein 
is involved in  neuronal  ce l l  m igration, neurite outgrowth and axon bund l ing (fascicu lation),  
mye l i nation, and cel l-ce l l  adhesion on d ifferentiated neurons.  
The aims of this thesis (Chapter 1) were : to deve lop a tool to predict the chance of detecting 
a m utation in the L1CAM gene in patients suspected of having Ll syndrome (Chapter 2); to 
look for genotype-phenotype correlations (Chapter 2); to set up an easi ly access ib le L1CAM 
mutation database and inc lude a l l  d isease-caus ing and  non-disease-ca using mutations, a l l  
unclassified va riants ( UVs) and a l l  re levant patient data (Chapter 4 ) ;  to  prove the pathogenicity 
of some UVs caused by incorrect RNA spl icing (Cha pter S); to look for possible other c l in ical 
features caused by an  L1CAM mutation (Chapters 6 and 7);  and to identify new genes involved 
in L1 syndrome (Chapter 8) .  
In Chapter 2 the DNA of 367 referred patients suspected of having Ll syndrome was ana lyzed 
for mutations in  the cod ing sequences and the exon- intron boundaries of the L1CAM gene. 
A subgroup of 100 patients was a lso investigated for m utations in the promoter and two 
regu latory sequences of the L1CAM gene, e.g. the neura l  restrictive s i lencer  e lement ( N RSE) 
and the homeodomain and pa ired doma in  b ind ing s ite ( H P D), and for la rge dup l ications to 
determine whether there were additional m utations in  these regu latory regions or  any 
dup l ications. As a result in 73 patients (20%) 68 different mutations were detected :  61 a re 
conside red to be d isease-caus ing and 7 to be u nc lassified variants (UVs) .  I n  one patient a 
dupl ication from exons 2-10 was identified .  No m utations were detected in the promoter, the 
HPD or the N RSE sites of the 100 patients ana lyzed .  Based on these resu lts it was concluded, 
that broadening the DNA screening procedure to inc lude regu latory sequences ana lysis is not 
worthwhi le, a lthough screen ing for dupl ications m ight be beneficia l .  
Furthermore, c l i n ical data on 106 patients, 3 1  of  whom carried a mutation, were col lected 
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and used for statistical analysis. In patients with three or more clinical characteristics of 
Ll syndrome, the mutation detection rate was 66% compared to 16% in patients with one 
or two characteristics (odds ratio (OR) 10.1, 95% confidence interval (Cl} 3.8 to 27.1). The 
detection rate was 18% in families with one affected male and 51% in families with more than 
one affected family member. A combination of these two characteristics, i.e. patients having 
a positive family history for Ll syndrome and having three or more clinical characteristics, 
results in a detection rate of 85% (OR 10.4, 95% Cl 3.6 to 30.1). Using the data of the whole 
group a diagram could be drawn up, showing the mutation detection rate related to the 
number of clinical characteristics and the number of affected family members. By using this 
diagram, clinicians can now accurately predict the chance of finding a mutation in a patient, 
thus fulfilling one of the aims of the thesis. 
The analysis also confirmed a previously reported genotype-phenotype correlation: children 
harboring a truncating mutation died more frequently (52%) before the age of 3, than 
children with a missense mutation (8%} (Fisher exact p=0.02). In contrast to the findings of 
other groups, we did not find a difference in the severity of hydrocephalus in patients with a 
missense mutation in key residues versus surface residues. 
Finally, the occurrence of (maternal) germ line mosaicism for an L1CAM mutation was proven in 
this study and three females with Ll syndrome carrying an L1CAM mutation were reported. 
The latter finding, the detection of L1CAM mutations in women with the Ll syndrome, is 
an important observation. To date, it was believed that mutations in the L1CAM gene did 
not really cause Ll syndrome in women, since only a very mild phenotype was observed in 
approximately 5% of the mutation carriers. Our results show that also severe phenotypes of 
the Ll syndrome do occur in women, which has very important consequences for counseling, 
notably for prenatal diagnostics. 
Chapter 3 describes a novel mutation in the L1CAM gene in a male with X-linked hydrocephalus 
who had multiple small gyri, hypoplasia of the white matter, agenesis of the corpus callosum, 
and lack of cleavage of the thalami. Three brothers with congenital hydrocephalus died in 
the neonatal period. Mutation analysis of the L1CAM gene revealed a missense mutation, 
p.Ala415Pro in the lg 4 domain of the Ll protein. Since alanine 415 is considered a key residue 
crucial for protein folding, it is likely that the X-linked hydrocephalus and cerebral dysgenesis 
are a result of the abnormal structure and function of the mutant Ll protein. 
In Chapter 4 the construction of the L1CAM mutation database is described. About 240 
different L1CAM mutations have been reported in the literature, disease-causing and non­
disease-causing mutations as well as unclassified variants. Since the amount of information 
is growing rapidly and it is important for geneticists and clinicians to have easy access to this 
information, the existing database was renewed and updated. New information recorded in 
the database comprises: (1) clinical data (including age at early death), (2) family anamnesis, (3) 
the reported clinical classification, (4) elements which co-determine the possible pathogenicity 
of a variant, e.g. co-segregation of the variant in the family, de nova appearance in the patient 
or de nova appearance in the mother of the patient (5) in silica data concerning the variant, (6) 
effect of a variant in a functional assay, and (7) effect of a variant on the pre-mRNA splicing. As 
a result, the database now offers much more complete information, allowing conclusions to be 
drawn on the pathogenicity and severity of L1CAM mutations based on multiple factors. The 
database will be updated monthly with newly published data. 
The L1CAM Mutation Database is at: www.llcammutationdatabase.info. 
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In Chapter 5 the resu lts a re descri bed from us ing an ex vivo RNA spl ic ing assay as a tool to 
fu rther substantiate the assumed pathogenicty of certa in LlCAM variants. 
Ana lyzing the seven unclassified variants (UVs) detected in the study described in chapter 2 
with in silico prediction p rograms, it was concluded that at least 3/7 UVs might be involved i n  
aberrant spl icing of  the  pre-mRNA. I n  order to  prove th i s  effect an ex vivo RNA sp l icing assay 
was used and all three UVs (c .76+5G>A, c . 1546G>A (Asp516Asn)  and c .1546G>T (p .Asp516Tyr))  
were found to be pathogen ic. The re l ia b i l ity of the ex vivo RNA sp l ic ing assay was confirmed 
with the LlCAM c.645C>T mutation, a mutation previously proven to be pathogenic due to 
i ncorrect sp l icing (Chapter 2) .  
I n  concl usion, 64 ( instead of 61) of the 68 mutations described in  chapter 2 are now considered 
as pathogen ic. 
Chapter 6 deals with the genetic ana lys is of a boy with Ll syndrome and nephrogenic diabetis 
i ns ip idus (NDI ) . We wondered whether this phenotype cou ld  be expla ined by mutations i n  
the LlCAM gene alone o r  by  a l a rge deletion inc lud ing the LlCAM and the  AVPR2 genes. The 
deletion hypothesis was based on the fact that N DI is caused by mutations in  the AVPR2 gene, 
which is located close to the L1CAM gene on the X chromosome. 
A deletion of 61,577 bp was detected, encompassing the entire LlCAM and AVPR2 genes. In 
conclusion, the ND I  phenotypic features are caused by the loss of the AVPR2 gene rather than 
the loss of the LlCAM gene.  
I n  Chapter 7 the molecu lar  characterization of a patient affected with X- l i nked hyd rocepha lus  
and H irschsprung's ( HSCR) d isease is outl ined . Karyotype ana lysis showed a de nova reciproca l 
ba lanced translocation t(3; 17)(p 12;q21) .  Mutation ana lysis of the LlCAM gene and the RET 
gene, which is associated with HSCR d isease, showed a frame shift mutation in the LlCAM 
gene, c.2265delC, leading to a premature stop codon in the LlCAM gene, whereas in the 
RET gene no pathogenic m utation cou ld  be detected. Characterization of the ch romosome 
17 breakpoint showed interruption of the MYOlBA and TIAFl genes. Besides the LlCAM 
m utation, a poss ib le involvement of the MYO18A and TIAFl genes on the phenotype cannot 
be excluded. To date, most patients reported with co-occurrence of HSCR and Ll syndrome 
were proven to have mutations i n  the LlCAM gene, which was proposed as a candidate HSCR 
gene. But the low incidence of HCSR d isease in  patients with LlCAM mutations (about 3%) and 
the absence of  LlCAM m utations in  males affected with isolated HSCR suggest that LlCAM i s  
not a causative gene for HSCR, but that  i t  l i kely acts as a mod ifier gene for the development 
of HSCR. 
Because on ly 20% of the patients c l in ica l ly suspected of having L1 syndrome carry a mutation 
i n  the LlCAM gene, it was hypothesized that other genes m ight be i nvolved in Ll syndrome. In 
Chapter 8 we searched for such genes on the X-chromosome by screening for de letions i n  60 
patients suspected of having Ll syndrome using a h igh density X-chromosomal array, assuming 
that the deletion wou ld ha rbor a new Ll syndrome gene. 
Ana lysis of the resu lts revealed e leven candidate d isease-causing de letions in  twelve patients, 
i nvolving eleven candidate genes : OGAT2L6, POU3F4, GOil, ASMTL, ATP6AP1, M/Dl, FRMPO4, 
MAP3K15, TGIF2LX, ODX53, and TMEM27. To substantiate their  involvement in Ll syndrome 
it was decided to sequence the five most promis ing candidate genes, OGAT2L6, POU3F4, 
GOil, TGIF2LX and OOX53 i n  95 L1 syndrome patients. This ana lysis showed only one gene, 
GOil, to be further involved, as in  addition to the deletion found a variant was a lso detected, 
c . 153-3C> T, in  one of the 95 patients. This varia nt is most p robably d isease caus ing because it 
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influenced correct RNA splicing in an ex vivo RNA splicing assay. 
We concluded that these five genes do not appear to be major players in Ll syndrome, but a 
role could not be excluded for these genes in the disease development. Furthermore, as only 
five of the eleven genes were sequenced, it is still possible, that one or more of the remaining 
six genes could be more frequently involved in patients suspected of having L1 syndrome. 
Since we searched for new genes by looking for deletions (> 2kb), we would have missed any 
genes that only have point mutations or small deletions. To study this X-chromosome-specific 
exome resequencing will be carried out for a selected group of patients suspected of having Ll 
syndrome by using next generation sequencing technique. 
We concluded that several more genes, in addition to the LlCAM gene, might be involved 
in Ll syndrome: so far the GD/1 gene emerges as the best gene, but further research will be 
necessary. 
In Chapter 9 the results described in this thesis are discussed and the future plans are presented. 
The most important plans for our future research are to: (1) set up a good functional assay and 
(2) search for new genes that can explain the L1 syndrome in patients suspected of having Ll 





Het Ll syndroom is een X chromosoom gebonden recessieve aandoening, die bij een op de 
30.000 pasgeboren jongetjes voorkomt. Vier verschillende neurologische aandoeningen, die 
alle vier veroorzaakt warden door mutaties in het L1CAM gen, behoren tot het syndroom. 
De meest ernstige vorm van de vier aandoeningen staat bekend ender de naam X-gebonden 
hydrocefalie (waterhoofd), oak wel bekend als hydrocefalie veroorzaakt door een vernauwing 
van het aqueduct van Sylvius ( HSAS: b.vdrocefalie veroorzaakt door �tenose van het--9.queduct van 
,S_ylvius) . Andere klinische kenmerken van dit syndroom zijn duimen gefixeerd in de adductiestand 
(zie figuur 1 pagina 12), mentale retardatie (verstandelijke beperking) en spasticiteit van de 
benen (loopstoornis). In de meeste families overlijden de aangedane jongetjes voor, tijdens 
of vlak na de geboorte. Een veel minder ernstige uiting van de aandoening staat bekend 
onder het acroniem MASA syndroom, dat gekenmerkt wordt door een lichte of matige vorm 
van mentale retardatie, afasie (een spraakstoornis, meestal vertraagde spraakontwikkeling), 
een loopstoornis en eveneens geadduceerde duimen. X-gebonden gecompliceerde erfelijke 
spastische paraplegie type 1 (spastische verlamming aan beide zijden van het lichaam) (X-linked 
SPGl) en de X-gebonden gecompliceerde vorm van de agenesie van de corpus callosum (het 
gedeeltelijk of geheel ontbreken van de hersenbalk) (X-linked ACC) behoren ook tot het Ll 
syndroom, maar komen zeer zelden voor. Deze laatste twee vormen kunnen gepaard gaan met 
een lichte mate van mentale retardatie. Samengevat zijn de zeven belangrijkste kenmerken 
van het Ll syndroom; een hydrocefalie, een aqueductstenose, mentale retardatie, duimen 
in de adductiestand, agenesie of dysgenesie van de corpus callosum, afasie en spastische 
paraplegie. 
Zoals gezegd warden deze syndromen veroorzaakt door mutaties in het L1CAM gen, dat 
gelegen is op het X-chromosoom op positie Xq28. Het gen codeert voor het neurale celadhesie 
molecuul Ll (Ll eiwit) en komt voornamelijk tot expressie in het zenuwstelsel. Het bestaat uit 
29 exonen en codeert voor een eiwit van 1257 aminozuren. Het eerste exon van 125 bp is niet 
coderend. Het Ll eiwit is een transmembraan glycoprotein van ongeveer 200 kD  behorende 
tot de immunoglobuline superfamilie van celadhesie moleculen en bevat dertien verschillende 
domeinen, te weten zes immunoglobuline- en vijf fibronectine 1 1 1 -achtige extracellulaire 
domeinen, een transmembraan domein en een kart cytoplasmisch domein. Het L1 eiwit is 
betrokken bij neuronale eel migratie, neuriet groei en axon bundeling, myeline vorming en 
eel-eel adhesie van gedifferentieerde neuronen. 
De doelstellingen van het promotieonderzoek (Hoofdstuk 1) zoals beschreven in dit proefschrift 
waren: een methode ontwikkelen die het mogelijk maakt om een uitspraak te doen over de 
kans om bij een patient verdacht van het L1 syndroom een mutatie in het LlCAM gen te vinden; 
het vaststellen van mogelijke genotype-fenotype correlaties (Hoofdstuk 2}; het opzetten van 
een goede LlCAM mutatie databank met alle beschreven en door ons gevonden pathogene 
en niet-pathogene mutaties, met alle niet geclassificeerde varianten (UV's) en met relevante 
patientgegevens (Hoofdstuk 4); te bewijzen dat sommige niet geclassificeerde varianten 
pathogeen zijn, omdat ze een foutieve pre-mRNA splicing veroorzaken (Hoofdstuk 5); te zoeken 
naar mogelijke andere klinische kenmerken veroorzaakt door L1CAM mutaties (Hoofdstuk 6 
en 7); en het identificeren van nieuwe genen, die als ze ontbreken of zijn gemuteerd het L1 
syndroom zouden kunnen veroorzaken (Hoofdstuk 8) . 
In Hoofdstuk 2 is het DNA van 367 L1 syndroom verdachte patienten geanalyseerd op mutaties 
in de coderende exonen en de exon-intron overgangen van het LlCAM gen. Een subgroep 
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van 100 patienten werd ook onderzocht op mutaties in de promotor en twee regulatoire 
gebieden van het L1CAM gen, te weten het "Neural Restrictive Silencer Element" (NRSE) en het 
"Homeodomain en Paired Domain" bindingsgebied (HPD) . Ook is in een subgroep onderzoek 
gedaan naar grate duplicaties. Als resultaat werden in 73 patienten (20%) 68 verschillende 
mutaties gevonden, waarvan 61 door ons werden geclassificeerd als pathogene mutaties en 7 
als UV's. In een patient werd een duplicatie van exon 2 tot en met exon 10 gevonden. Er werden 
geen mutaties aangetoond in de promotor, de NRSE of het HPD gebied. Op basis hiervan is 
geconcludeerd dat uitbreiding van het DNA mutatie onderzoek met regulatoire gebieden, niet 
lonend is, terwijl onderzoek naar duplicaties wel iets oplevert. 
Van 106 patienten, waarvan 31 met een mutatie, werden de klinische gegevens verzameld en 
deze werden gebruikt voor een statistische analyse. Hieruit bleek dat in patienten met drie of 
meer van de zeven hierboven beschreven klinische Ll kenmerken de mutatie detectiegraad 
66% is en slechts 16% in patienten met een of twee Ll karakteristieken (odds ratio (OR) 10,1; 
95% betrouwbaarheids interval (Cl) 3,8 tot 27,1) . Verder bleek de detectiegraad 18% in families 
met een aangedaan persoon en 51% in families met meer dan een aangedaan familielid. Een 
combinatie van deze twee, d.w.z. patienten met een positieve familie geschiedenis voor het 
Ll syndroom en met drie of meer klinische Ll kenmerken, leidt tot een detectiegraad van 85% 
(OR 10,4; 95% Cl 3,6 tot 30,1) . Door gebruik te maken van de gegevens van de gehele groep 
patienten, kon er een grafiek warden gemaakt, waaruit de mutation detectiegraad kan warden 
afgelezen als functie van het aantal klinische Ll kenmerken van een patient en het aantal 
aangedane familieleden. Met deze grafiek, een goede tool voor artsen, kan vrij nauwkeurig 
warden voorspeld hoe groat de kans is om in een patient met het Ll syndroom een mutatie 
te vinden. 
De analyse bevestigde ook een eerder gepubliceerde genotype-fenotype correlatie: kinderen 
met een truncerende mutatie stierven vaker (52%) voor hun derde levensjaar dan kinderen 
met een missense mutatie (8%) (Fisher exact p=0.02). In tegenstelling tot de bevindingen 
van anderen, vonden wij geen verschil in de ernst van de hydrocefalie bij patienten met een 
missense mutatie in 'key' aminozuren versus aminozuren aan de buitenkant van het eiwit. 
Tot slot is in een familie bewezen dat er sprake was van een maternale kiemcel moza'iek en 
werd bij drie vrouwen met het Ll syndroom een mutatie in het LlCAM gen aangetoond. De 
laatste bevinding, het vinden van l1CAM mutaties in vrouwen met het Ll syndroom, is een 
belangrijke observatie. Tot nu toe was de gedachte dat mutaties in het l1CAM gen eigenlijk 
geen volledig L1 syndroom gaven bij vrouwen. Wat wel werd gezien was een zeer mild fenotype 
bij ongeveer 5% van de mutatiedraagsters. Onze resultaten laten zien dat ook ernstige vormen 
van het Ll syndroom bij vrouwen kunnen voorkomen. Deze bevinding heeft implicaties voor 
de counseling, zeker in geval van prenatale diagnostiek . 
Hoofdstuk 3 beschrijft een nieuwe mutatie in het LlCAM gen van een jongetje met X-gebonden 
hydrocefalie, met meerdere kleine gyri (hersenwindingen), onderontwikkeling van de witte stof 
in de hersenen, afwezigheid van de hersenbalk en niet gescheiden thalami.  Drie broertjes met 
een aangeboren hydrocefalie stierven neonataal. Mutatie analyse van het L1CAM gen toonde 
een missense mutatie aan, p.Ala415Pro, in het lg 4 domein van het Ll eiwit. Aangezien alanine 
415 beschouwd wordt als een heel belangrijk (key) aminozuur, dat cruciaal zou zijn voor de 
correcte eiwit vouwing, is het zeer waarschijnlijk dat de hydrocefalie en de hersenafwijkingen 
in dit patientje het gevolg zijn van een abnormale structuur en functie van het Ll eiwit. 
In Hoofdstuk 4 wordt de opbouw van de L1CAM mutatie databank beschreven. Tot op 
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heden zij n er in de literatuur ongeveer 240 verschillende LlCAM mutaties gerapporteerd, 
waaronder ziekteverwekkende, niet-ziekteverwekkende en UV's. Aangezien de hoeveelheid 
informatie sterk groeit, is het van belang dat artsen en genetici snel en gemakkelijk toegang 
hebben tot deze informatie. De bestaande, verouderde, databank werd daarom vernieuwd 
en uitgebreid. De databank bevat nu, naast een ge-update lijst van mutaties, oak informatie 
zoals: (1) klinische gegevens (incl. leeftijd bij vroegtijdig overlijden) (2) familie anamnese, 
(3) de gerapporteerde klinische classificatie van de mutaties, (4) parameters die van belang 
zijn voor het vaststellen van de mogelijke pathogeniteit van een mutatie zoals bijvoorbeeld 
cosegregatie van de mutatie in de familie, het de nova voorkomen van de mutatie bij de 
patient of bij de moeder van de patient (5) in silica gegevens betreffende de mutatie, (6) 
gegevens van het gedrag van een variant in een functionele test en (7) het effect van de 
mutatie op de mRNA splicing. Het resultaat is een databank met veel meer informatie dan 
voorheen, waardoor conclusies betreffende de pathogeniteit en de ernst van de mutaties 
in het L1CAM gen op basis van meer factoren gedaan kan warden . De database zal iedere 
maand warden ge-update met de nieuw gepubliceerde en door ans gegenereerde gegevens 
en is te vinden op: www.llcammutationdatabase.info. 
In Hoofdstuk 5 warden de resultaten van een ex vivo RNA splicing onderzoek beschreven. 
Een analyse van 7 UV's uit het onderzoek beschreven in Hoofdstuk 2, met verschillende RNA 
splicing predictie programma's, leidde tot de conclusie dat tenminste 3 van de 7 aanleiding 
zouden kunnen geven tot afwijkende mRNA splicing. Om dit te bewijzen werd gebruik 
gemaakt van een ex vivo RNA splicing test. Alie drie UV's (c.76+5G>A, c.1546G>A (Asp516Asn) 
en c.1546G>T (p.Asp516Tyr)) bleken pathogeen te zijn, vanwege incorrecte splicing. De 
betrouwbaarheid van de ex vivo RNA splicing test kon warden aangetoond met de LlCAM 
c.645C>T mutatie, waarvan eerder met een andere methode werd vastgesteld (Hoofdstuk 2) 
dat deze pathogeen was vanwege incorrecte RNA splicing. 
Als gevolg warden thans 64 (ipv 61) van de 68 mutaties, beschreven in hoofdstuk 2 als 
pathogeen beschouwd. 
Hoofdstuk 6 handelt over het genetisch onderzoek bij een jongetje met Ll syndroom en tevens 
nefrogene diabetes insipidus (NOi) . De vraag hierbij was of het fenotype verklaard kon warden 
door mutaties in het LlCAM gen alleen, of door een grate deletie die zowel het L1CAM gen 
als het AVPR2 gen bevat. De deletie hypothese was gebaseerd op het feit dat NOi veroorzaakt 
wordt door mutaties in het AVPR2 gen, dat vlak bij het LlCAM gen op het X chromosoom ligt. 
Er werd een deletie aangetoond van 61.577 bp, die het volledige LlCAM en AVPR2 gen bevat. 
Het NDI fenotype wordt dus veroorzaakt door verlies van het AVPR2 gen en niet door een 
mutatie in het L1CAM gen .  
In Hoofdstuk 7 wordt de  moleculaire karakterisatie van een patient met een X-gebonden 
hydrocefalie en de ziekte van Hirschsprung (HSCR) beschreven. Karyotypering liet een de novo 
reciproke gebalanceerde translocatie t(3;17)(p12;q21) zien. Mutatie analyse van het L1CAM 
gen en het RETgen, dat betrokken is bij de ziekte van HSCR, toonde een frameshift mutatie aan 
in het L1CAM gen, c.2265de1C, die leidt tot een vroegtijdig stop in het gen, terwijl in het RET 
gen geen pathogene mutatie kon warden gedetecteerd. Karakterisatie van het chromosoom 
17 breukpunt liet een interruptie van de MY018A en TIAF1 genen zien, met als gevolg dat 
naast de mogelijke betrokkenheid van de LlCAM mutatie, oak de afwijkingen in het MY018A 
en T/AF1 gen van invloed zouden kunnen zijn op het fenotype. Tot op heden blijken de meeste 
patienten met zowel HSCR als Ll syndroom mutaties te hebben in het L1CAM gen, waardoor 
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het L1CAM gen als een kandidaat gen voor de ziekte van HSCR werd gezien. Echter het feit dat 
slechts 3% van de patienten, die een mutatie in het L1CAM gen hebben oak de ziekte van HSCR 
hebben en de afwezigheid van L1CAM mutaties in jongens met alleen de ziekte van HSCR, 
suggereert dat het L1CAM geen oorzakelijk gen is voor HSRC, maar eerder een rol speelt als 
modifier in de ontwikkeling van deze ziekte. 
Aangezien slechts 20% van de Ll syndroom patienten een mutatie in het L1CAM gen hebben, 
kan warden verondersteld dat oak andere genen betrokken zouden kunnen zijn bij het Ll 
syndroom. In Hoofdstuk 8 beschrijven we het onderzoek naar dergelijke genen door te 
zoeken naar deleties in 60 Ll syndroom patienten m.b.v. een high density X-chromosomale 
array, aannemende dat deze deleties dergelijke nieuwe Ll syndroom genen zouden kunnen 
bevatten. 
Analyse van de resultaten leverde 11 kandidaat ziekte veroorzakende deleties op, in 12 
patienten, die leidde tot 11 kandidaat genen t.w: DGAT2L6, POU3F4, GD/1, ASMTL, ATP6AP1, 
M/01, FRMPD4, MAP3K15, TGIF2LX, DDX53 en TMEM27. Om hun betrokkenheid bij het L1 
syndroom te kunnen onderbouwen, werd besloten om van 95 L1 syndroom patienten de vijf 
meest belovende kandidaat genen; DGAT2L6, POU3F4, GD/1, TGIF2LX en DDX53 te sequencen. 
Uit dit onderzoek bl eek a I leen extra betrokkenheid voor het GD/1 gen, omdat in een patient een 
mutatie werd gevonden, c.153-3C>T. Dit is zeer waarschijnlijk een ziekte verwekkend mutatie, 
omdat de mutatie incorrecte RNA splicing veroorzaakt in een ex vivo RNA splicing test. 
De conclusie is, dat deze vijf genen geen belangrijke rol spelen bij de ontwikkeling van het Ll 
syndroom, maar een zekere rol m.n. voor het GD/1 gen, kan niet warden uitgesloten. Het is 
ook mogelijk dat een (of meer) van de zes niet geanalyseerde genen meer betrokken is bij de 
tot standkoming van het Ll syndroom. 
Omdat we gescreend hebben voor deleties (>2 kb) is het niet uit te sluiten dat we genen gemist 
hebben die alleen maar puntmutaties of heel k leine deleties hebben. Om mogelijk nieuwe 
genen op te sporen, zullen wij met behulp van de next generation sequencing techniek een 
X-chromosoom-specifieke exoom resequencing gaan uitvoeren bij een geselecteerde groep L1 
syndroom patienten. 
Samenvattend concluderen wij dat er naast het L1CAM gen andere genen betrokken zouden 
kunnen zijn bij de ontwikkeling van het Ll syndroom, waarbij het GD/1 gen de beste kandidaat 
lijkt tot nu toe, maar verder onderzoek is nodig. 
In Hoofdstuk 9 worden de verkregen resultaten bediscussieerd en de toekomst plannen 
gepresenteerd, waarvan de belangrijkste zijn: (1) het opzetten van een betrouwbare functionele 
test en (2) het onderzoek naar nieuwe genen, waarmee het Ll syndroom bij patienten, die 






En dan is het proefschrift opeens af ! Na de ups en downs in het onderzoek en vervolgens de 
inspanning om het op papier te krijgen, is dat een goed gevoel. Ondanks het feit dat mijn 
naam als enige op de omslag staat, is het zonneklaar dat het proefschrift niet tot stand zou zijn 
gekomen zonder de hulp van velen. 
Als eerste wil ik mijn promotor, professor dr. R.M.W. Hofstra, noemen. Beste Robert, 
bedankt voor het vertrouwen dat je in mij had. De start was wat traag, omdat de diagnostiek 
voortdurend aan mij trok. Keer op keer maakten we een nieuw tijdpad en als ik een beetje 
bedenkelijk keek of het wel haalbaar was, kwam jij altijd met de opwekkende woorden: "gaat 
lukken, het meeste is al af". Je optimisme hielp mij om er weer tegenaan te gaan. Het laatste 
anderhalf jaar hebben we er heel hard aangetrokken en ik ben je heel dankbaar voor je hulp 
op de momenten dat ik dacht vast te lopen en voor de snelheid waarmee je mijn stukken van 
waardevol commentaar voorzag. 
Ook ben ik veel dank verschuldigd aan professor dr. C.H.C.M. Buys, omdat hij mij in 2000 de 
kans gaf om na een carriere in de industriele biotechnologie een nieuwe uitdaging aan te gaan 
in de humane genetica. Beste Charles, bedankt voor deze mogelijkheid en het geloof dat je in 
mij had dat ik die overstap zou kunnen ma ken. lk dank je ook voor de grate vrijheid, die jij mij 
gaf in mijn werk als hoofd van de DNA diagnostiek . 
De beoordelingscommissie, professor dr. C.T.R.M. Schrander-Stumpel, professor dr. O. F. 
Brouwer en professor dr. H. van Bokhoven, wil ik hartelijk danken voor het positief beoordelen 
van het proefschrift. Een apart bedankje voor professor Schrander-Stumpel is hier zeker op zijn 
plaats . Beste Connie, bedankt voor de samenwerking op het gebied van het Ll syndroom. Onze 
gezamenlijke publicaties over het Ll syndroom kwamen tot stand doordat jij, als specialist 
op dit gebied (in 1995 promoveerde jij zelf op dit onderwerp), aan mij vroeg de moleculair 
genetische kant op mij te nemen. 
Dit proefschrift zou niet tot stand zijn gekomen zonder de inspanningen van Krista van Dijk-Bos. 
Beste Krista, jou wil ik vooral bedanken voor de enorme hoeveelheid werk die je hebt verzet. 
Je hebt dit van het begin tot het eind met veel enthousiasme en inzet gedaan. Je had vaak aan 
een half woord genoeg om voortvarend aan de slag gaan. In het begin zat het onderzoek een 
beetje tegen, maar we bleven erin geloven en dat maakten de momenten dat je enthousiast 
met een goed resultaat de kamer kwam binnenstappen extra leuk. Wat mij betreft hebben we 
fijn en goed samengewerkt. 
Verder wil ik de analisten bedanken, die binnen de DNA diagnostiek de mutatie analyse van 
het LlCAM gen hebben uitgevoerd: Edwin Verlind, die de mutatie analyse heeft opgezet, Annet 
Vrieling, Gerwin Jansen, Bea Hiemstra en Annelies ten Berge. Jullie resultaten hebben mede 
tot een mooie publicatie geleid. 
Ook een aantal stagiaires hebben een bijdrage geleverd aan het onderzoek. De LlCAM 
regulatiore gebieden zijn door Alieke Souilljee gesequenced. Mireille Mulder heeft de MLPA 
analyse opgezet. Een moeilijk onderzoek, maar het heeft resultaat opgeleverd. Irene Molthof 
heeft een eerste aanzet gegeven tot het ontwikkelen van een functionele assay. Jammer 
genoeg zijn we hier niet zover meegekomen dat de resultaten konden warden opgenomen, 
maar het heeft wel een mooi plaatje opgeleverd voor de omslag van mijn proefschrift. Alie 
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drie hartelijk dank. Martijn Bruining en Jenneke Stegeman, die beiden hun wetenschappelijke 
stage bij mij gedaan hebben, wil ik bedanken voor het opzetten van de patienten database en 
hun inspanning om een questionnaire te ma ken, uit te zetten en te interpreteren. Het resultaat 
is terug te vinden in hoofdstuk 2. Met dank oak aan Irene Stolte-Dijkstra die als ervaren klinisch 
geneticus beide laatst genoemde stagiaires heeft begeleid voor het klinische deel. Dank oak 
aan Hermien de Wal le. Hermien bedankt voor het analyseren van de grote berg gegevens en 
voor het feit dat je gewoon weer aan de gang ging als ik met een nieuwe of aanvullende vraag 
kwam. 
Klaas Kok en Pieter van de Vl ies wil ik bedanken voor het arraywerk en het meedenken met 
het onderzoek naar nieuwe genen. K laas, bedankt oak voor de hulp bij het vastleggen van de 
resultaten in een artikel. 
Heel leuk vond ik het enthousiasme waarmee Christine van der Werf te werk ging bij het 
maken van constructen voor het RNA splicing onderzoek, onder tijdsdruk, en ondanks haar 
eigen drukke werkzaamheden. Samen met Krista is er een goed resultaat neergezet. Hartelijk 
dank. 
Next, I would like to thank the many clinicians from all over the world for sending in patient 
material and for their trust in our diagnostic laboratory. Although I have never met most of 
you personally, over time I have developed a very friendly and fruitful relationship with many 
of you. 
I much appreciate all the clinicians who have spent some of their precious time, completing 
the questionnaire. Your efforts have proved to be very worthwhile. 
Last but not least, I would like to thank all my co-authors who were involved in the various 
scientific papers. I real ly enjoyed working with you. 
De stafleden van de sectie DNA diagnostiek, Annemieke van der Hout, Renee Niessen, Henny 
Lemmink en Jan Jongbloed, verdienen een aparte vermelding. Zander hun extra inspanningen 
om een deel van mijn werk ten behoeve van de patientenzorg, vooral het laatste anderhalf 
jaar, over te nemen, was mijn promotie onderzoek waarschijnl ijk niet tot een goed einde 
gekomen. Heel erg bedankt hiervoor. 
Uiteraard wil ik ook alle analisten van de sectie DNA diagnostiek bedanken voor de fijne 
samenwerking en de steun die ik heb gekregen tijdens het werk aan het boekje. 
Jackie Senior wil ik heel hartelijk danken voor het corrigeren van het Engels. Het proefschrift 
is er absoluut beter van geworden. Margaret Burton wil ik bedanken voor het corrigeren van 
hoofdstuk 2. 
Krista van Dijk en Arjan Bijlsma hebben beiden direct toegestemd toen ik hen vroeg mijn 
paranimf te worden. Krista, ik vind het een leuke afsluiting van onze samenwerking, want 
kart na het afronden van het Ll onderzoek ben je naar een ander team overgestapt en is 
onze samenwerking grotendeels beeindigd. Arjan, mijn neef, als student natuurkunde heb je 
inmiddels een aantal malen een promotie meegemaakt en vind je het heel leuk om eens "aan 
de andere kant" te staan en ik vind het leuk jou naast mij te hebben. Je nam, zoals altijd, ook 
deze taak heel serieus en je ging voortvarend aan de slag met je taak. Heel erg bedankt. Bob 
Vos, mijn andere neef, vond het een leuke uitdaging om voor mijn proefschrift het ontwerp 
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voor de omslag te maken. lk was blij verrast toen ik het resultaat zag. Bob, heel erg bedankt, 
want door jouw creativiteit en artisticiteit, dekt de vlag heel fraai de lading. 
Mijn familie, vrienden en kennissen wil ik bedanken voor het begrip dat ze vooral de laatste 
tijd getoond hebben, voor het feit dat zo ik weinig tijd had voor iedereen. De tijd werd zelfs zo 
schaars dat ik een jaar lang mijn vrijwilligerswerk in Roden heb moeten stilleggen en deels aan 
anderen heb moeten overdragen. Fijn dat dit kon, bedankt, daar komt nu snel een eind aan. De 
banden warden weer aangetrokken en de activiteiten warden weer hervat. 
En als laatste, maar een heel belangrijke factor in mijn leven, wil ik mijn ouders bedanken voor 
alles wat zij voor mij gedaan hebben en nog steeds doen. Lieve pa en ma, heel erg bedankt 
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studeren en voor alles wat jullie me hebben meegegeven. Van jongs af aan hebben jullie ons 
voorgehouden hoe belangrijk het is om een goede opleiding te volgen en onafhankelijk te zijn. 
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